<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="inhibit">
            <roleset id="inhibit.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="the entity being inhibited by agent to get binding&#x0A;" />
                    <role n="2" descr="the action or property being inhibited&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>10 mM EDTA is totally inhibiting ligand that is concentration-dependent and saturable, inhibiting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A0 inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A0 inhibits specific isoforms of multiple PDE4 phosphosterase AMP coded by PDE4C.</text>
                    <arg n="1">specific isoforms of multiple PDE4 phosphosterase AMP</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A0 inhibits the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>A0 is able to completely inhibit ligand that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>A0 is capable of completely inhibiting binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>A0 is observed to inhibit multiple PDE4 AMP-specific isoforms of phosphoesterase encoded by PDE4C.</text>
                    <arg n="1">multiple PDE4 AMP-specific isoforms of phosphoesterase</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>A2 can be inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>A2 is capable of being inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>A2 is inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>A2 may have been inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>A2 will be inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>CRP-cAMP can strongly inhibit depending on sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>CRP-cAMP can strongly inhibit sigma (54)-gnAp2 dependent by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>CRP-cAMP has strongly inhibited sigma (54)-dependent glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>CRP-cAMP has the ability to strongly inhibit depending on sigma (54)-gnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54)-gnAp2 dependent by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>CRP-cAMP is able to strongly inhibit sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>CRP-cAMP is able to strongly inhibit sigma (54)-gnAp2 dependent by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>CRP-cAMP may have strongly inhibited depending on sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>CRP-cAMP may have strongly inhibited sigma (54)-gnAp2 dependent by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>CRP-cAMP strongly inhibited depending on sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>CRP-cAMP strongly inhibited sigma (54)-gnAp2 dependent by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>CRP-cAMP strongly inhibits depending on sigma (54)-gnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>CRP-cAMP will strongly inhibit sigma (54)-gnAp2 dependent by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>EDTA 10mM can fully inhibit ligand that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>EDTA 10mM can totally inhibit binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>EDTA 10mM fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>EDTA 10mM may have completely inhibited binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>EDTA 10mM may have completely inhibited ligand which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>For example, phosphatase associated with another protein has been inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>For example, phosphatase associated with other protein can be inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>For example, phosphatase associated with other protein is inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>For example, phosphatase associated with other protein may have been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>For example, phosphatase is associated with another protein and is therefore inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>For example, phosphatase is associated with other protein and is therefore inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>For example, phosphatase may have been associated with other protein and has therefore been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>For example, phosphatease associated with other protein has been inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>For example, phosphatease associated with other protein is inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>For example, phosphatease associated with other protein may have been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>For example, phosphatease associated with other protein was inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>For example, phosphatease associated with other proteins may be inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>GM132 proteasome inhibitors and laactacytin can inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW inhibits GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW is able to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may have inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may have inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent activation was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW inhibits depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW is observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadX-dependent activation is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex can inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex has inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex has the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex will inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the glnAp2 promoter activity can be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the glnAp2 promoter activity is inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>Here, we have found that descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacitstin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>Here, we have found that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacyttin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>Here, we have found that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that CRP-cAMP complex has the ability to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that CRP-cAMP complex is able to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that CRP-cAMP complex is observed to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that gnAp2 promoting activity has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that gnAp2 promoting activity is able to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that gnAp2 promoting activity is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that gnAp2 promoting activity will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex is observed to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>In addition, A0 inhibited the A2 connection (Lrp/PapI) near the GATC1028 site and altered the Lrp connection to the GATC1130 site.</text>
                </example>
                <example src="EGRAM" no="88">
                    <text>In addition, A0 inhibited the Lrp/PapI bond near the GATC site and alters the Lrp bond to the GATC site1130.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>In addition, A0 inhibits Lrp/PapI binding near the GATC 1028 site and alters Lrp binding to the GATC 1130 site.</text>
                </example>
                <example src="EGRAM" no="90">
                    <text>In addition, A0 inhibits Lrp/PapI near the GATC1028 site and alters the Lrp ligament to the GATC1130 site.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>In addition, A0 inhibits the Lrp/PapI bond near the GATC site and alters the Lrp bond to the GATC site1130.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>In addition, crew methylation is able to inhibit the A2 connection (Lrp/PapI) near the GATC site and alter the Lrp connection to the GATC site.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>In addition, methylation of prey has inhibited Lrp/PapI binding near the GATC1028 site and alters Lrp binding to the GATC1130 site.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>In addition, methylation of prey may have inhibited Lrp/PapI binding near the GATC1028 site and alters Lrp binding to the GATC1130 site.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>In addition, methylation of snails inhibits the Lrp/PapI binding near the GATC site1028 and alters the Lrp binding at the GATC site1130.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>In addition, methylation of snails is able to inhibit Lrp/PapI connection near the GATC site and alters the Lrp connection at the GATC site1130.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>In addition, methylation of the bar inhibited the A2 connection (Lrp/PapI) near the GATC1028 site and alters the Lrp connection to the GATC1130 site.</text>
                </example>
                <example src="EGRAM" no="98">
                    <text>In addition, nails methylation may have inhibited the Lrp/PapI connection near the GATC 1028 site and altered the Lrp connection to the GATC 1130 site.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>In this study, we found that reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacistin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>In this work, we found that descending regulation of the phosphorylation status, state5 and state6 was inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>In this work, we found that reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>In this work, we found that reduced regulation of Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacistin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>Intriguingly, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, have selectively inhibited late clathrin-coated vesicle formation events involving membrane fission, the SH3A intersectin was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>Intriguingly, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, selectively inhibit late clathrin-coated vesicle formation events inhibited membrane fission, the SH3A intersect was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>Intriguingly, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, are able to selectively inhibit late clathrin-coated vesicle formation events involving membrane fission, the SH3A intersect was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>Intriguingly, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, they are observed to selectively inhibit late clathrin-coated vesicle formation events involving membrane fission, the SH3A intersect was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>MAD-3 co-expression also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>MAD-3 co-expression also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>MAD-3 co-expression also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>MAD-3 co-expression may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Mad-3 co-expression also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Mad-3 co-expression also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Mad-3 co-expression has also inhibited functional activation of an HIV reporter plasmid by p49/p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Mad-3 may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in T cells affected by jurkat.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>N-terminal SH3 domain (SH3A), unlike other intersectin SH3 inhibited or several endocrine proteins, specifically inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>N-terminal domain H3 (HH3A), unlike other intersectin H3 inhibited or several endocytic proteins, specifically inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>N-terminal domain H3 (HH3A), unlike other intersection HH3 domains or several endocytic proteins, is able to specifically inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>N-terminal domain H3 (HH3A), unlike other intersection HH3 domains or several endocytic proteins, specifically inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>N-terminal domain H3 (HH3A), unlike other intersection HH3 inhibited or several endocytic proteins, specifically inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>N-terminal domain SH3 (SH3A), unlike other domains of intersectin SH3 or several endocrine proteins, is able to specifically inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>N-terminal domain SH3 (SH3A), unlike other domains of intersectin SH3 or several endocrine proteins, specifically inhibits intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>NK cell-mediated cytotoxicity is capable of being inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>NK-mediated cytotoxicity has been inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>Natural killer cells (NK) express cell surface receptors for immunoglobulin and lectin type C that recognise class I peptides of the greater compatibility complex (MHC) and may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>Natural killer cells (NK) express cell surface receptors for immunoglobulin and type C lectin that recognize class I peptides of the major histocompatibility complex (MHC) and may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>Natural killer cells (NK) express cell surface receptors for immunoglobulin and type C lectins superfamilies that inhibited class I peptides of the greater compatibility complex (MHC) and inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>Natural killer cells (NK) express cell surface receptors for immunoglobulin superfamilies and C-type lectins that inhibited class I peptides of the major histocompatibility complex (MHC) and inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>PDE4C is one of four mammalian genes that encode cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>PDE4C is one of four mammalian genes that encode multiple AMP-specific isoforms PDE4 and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>PDE4C is one of four mammalian genes that encode multiple cyclic PDE4 AMP-specific isoform phosphodiesterase that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>PDE4C is one of four mammalian genes that encode multiple cyclic PDE4 AMP-specific isoform phosphodiesterase that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific cyclic PDE4 isoforms and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Protease inhibitors A0 MG132 and lactacistin may have inhibited decreased regulation of Stat4, Stat5 and Stat6 phosphorylated and A0 (proteasome inhibitors MG132 and lactacistin) may have inhibited decreased regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Roipram can inhibit multiple PDE4-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Roipram has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Roipram has the ability to inhibit multiple PDE4-specific isoform phosphorylatase isoforms encoded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>Roipram has the ability to inhibit phosphorylase-specific multiple PDE4-isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Roipram inhibited multiple PDE4-specific isoform phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Roipram inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Roipram is able to inhibit multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Roipram may inhibit multiple PDE4-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then protein synthesis was inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis has been inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis was about to be inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis was inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis will be inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then protein synthesis will be inhibited by 50 mg/ml of chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml chloramphenicol to inhibiting protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of chloramphenicol to inhibiting protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then protein synthesis was inhibited by 50 mg/ml of chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then protein synthesis is inhibited by 50 mg/ml of chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then protein synthesis was about to be inhibited by 50 mg/ml of chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then protein synthesis was inhibited by 50 mg/ml of chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>The intrigue is that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I selectively inhibits delayed clattrin-coated vesicles formation events involving membrane fission, the SH3A intersect was unique in its ability to block previous</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>The intrigue is that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, selectively inhibited delayed clattrin-coated vesicles formation events involving membrane fission, the SH3A intersect was unique in its ability to block previous</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>The intrigue is that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, will selectively inhibit late events of clathrin-coated vesicles formation involving membrane fission, SH3A was only in its ability to block previous stages</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>The intrigue is that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, selectively inhibit late clathrin-coated vesicle formation events involving membrane fission, SH3A was only in its ability to inhibit earlier stages</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>The intrigue is that the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endocile proteins endophyline I, ampphiphisine II and symphpine I), selectively inhibit late clathrin-coated vesicle formation events inhibited membrane fission, the SH3A was only in its ability to block earlier stages (</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit final events of clathrin coated vesicle formation involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>This synthetic peptide binds to P and is able to inhibit its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>This synthetic peptide inhibited to P and inhibits the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>This synthetic peptide that binds to P may have inhibited is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>Transient overexpression in body cells has inhibit that a hot protein kinase inhibitor is produced by mitochondrial DNA of the protein kinase, and protein extracts from transfected body cells inhibits both alpha isoforms as C beta of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both C alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts of transcedural body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transfected body cells could have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transcedit body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transcent body cells has inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from the transcedit body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the isoforms C alpha and C beta of the catalytic subunit PKA are observed to be inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the isoforms C alpha and C beta of the catalytic subunit PKA can be inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>Transient overexpression in body cells verified that a hot protein kinase inhibitor is inhibit by the mitochondrial DNA of the protein kinase, and protein extracts from transfected body cells inhibits both alpha and C beta isoforms of the catalytic subunit of PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>Transient overexpression in cells has inhibit that a thermostable protein kinase inhibitor is produced by human DNA PKI, and protein extracts from transfect body cells inhibits both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfect body cells can inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transcent body cells is capable of inhibiting both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfect body cells may have inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the isoforms C alpha and C beta of the catalytic subunit PKA will be inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transfect body cells inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>a proteasome MG132 inhibitor and lactacitstin may have inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>an inhibitor of the MG132 protein and lactacittine is able to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>binding is a dependent and saturable concentration and can be totally inhibited with DTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>binding is a dependent and saturable concentration and has been totally inhibited with DTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>binding is a dependent and saturable concentration and is observed to be totally inhibited with DTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>binding is a dependent and saturable concentration and is totally inhibited with EDTA of 10 mM, inhibited that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>cytotoxicity mediated by NK cells is capable of being inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>cytotoxicity mediated by NK cells is observed to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>depending on sigma (54)-gnAp2 is strongly inhibited by CRP-cAMP by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="210">
                    <text>function and location of phosphatases will be inhibited if phosphatase is associated with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="EGRAM" no="211">
                    <text>function and location of phosphateases would be inhibited if phosphatase were associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="EGRAM" no="212">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T-lycemic cells transfected, wil is also inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="213">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells is also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="214">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells was also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="215">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 in T cells of Jurkat transfects is also inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="EGRAM" no="216">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in Jurkat T-leukemia transfect cells has also been inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="217">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transfectuously affected T-leukemia cells, wil is also inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="218">
                    <text>inhibitors of the MG132 proteasome and lactacyttin can inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="219">
                    <text>intermediate events leading to the formation of clathrin coated wells are observed to be inhibited by A0 (the N-terminal domain SH3 (SH3A) which is different from other intersectin SH3 domains or various endocite proteins.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="EGRAM" no="220">
                    <text>intermediate events leading to the formation of clathrin coated wells have been inhibited by A0 (the N-terminal domain SH3 (SH3A) which is different from other intersectin SH3 domains or various endocite proteins.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>intermediate events that lead to the formation of clathrin-coated cubes will be inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other SH3 domains of intersectin or from several endocytic proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>intermediate events that lead to the formation of clathrin-coated paddocks was inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other SH3 domains of intersectin or from several endocytic proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>intermediate events that lead to the formation of clathrin-coated pins are inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other SH3 domains of intersectin or several endocytic proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is able to be inhibited by N-terminal domain SH3 (SH3A), which is different from other SH3 domains of intersectin or from several endocytic proteins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>intermediate events that lead to the formation of clathrin-coated wells can be inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other domains of intersectin SH3 or several endocrine proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other domains of intersectin SH3 or several endocrine proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>intermediate events that lead to the formation of clathrin-coated wells was inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other domains of intersectin SH3 or several endocrine proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>intermediate events that lead to the formation of clathrin-coated wells will be inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other domains of intersectin SH3 or several endocrine proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>late clathrin coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>late clathrin-coated vesicle formation events are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>late clathrin-coated vesicle formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>late clathrin-coated vesicles formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>late events of clathrin-coated vesicles formation are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="236">
                    <text>late events of clathrin-coated vesicles formation is able to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="237">
                    <text>late events of clathrin-coated vesicles formation is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="238">
                    <text>late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="239">
                    <text>late events of clathrin-coated vesicles formation were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>ligand is a dependent and saturable concentration and can be fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>ligand is a dependent and saturable concentration and is able to be fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>ligand is a dependent and saturable concentration and is fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>ligand is a dependent and saturable concentration and was fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>ligand is concentration-dependent and saturable and is able to be fully inhibited with 10 mM EDTA , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>ligand is concentration-dependent and saturable and it is inhibited that 10mM EDTA is totally inhibited, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>nitric oxide (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>nitric oxide (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>nitric oxide (NO) inhibited the soluble isoform of guanylate cyclase in platelets and inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>nitric oxide (NO) inhibiting platelet function activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>nitric oxide (NO) inhibiting platelet function activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>nitric oxide activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>nitric oxide inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>nitric oxide inhibited platelet function activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>nitric oxide inhibited platquet function activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>nitric oxide inhibited the soluble isoform of guanilate cyclase in platelets and inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>nitric oxide inhibited the soluble isoform of guanilate cyclase in platelets and inhibits platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>nitric oxide inhibited the soluble isoform of guanylate cyclase in platelets and inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>nitric oxide inhibits platelet function activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>nitric oxide inhibits platquet function activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>platelet function can be inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>platelet function is capable of being inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>platelet function is inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="264">
                    <text>platelet function may have been inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="265">
                    <text>platelet function was inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="266">
                    <text>platelet function will be inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="267">
                    <text>platquet function was inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="268">
                    <text>rolipram inhibited PDE44 cyclic AMP-specific isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="EGRAM" no="269">
                    <text>rolipram inhibits PDE44 cyclic AMP-phosphodiesterases codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="EGRAM" no="270">
                    <text>rolipram inhibits PDE44 cyclic AMP-phosphodiesterases encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="EGRAM" no="271">
                    <text>rolipram is able to inhibit PDE44 cyclic AMP-specific phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="EGRAM" no="272">
                    <text>sigma (54) - glnAp2 was strongly inhibited by CRP-cAMP 21 times.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="EGRAM" no="273">
                    <text>sigma (54)-dependent glnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="274">
                    <text>sigma (54)-dependent glnAp2 is observed to be strongly inhibited by CRP-cAMP, by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="275">
                    <text>sigma (54)-dependent glnAp2 is strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="276">
                    <text>sigma (54)-gnAp2 is strongly inhibited by CRP-cAMP by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="277">
                    <text>the function of phosphateases and localization will be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="EGRAM" no="278">
                    <text>the function of phosphateases and localization would be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="EGRAM" no="279">
                    <text>this synthetic peptide binding to P can inhibit its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="280">
                    <text>this synthetic peptide binding to P may have inhibited its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="281">
                    <text>this synthetic peptide binds to P to inhibit its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="282">
                    <text>this synthetic peptide inhibited to P and then inhibits its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="283">
                    <text>this synthetic peptide inhibits to P and inhibits its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>10 mM EDTA (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>10 mM EDTA (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>10 mM EDTA (NO) inhibiting ligand activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>10 mM EDTA (NO) inhibiting ligand activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>10 mM EDTA activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>10 mM EDTA also has the ability to inhibit ligand in transient transfected T-cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>10 mM EDTA also inhibited ligand in transfected T-leukemia cells transfected.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>10 mM EDTA also inhibits ligand in transient transfected T-cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>10 mM EDTA also inhibits ligand in transiently transfected T-leukemia cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>10 mM EDTA can fully inhibit ligand that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>10 mM EDTA can inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>10 mM EDTA can totally inhibit ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>10 mM EDTA co-expression also has the ability to inhibit ligand in T-leukemia transnetly affected cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>10 mM EDTA fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>10 mM EDTA has also inhibited ligand in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>10 mM EDTA inhibited ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>10 mM EDTA inhibited ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>10 mM EDTA inhibits ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>10 mM EDTA inhibits ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>10 mM EDTA is able to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>10 mM EDTA may also have inhibited ligand in T cells affected by jurkat.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>10 mM EDTA may also have inhibited ligand in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>10 mM EDTA may have completely inhibited ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>10 mM EDTA may have completely inhibited ligand which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>10 mM EDTA may have inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>A0 inhibited binding.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>A0 inhibited final events of clathrin coated vesicle formation.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>A0 inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>A0 inhibited ligand.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>A0 inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>A0 inhibits binding.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>A0 inhibits final events of clathrin coated vesicle formation.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>A0 inhibits late events of clathrin-coated vesicles formation.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>A0 inhibits ligand.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>A0 inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>A0 is able to completely inhibit binding that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>A0 is able to completely inhibit final events of clathrin coated vesicle formation that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>A0 is able to completely inhibit late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>A0 is able to completely inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>A0 is able to completely inhibit the regulation of phosphorylated state, state5 and state6 that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>A0 is capable of completely inhibiting final events of clathrin coated vesicle formation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>A0 is capable of completely inhibiting late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>A0 is capable of completely inhibiting ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>A0 is capable of completely inhibiting negative regulation of Stat4, Stat5 and Stat6 phosphorylated that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>A0 is capable of completely inhibiting the regulation of phosphorylated state, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>A2 can be inhibited by CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>A2 can be inhibited by Roipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>A2 can be inhibited by protein extracts from transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>A2 can be inhibited by protein extracts of infected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>A2 can be inhibited by protein extracts of the transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>A2 can be inhibited by protein extracts of transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>A2 is capable of being inhibited by CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>A2 is capable of being inhibited by Roipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>A2 is capable of being inhibited by protein extracts from transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>A2 is capable of being inhibited by protein extracts of infected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>A2 is capable of being inhibited by protein extracts of the transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>A2 is capable of being inhibited by protein extracts of transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>A2 is inhibited by CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>A2 is inhibited by Roipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>A2 is inhibited by protein extracts from transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>A2 is inhibited by protein extracts of infected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>A2 is inhibited by protein extracts of the transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>A2 is inhibited by protein extracts of transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>A2 may have been inhibited by CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>A2 may have been inhibited by Roipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>A2 may have been inhibited by protein extracts from transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>A2 may have been inhibited by protein extracts of infected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>A2 may have been inhibited by protein extracts of the transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>A2 may have been inhibited by protein extracts of transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>A2 will be inhibited by CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>A2 will be inhibited by Roipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>A2 will be inhibited by protein extracts from transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>A2 will be inhibited by protein extracts of infected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>A2 will be inhibited by protein extracts of the transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>A2 will be inhibited by protein extracts of transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>AAM-3 expression (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>AAM-3 expression (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>AAM-3 expression (NO) inhibiting functional activation of an HIV plasmid reporter for p49/p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>AAM-3 expression (NO) inhibiting functional activation of an HIV plasmid reporter for p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>AAM-3 expression activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>AAM-3 expression also has the ability to inhibit functional activation of an HIV plasmid reporter for p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>AAM-3 expression also inhibited functional activation of an HIV plasmid reporter for p49/p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>AAM-3 expression also inhibits functional activation of an HIV plasmid reporter for p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>AAM-3 expression also inhibits functional activation of an HIV plasmid reporter for p49/p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>AAM-3 expression can fully inhibit functional activation of an HIV plasmid reporter for p49/p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>AAM-3 expression can inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>AAM-3 expression can totally inhibit functional activation of an HIV plasmid reporter for p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>AAM-3 expression co-expression also has the ability to inhibit functional activation of an HIV plasmid reporter for p49/p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>AAM-3 expression fully inhibiting concentration-dependent functional activation of an HIV plasmid reporter for p49/p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>AAM-3 expression has also inhibited functional activation of an HIV plasmid reporter for p49/p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>AAM-3 expression inhibited functional activation of an HIV plasmid reporter for p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>AAM-3 expression inhibited functional activation of an HIV plasmid reporter for p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>AAM-3 expression inhibits functional activation of an HIV plasmid reporter for p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>AAM-3 expression inhibits functional activation of an HIV plasmid reporter for p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>AAM-3 expression is able to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>AAM-3 expression may also have inhibited functional activation of an HIV plasmid reporter for p49/p65 in T cells affected by jurkat.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>AAM-3 expression may also have inhibited functional activation of an HIV plasmid reporter for p49/p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>AAM-3 expression may have completely inhibited functional activation of an HIV plasmid reporter for p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>AAM-3 expression may have completely inhibited functional activation of an HIV plasmid reporter for p49/p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>AAM-3 expression may have inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>CRP-cAMP can strongly inhibit sigma (54) - glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>CRP-cAMP can strongly inhibit sigma (54)-dependent glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>CRP-cAMP can strongly inhibit sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>CRP-cAMP complex (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>CRP-cAMP complex (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>CRP-cAMP complex (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>CRP-cAMP complex (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>CRP-cAMP complex (NO) inhibiting activity promotionAp2 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>CRP-cAMP complex (NO) inhibiting activity promotionAp2 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>CRP-cAMP complex (NO) inhibiting gnAp2 promoting activity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>CRP-cAMP complex (NO) inhibiting gnAp2 promoting activity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>CRP-cAMP complex activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>CRP-cAMP complex activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>CRP-cAMP complex also has the ability to inhibit activity promotionAp2 in transient transfected T-cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>CRP-cAMP complex also has the ability to inhibit gnAp2 promoting activity in transient transfected T-cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>CRP-cAMP complex also inhibited activity promotionAp2 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>CRP-cAMP complex also inhibited gnAp2 promoting activity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>CRP-cAMP complex also inhibits activity promotionAp2 in transient transfected T-cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>CRP-cAMP complex also inhibits activity promotionAp2 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>CRP-cAMP complex also inhibits gnAp2 promoting activity in transient transfected T-cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>CRP-cAMP complex also inhibits gnAp2 promoting activity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>CRP-cAMP complex can fully inhibit activity promotionAp2 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>CRP-cAMP complex can fully inhibit gnAp2 promoting activity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>CRP-cAMP complex can inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>CRP-cAMP complex can inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>CRP-cAMP complex can totally inhibit activity promotionAp2 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>CRP-cAMP complex can totally inhibit gnAp2 promoting activity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>CRP-cAMP complex co-expression also has the ability to inhibit activity promotionAp2 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>CRP-cAMP complex co-expression also has the ability to inhibit gnAp2 promoting activity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>CRP-cAMP complex fully inhibiting concentration-dependent activity promotionAp2 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>CRP-cAMP complex fully inhibiting concentration-dependent gnAp2 promoting activity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>CRP-cAMP complex has also inhibited activity promotionAp2 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>CRP-cAMP complex has also inhibited gnAp2 promoting activity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>CRP-cAMP complex has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>CRP-cAMP complex inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>CRP-cAMP complex inhibited activity promotionAp2 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>CRP-cAMP complex inhibited activity promotionAp2 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>CRP-cAMP complex inhibited gnAp2 promoting activity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>CRP-cAMP complex inhibited gnAp2 promoting activity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>CRP-cAMP complex inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>CRP-cAMP complex inhibits activity promotionAp2 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>CRP-cAMP complex inhibits activity promotionAp2 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>CRP-cAMP complex inhibits gnAp2 promoting activity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>CRP-cAMP complex inhibits gnAp2 promoting activity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>CRP-cAMP complex is able to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>CRP-cAMP complex is able to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>CRP-cAMP complex may also have inhibited activity promotionAp2 in T cells affected by jurkat.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>CRP-cAMP complex may also have inhibited activity promotionAp2 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>CRP-cAMP complex may also have inhibited gnAp2 promoting activity in T cells affected by jurkat.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>CRP-cAMP complex may also have inhibited gnAp2 promoting activity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>CRP-cAMP complex may have completely inhibited activity promotionAp2 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>CRP-cAMP complex may have completely inhibited activity promotionAp2 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>CRP-cAMP complex may have completely inhibited gnAp2 promoting activity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>CRP-cAMP complex may have completely inhibited gnAp2 promoting activity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>CRP-cAMP complex may have inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>CRP-cAMP complex may have inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>CRP-cAMP has strongly inhibited depending on sigma (54)-gnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>CRP-cAMP has strongly inhibited sigma (54) - glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>CRP-cAMP has strongly inhibited sigma (54)-gnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>CRP-cAMP has strongly inhibited sigma (54)-gnAp2 dependent by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>CRP-cAMP has the ability to inhibit phosphorylase-specific depending on sigma (54)-gnAp2-isoforms coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>CRP-cAMP has the ability to inhibit phosphorylase-specific sigma (54) - glnAp2-isoforms coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>CRP-cAMP has the ability to inhibit phosphorylase-specific sigma (54)-dependent glnAp2-isoforms coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>CRP-cAMP has the ability to inhibit phosphorylase-specific sigma (54)-gnAp2 dependent-isoforms coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>CRP-cAMP has the ability to inhibit phosphorylase-specific sigma (54)-gnAp2-isoforms coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>CRP-cAMP has the ability to strongly inhibit depending on sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54) - glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54) - glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54)-dependent glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54)-dependent glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54)-gnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54)-gnAp2 dependent by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>CRP-cAMP inhibited depending on sigma (54)-gnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>CRP-cAMP inhibited sigma (54) - glnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>CRP-cAMP inhibited sigma (54)-dependent glnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>CRP-cAMP inhibited sigma (54)-gnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>CRP-cAMP inhibited sigma (54)-gnAp2 dependent coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>CRP-cAMP inhibits depending on sigma (54)-gnAp2 codified by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>CRP-cAMP inhibits sigma (54) - glnAp2 codified by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>CRP-cAMP inhibits sigma (54)-dependent glnAp2 codified by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>CRP-cAMP inhibits sigma (54)-gnAp2 codified by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>CRP-cAMP inhibits sigma (54)-gnAp2 dependent codified by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>CRP-cAMP is able to inhibit depending on sigma (54)-gnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>CRP-cAMP is able to inhibit depending on sigma (54)-gnAp2.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>CRP-cAMP is able to inhibit sigma (54) - glnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>CRP-cAMP is able to inhibit sigma (54) - glnAp2.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>CRP-cAMP is able to inhibit sigma (54)-dependent glnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>CRP-cAMP is able to inhibit sigma (54)-dependent glnAp2.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>CRP-cAMP is able to inhibit sigma (54)-gnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>CRP-cAMP is able to inhibit sigma (54)-gnAp2 dependent coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>CRP-cAMP is able to inhibit sigma (54)-gnAp2 dependent.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>CRP-cAMP is able to inhibit sigma (54)-gnAp2.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>CRP-cAMP is able to strongly inhibit depending on sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>CRP-cAMP is able to strongly inhibit sigma (54) - glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>CRP-cAMP is able to strongly inhibit sigma (54)-dependent glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>CRP-cAMP may have strongly inhibited sigma (54) - glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>CRP-cAMP may have strongly inhibited sigma (54)-dependent glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>CRP-cAMP may have strongly inhibited sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>CRP-cAMP may inhibit depending on sigma (54)-gnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>CRP-cAMP may inhibit sigma (54) - glnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>CRP-cAMP may inhibit sigma (54)-dependent glnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>CRP-cAMP may inhibit sigma (54)-gnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>CRP-cAMP may inhibit sigma (54)-gnAp2 dependent coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>CRP-cAMP strongly inhibited sigma (54) - glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>CRP-cAMP strongly inhibited sigma (54)-dependent glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>CRP-cAMP strongly inhibited sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>CRP-cAMP strongly inhibits sigma (54) - glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>CRP-cAMP strongly inhibits sigma (54)-dependent glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>CRP-cAMP strongly inhibits sigma (54)-gnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>CRP-cAMP strongly inhibits sigma (54)-gnAp2 dependent by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>CRP-cAMP will strongly inhibit depending on sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>CRP-cAMP will strongly inhibit sigma (54) - glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>CRP-cAMP will strongly inhibit sigma (54)-dependent glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>CRP-cAMP will strongly inhibit sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>DTA of 10 mM (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>DTA of 10 mM (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>DTA of 10 mM (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>DTA of 10 mM (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>DTA of 10 mM (NO) inhibiting binding activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>DTA of 10 mM (NO) inhibiting binding activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>DTA of 10 mM (NO) inhibiting ligand activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>DTA of 10 mM (NO) inhibiting ligand activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>DTA of 10 mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>DTA of 10 mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>DTA of 10 mM also has the ability to inhibit binding in transient transfected T-cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>DTA of 10 mM also has the ability to inhibit ligand in transient transfected T-cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>DTA of 10 mM also inhibited binding in transfected T-leukemia cells transfected.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>DTA of 10 mM also inhibited ligand in transfected T-leukemia cells transfected.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>DTA of 10 mM also inhibits binding in transient transfected T-cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>DTA of 10 mM also inhibits binding in transiently transfected T-leukemia cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>DTA of 10 mM also inhibits ligand in transient transfected T-cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>DTA of 10 mM also inhibits ligand in transiently transfected T-leukemia cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>DTA of 10 mM can fully inhibit binding that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>DTA of 10 mM can fully inhibit ligand that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>DTA of 10 mM can inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>DTA of 10 mM can inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>DTA of 10 mM can totally inhibit binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>DTA of 10 mM can totally inhibit ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>DTA of 10 mM co-expression also has the ability to inhibit binding in T-leukemia transnetly affected cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>DTA of 10 mM co-expression also has the ability to inhibit ligand in T-leukemia transnetly affected cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>DTA of 10 mM fully inhibiting concentration-dependent binding and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>DTA of 10 mM fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>DTA of 10 mM has also inhibited binding in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>DTA of 10 mM has also inhibited ligand in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>DTA of 10 mM inhibited binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>DTA of 10 mM inhibited binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>DTA of 10 mM inhibited ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>DTA of 10 mM inhibited ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>DTA of 10 mM inhibits binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>DTA of 10 mM inhibits binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>DTA of 10 mM inhibits ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>DTA of 10 mM inhibits ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>DTA of 10 mM is able to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>DTA of 10 mM is able to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>DTA of 10 mM may also have inhibited binding in T cells affected by jurkat.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>DTA of 10 mM may also have inhibited binding in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>DTA of 10 mM may also have inhibited ligand in T cells affected by jurkat.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>DTA of 10 mM may also have inhibited ligand in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>DTA of 10 mM may have completely inhibited binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>DTA of 10 mM may have completely inhibited binding which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>DTA of 10 mM may have completely inhibited ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>DTA of 10 mM may have completely inhibited ligand which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>DTA of 10 mM may have inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>DTA of 10 mM may have inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>EDTA 10mM (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>EDTA 10mM (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>EDTA 10mM (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>EDTA 10mM (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>EDTA 10mM (NO) inhibiting binding activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>EDTA 10mM (NO) inhibiting binding activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>EDTA 10mM (NO) inhibiting ligand activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>EDTA 10mM (NO) inhibiting ligand activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>EDTA 10mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>EDTA 10mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>EDTA 10mM also has the ability to inhibit binding in transient transfected T-cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>EDTA 10mM also has the ability to inhibit ligand in transient transfected T-cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>EDTA 10mM also inhibited binding in transfected T-leukemia cells transfected.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>EDTA 10mM also inhibited ligand in transfected T-leukemia cells transfected.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>EDTA 10mM also inhibits binding in transient transfected T-cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>EDTA 10mM also inhibits binding in transiently transfected T-leukemia cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>EDTA 10mM also inhibits ligand in transient transfected T-cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>EDTA 10mM also inhibits ligand in transiently transfected T-leukemia cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>EDTA 10mM can fully inhibit binding that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>EDTA 10mM can inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>EDTA 10mM can inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>EDTA 10mM can totally inhibit ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>EDTA 10mM co-expression also has the ability to inhibit binding in T-leukemia transnetly affected cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>EDTA 10mM co-expression also has the ability to inhibit ligand in T-leukemia transnetly affected cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>EDTA 10mM fully inhibiting concentration-dependent binding and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>EDTA 10mM has also inhibited binding in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>EDTA 10mM has also inhibited ligand in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>EDTA 10mM inhibited binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>EDTA 10mM inhibited binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>EDTA 10mM inhibited ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>EDTA 10mM inhibited ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>EDTA 10mM inhibits binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>EDTA 10mM inhibits binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>EDTA 10mM inhibits ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>EDTA 10mM inhibits ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>EDTA 10mM is able to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>EDTA 10mM is able to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>EDTA 10mM may also have inhibited binding in T cells affected by jurkat.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>EDTA 10mM may also have inhibited binding in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>EDTA 10mM may also have inhibited ligand in T cells affected by jurkat.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>EDTA 10mM may also have inhibited ligand in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>EDTA 10mM may have completely inhibited binding which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>EDTA 10mM may have completely inhibited ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>EDTA 10mM may have inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>EDTA 10mM may have inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>EDTA of 10 mM (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>EDTA of 10 mM (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>EDTA of 10 mM (NO) inhibiting ligand activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>EDTA of 10 mM (NO) inhibiting ligand activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>EDTA of 10 mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>EDTA of 10 mM also has the ability to inhibit ligand in transient transfected T-cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>EDTA of 10 mM also inhibited ligand in transfected T-leukemia cells transfected.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>EDTA of 10 mM also inhibits ligand in transient transfected T-cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>EDTA of 10 mM also inhibits ligand in transiently transfected T-leukemia cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>EDTA of 10 mM can fully inhibit ligand that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>EDTA of 10 mM can inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>EDTA of 10 mM can totally inhibit ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>EDTA of 10 mM co-expression also has the ability to inhibit ligand in T-leukemia transnetly affected cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>EDTA of 10 mM fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>EDTA of 10 mM has also inhibited ligand in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>EDTA of 10 mM inhibited ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>EDTA of 10 mM inhibited ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>EDTA of 10 mM inhibits ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>EDTA of 10 mM inhibits ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>EDTA of 10 mM is able to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>EDTA of 10 mM may also have inhibited ligand in T cells affected by jurkat.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>EDTA of 10 mM may also have inhibited ligand in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>EDTA of 10 mM may have completely inhibited ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>EDTA of 10 mM may have completely inhibited ligand which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>EDTA of 10 mM may have inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>For example, P associated with This synthetic peptide can be inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>For example, P associated with This synthetic peptide can be inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>For example, P associated with This synthetic peptide has been inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>For example, P associated with This synthetic peptide has been inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>For example, P associated with This synthetic peptide is inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>For example, P associated with This synthetic peptide is inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>For example, P associated with This synthetic peptide may be inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>For example, P associated with This synthetic peptide may be inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>For example, P associated with This synthetic peptide may have been inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>For example, P associated with This synthetic peptide may have been inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>For example, P associated with This synthetic peptide was inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>For example, P associated with This synthetic peptide was inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>For example, P associated with this synthetic peptide can be inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>For example, P associated with this synthetic peptide has been inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>For example, P associated with this synthetic peptide is inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>For example, P associated with this synthetic peptide may be inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>For example, P associated with this synthetic peptide may have been inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>For example, P associated with this synthetic peptide was inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>For example, P is associated with This synthetic peptide and is therefore inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>For example, P is associated with This synthetic peptide and is therefore inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>For example, P is associated with this synthetic peptide and is therefore inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>For example, P may have been associated with This synthetic peptide and has therefore been inhibited in is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>For example, P may have been associated with This synthetic peptide and has therefore been inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>For example, P may have been associated with this synthetic peptide and has therefore been inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>For example, phosphatase associated with another protein can be inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>For example, phosphatase associated with another protein can be inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>For example, phosphatase associated with another protein has been inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>For example, phosphatase associated with another protein is inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>For example, phosphatase associated with another protein is inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>For example, phosphatase associated with another protein may be inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>For example, phosphatase associated with another protein may be inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>For example, phosphatase associated with another protein may have been inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>For example, phosphatase associated with another protein may have been inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>For example, phosphatase associated with another protein was inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>For example, phosphatase associated with another protein was inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>For example, phosphatase associated with other protein can be inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>For example, phosphatase associated with other protein can be inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>For example, phosphatase associated with other protein has been inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>For example, phosphatase associated with other protein has been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>For example, phosphatase associated with other protein has been inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>For example, phosphatase associated with other protein is inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>For example, phosphatase associated with other protein is inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>For example, phosphatase associated with other protein may be inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>For example, phosphatase associated with other protein may be inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>For example, phosphatase associated with other protein may be inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>For example, phosphatase associated with other protein may have been inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>For example, phosphatase associated with other protein may have been inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>For example, phosphatase associated with other protein was inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>For example, phosphatase associated with other protein was inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>For example, phosphatase associated with other protein was inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>For example, phosphatase is associated with another protein and is therefore inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>For example, phosphatase is associated with other protein and is therefore inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>For example, phosphatase is associated with other protein and is therefore inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>For example, phosphatase may have been associated with another protein and has therefore been inhibited in function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>For example, phosphatase may have been associated with another protein and has therefore been inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>For example, phosphatase may have been associated with other protein and has therefore been inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>For example, phosphatase may have been associated with other protein and has therefore been inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>For example, phosphatease associated with other protein can be inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>For example, phosphatease associated with other protein can be inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>For example, phosphatease associated with other protein can be inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>For example, phosphatease associated with other protein has been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>For example, phosphatease associated with other protein has been inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>For example, phosphatease associated with other protein is inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>For example, phosphatease associated with other protein is inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>For example, phosphatease associated with other protein may be inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>For example, phosphatease associated with other protein may be inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>For example, phosphatease associated with other protein may be inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>For example, phosphatease associated with other protein may have been inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>For example, phosphatease associated with other protein may have been inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>For example, phosphatease associated with other protein was inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>For example, phosphatease associated with other protein was inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>For example, phosphatease associated with other proteins can be inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>For example, phosphatease associated with other proteins has been inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>For example, phosphatease associated with other proteins is inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>For example, phosphatease associated with other proteins may have been inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>For example, phosphatease associated with other proteins was inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>For example, phosphatease is associated with other protein and is therefore inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>For example, phosphatease is associated with other protein and is therefore inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>For example, phosphatease is associated with other protein and is therefore inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>For example, phosphatease is associated with other proteins and is therefore inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>For example, phosphatease may have been associated with other protein and has therefore been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>For example, phosphatease may have been associated with other protein and has therefore been inhibited in the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>For example, phosphatease may have been associated with other protein and has therefore been inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>For example, phosphatease may have been associated with other proteins and has therefore been inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>GM132 proteasome inhibitors and laactacytin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>GM132 proteasome inhibitors and laactacytin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>GM132 proteasome inhibitors and laactacytin (NO) inhibiting negative regulation of Stat4, Stat5 and Stat6 phosphorylated activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>GM132 proteasome inhibitors and laactacytin (NO) inhibiting negative regulation of Stat4, Stat5 and Stat6 phosphorylated activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>GM132 proteasome inhibitors and laactacytin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>GM132 proteasome inhibitors and laactacytin also has the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transient transfected T-cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>GM132 proteasome inhibitors and laactacytin also inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transfected T-leukemia cells transfected.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>GM132 proteasome inhibitors and laactacytin also inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transient transfected T-cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>GM132 proteasome inhibitors and laactacytin also inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transiently transfected T-leukemia cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>GM132 proteasome inhibitors and laactacytin can fully inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>GM132 proteasome inhibitors and laactacytin can totally inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>GM132 proteasome inhibitors and laactacytin co-expression also has the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated in T-leukemia transnetly affected cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>GM132 proteasome inhibitors and laactacytin fully inhibiting concentration-dependent negative regulation of Stat4, Stat5 and Stat6 phosphorylated and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>GM132 proteasome inhibitors and laactacytin has also inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>GM132 proteasome inhibitors and laactacytin inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>GM132 proteasome inhibitors and laactacytin inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>GM132 proteasome inhibitors and laactacytin inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>GM132 proteasome inhibitors and laactacytin inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>GM132 proteasome inhibitors and laactacytin is able to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>GM132 proteasome inhibitors and laactacytin may also have inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated in T cells affected by jurkat.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>GM132 proteasome inhibitors and laactacytin may also have inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>GM132 proteasome inhibitors and laactacytin may have completely inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>GM132 proteasome inhibitors and laactacytin may have completely inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>GM132 proteasome inhibitors and laactacytin may have inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>GadW (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>GadW (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>GadW (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>GadW (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>GadW (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>GadW (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>GadW (NO) inhibiting GadX-dependent activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>GadW (NO) inhibiting GadX-dependent activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>GadW (NO) inhibiting GadX-dependent activation activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>GadW (NO) inhibiting GadX-dependent activation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>GadW (NO) inhibiting depending on GadX activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>GadW (NO) inhibiting depending on GadX activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>GadW activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>GadW activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>GadW activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>GadW also has the ability to inhibit GadX-dependent activation in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>GadW also has the ability to inhibit GadX-dependent in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>GadW also has the ability to inhibit depending on GadX in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>GadW also inhibited GadX-dependent activation in transfected T-leukemia cells transfected.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>GadW also inhibited GadX-dependent in transfected T-leukemia cells transfected.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>GadW also inhibited depending on GadX in transfected T-leukemia cells transfected.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>GadW also inhibits GadX-dependent activation in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>GadW also inhibits GadX-dependent activation in transiently transfected T-leukemia cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>GadW also inhibits GadX-dependent in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>GadW also inhibits GadX-dependent in transiently transfected T-leukemia cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>GadW also inhibits depending on GadX in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>GadW also inhibits depending on GadX in transiently transfected T-leukemia cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>GadW can fully inhibit GadX-dependent activation that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>GadW can fully inhibit GadX-dependent that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>GadW can fully inhibit depending on GadX that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>GadW can inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>GadW can inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>GadW can inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>GadW can totally inhibit GadX-dependent activation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>GadW can totally inhibit GadX-dependent that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>GadW can totally inhibit depending on GadX that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>GadW co-expression also has the ability to inhibit GadX-dependent activation in T-leukemia transnetly affected cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>GadW co-expression also has the ability to inhibit GadX-dependent in T-leukemia transnetly affected cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>GadW co-expression also has the ability to inhibit depending on GadX in T-leukemia transnetly affected cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>GadW fully inhibiting concentration-dependent GadX-dependent activation and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>GadW fully inhibiting concentration-dependent GadX-dependent and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>GadW fully inhibiting concentration-dependent depending on GadX and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>GadW has also inhibited GadX-dependent activation in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>GadW has also inhibited GadX-dependent in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>GadW has also inhibited depending on GadX in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>GadW inhibited GadX-dependent activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>GadW inhibited GadX-dependent activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>GadW inhibited GadX-dependent activation activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>GadW inhibited GadX-dependent activation activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>GadW inhibited depending on GadX activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>GadW inhibited depending on GadX activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>GadW inhibits GadX-dependent activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>GadW inhibits GadX-dependent activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>GadW inhibits GadX-dependent activation activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>GadW inhibits GadX-dependent activation activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>GadW inhibits depending on GadX activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>GadW inhibits depending on GadX activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>GadW is able to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>GadW is able to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>GadW is able to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>GadW may also have inhibited GadX-dependent activation in T cells affected by jurkat.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>GadW may also have inhibited GadX-dependent activation in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>GadW may also have inhibited GadX-dependent in T cells affected by jurkat.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>GadW may also have inhibited GadX-dependent in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>GadW may also have inhibited depending on GadX in T cells affected by jurkat.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>GadW may also have inhibited depending on GadX in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>GadW may have completely inhibited GadX-dependent activation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>GadW may have completely inhibited GadX-dependent activation which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>GadW may have completely inhibited GadX-dependent that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>GadW may have completely inhibited GadX-dependent which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>GadW may have completely inhibited depending on GadX that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>GadW may have completely inhibited depending on GadX which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>GadW may have inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>GadW may have inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>GadW may have inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10 mM EDTA inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10 mM EDTA inhibits ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10 mM EDTA is able to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10 mM EDTA may have inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10 mM EDTA may inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while AAM-3 expression inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while AAM-3 expression inhibits functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while AAM-3 expression is able to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while AAM-3 expression may have inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while AAM-3 expression may inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex inhibits activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex inhibits gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex is able to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex is able to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex may have inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex may have inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex may inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex may inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM inhibits binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM inhibits ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM is able to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM is able to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM may have inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM may have inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM may inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM may inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM inhibits binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM inhibits ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM is able to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM is able to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM may have inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM may have inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM may inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM may inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM inhibits ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM is able to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM may have inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM may inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GM132 proteasome inhibitors and laactacytin inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GM132 proteasome inhibitors and laactacytin inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GM132 proteasome inhibitors and laactacytin is able to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GM132 proteasome inhibitors and laactacytin may have inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GM132 proteasome inhibitors and laactacytin may inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW inhibits GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW inhibits depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW is able to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW is able to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may have inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 co-expression inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 co-expression is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 co-expression may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 co-expression may inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 expression may have inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 expression may inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAR expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAR expression inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAR expression is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAR expression may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAR expression may inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 co-expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 co-expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 co-expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 co-expression may have inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 co-expression may inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 may have inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 may inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 may inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity was inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity was inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibits late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may have inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while a proteasome MG132 inhibitor and lactacitstin inhibits the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while a proteasome MG132 inhibitor and lactacitstin is able to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while a proteasome MG132 inhibitor and lactacitstin may have inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while a proteasome MG132 inhibitor and lactacitstin may inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while activity promotionAp2 is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while activity promotionAp2 was inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while activity promotionAp2 will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine inhibits regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine is able to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine may have inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine may inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding was inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding was inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins is able to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins may have inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins may inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins may have inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins may inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and C-type superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and C-type superfamilies inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and C-type superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and C-type superfamilies may have inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and C-type superfamilies may inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies may have inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies may inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cellular surface receptors for immunoglobulin and C-type lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cellular surface receptors for immunoglobulin and C-type lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cellular surface receptors for immunoglobulin and C-type lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cellular surface receptors for immunoglobulin and C-type lectin may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cellular surface receptors for immunoglobulin and C-type lectin may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while chloramphenicol inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while chloramphenicol inhibits protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while chloramphenicol is able to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while chloramphenicol may have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while chloramphenicol may inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while co-expression of AAM-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while co-expression of AAM-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while co-expression of AAM-3 is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while co-expression of AAM-3 may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while co-expression of AAM-3 may inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cytotoxicity mediated by NK cells is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cytotoxicity mediated by NK cells will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while depending on GadX is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while depending on GadX was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while depending on GadX will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descending regulation of the phosphorylation status, state5 and state6 is inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descending regulation of the phosphorylation status, state5 and state6 was inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV plasmid reporter for p49/p65 was inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 was inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while gnAp2 promoting activity is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while gnAp2 promoting activity was inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while gnAp2 promoting activity will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while inhibitors of the MG132 proteasome and lactacyttin inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while inhibitors of the MG132 proteasome and lactacyttin inhibits the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while inhibitors of the MG132 proteasome and lactacyttin is able to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while inhibitors of the MG132 proteasome and lactacyttin may have inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while inhibitors of the MG132 proteasome and lactacyttin may inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand is inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand was inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand was inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand was inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand was inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand will be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina inhibits descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina is able to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina may have inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina may inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide inhibits platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide inhibits platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide is able to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide is able to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide may have inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide may have inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide may inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nitric oxide may inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while platelet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while platelet function was inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while platelet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while platquet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while platquet function was inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while platquet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacitstin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacitstin inhibits descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacitstin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacitstin may have inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacitstin may inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacyttin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacyttin inhibits descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacyttin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacyttin may have inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacyttin may inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacistin inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacistin inhibits reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacistin is able to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacistin may have inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacistin may inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while protein synthesis was inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while reduced regulation of Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while regulation of phosphorylated status, stage 5 and stage 6 was inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the CRP-cAMP complex inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the CRP-cAMP complex is able to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the CRP-cAMP complex may have inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the CRP-cAMP complex may inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is able to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is able to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the glnAp2 promoter activity is inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the glnAp2 promoter activity was inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the regulation of phosphorylated state, state5 and state6 is inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the regulation of phosphorylated state, state5 and state6 was inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10 mM EDTA inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10 mM EDTA inhibits ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10 mM EDTA is observed to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while AAM-3 expression inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="862">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while AAM-3 expression inhibits functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="863">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while AAM-3 expression is observed to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="864">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while CRP-cAMP complex inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="865">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while CRP-cAMP complex inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="866">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while CRP-cAMP complex inhibits activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="867">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while CRP-cAMP complex inhibits gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="868">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while CRP-cAMP complex is observed to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="869">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while CRP-cAMP complex is observed to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="870">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="871">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="872">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM inhibits binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="873">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM inhibits ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="874">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM is observed to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="875">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM is observed to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="876">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA 10mM inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="877">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA 10mM inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="878">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA 10mM inhibits binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="879">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA 10mM inhibits ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="880">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA 10mM is observed to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="881">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA 10mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="882">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA of 10 mM inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="883">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA of 10 mM inhibits ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="884">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA of 10 mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="885">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GM132 proteasome inhibitors and laactacytin inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="886">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GM132 proteasome inhibitors and laactacytin inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="887">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GM132 proteasome inhibitors and laactacytin is observed to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="888">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="889">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="890">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW inhibits GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="891">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW inhibits GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="892">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW is observed to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="893">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW is observed to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="894">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadX-dependent is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="895">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="896">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 co-expression inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="897">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 co-expression is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="898">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="899">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="900">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 expression is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="901">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAR expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="902">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAR expression inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="903">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAR expression is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="904">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 co-expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="905">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 co-expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="906">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 co-expression is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="907">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="908">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="909">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="910">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="911">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="912">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="913">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK cell-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="914">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK cell-mediated cytotoxicity is observed to be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="915">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK cell-mediated cytotoxicity is observed to be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="916">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="917">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="918">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="919">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="920">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="921">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibits late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="922">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="923">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="924">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while a proteasome MG132 inhibitor and lactacitstin inhibits the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="925">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while a proteasome MG132 inhibitor and lactacitstin is observed to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="926">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while activity promotionAp2 is observed to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="927">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="928">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while an inhibitor of the MG132 protein and lactacittine inhibits regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="929">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while an inhibitor of the MG132 protein and lactacittine is observed to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="930">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while binding is observed to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="931">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while binding is observed to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="932">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="933">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="934">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="935">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="936">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="937">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="938">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="939">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="940">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins is observed to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="941">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="942">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="943">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="944">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="945">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="946">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="947">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors of immunoglobulin and C-type superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="948">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors of immunoglobulin and C-type superfamilies inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="949">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors of immunoglobulin and C-type superfamilies is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="950">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="951">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="952">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="953">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cellular surface receptors for immunoglobulin and C-type lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="954">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cellular surface receptors for immunoglobulin and C-type lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="955">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cellular surface receptors for immunoglobulin and C-type lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="956">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while chloramphenicol inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="957">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while chloramphenicol inhibits protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="958">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while chloramphenicol is observed to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="959">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while co-expression of AAM-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="960">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while co-expression of AAM-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="961">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while co-expression of AAM-3 is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="962">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cytotoxicity mediated by NK cells is observed to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="963">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while depending on GadX is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="964">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while descendant regulation of phosphorylation state, state5 and state6 is observed to be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="965">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while descendant regulation of phosphorylation state, state5 and state6 is observed to be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="966">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while descending regulation of the phosphorylation status, state5 and state6 is observed to be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="967">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="968">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="969">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="970">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="971">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of an HIV plasmid reporter for p49/p65 is observed to be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="972">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="973">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="974">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="975">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while gnAp2 promoting activity is observed to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="976">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while inhibitors of the MG132 proteasome and lactacyttin inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="977">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while inhibitors of the MG132 proteasome and lactacyttin inhibits the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="978">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while inhibitors of the MG132 proteasome and lactacyttin is observed to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="979">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late clathrin coated vesicles formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="980">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late clathrin-coated vesicle formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="981">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late clathrin-coated vesicle formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="982">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late clathrin-coated vesicles formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="983">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late events of clathrin-coated vesicles formation is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="984">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while ligand is observed to be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="985">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while ligand is observed to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="986">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while ligand is observed to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="987">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while ligand is observed to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="988">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="989">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina inhibits descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="990">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina is observed to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="991">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while negative regulation of Stat4, Stat5 and Stat6 phosphorylated is observed to be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="992">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="993">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="994">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide inhibits platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="995">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide inhibits platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="996">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide is observed to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="997">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide is observed to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="998">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while platelet function is observed to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="999">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while platquet function is observed to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1000">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while primary proteasome inhibitors MG132 and lactacitstin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1001">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while primary proteasome inhibitors MG132 and lactacitstin inhibits descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1002">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while primary proteasome inhibitors MG132 and lactacitstin is observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1003">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while primary proteasome inhibitors MG132 and lactacyttin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1004">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while primary proteasome inhibitors MG132 and lactacyttin inhibits descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1005">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while primary proteasome inhibitors MG132 and lactacyttin is observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1006">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while proteasome inhibitors MG132 and lactacistin inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1007">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while proteasome inhibitors MG132 and lactacistin inhibits reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1008">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while proteasome inhibitors MG132 and lactacistin is observed to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1009">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1010">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while reduced regulation of Stat4, Stat5 and Stat6 is observed to be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1011">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while regulation of phosphorylated status, stage 5 and stage 6 is observed to be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1012">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the CRP-cAMP complex inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1013">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1014">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the CRP-cAMP complex is observed to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1015">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1016">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1017">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1018">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1019">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1020">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is observed to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1021">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1022">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1023">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1024">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1025">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is observed to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1026">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1027">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the glnAp2 promoter activity is observed to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1028">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the regulation of phosphorylated state, state5 and state6 is observed to be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1029">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the regulation of the phosphorylated state, Stat5 and Stat6 is observed to be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1030">
                    <text>GadX-dependent activation are inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1031">
                    <text>GadX-dependent activation can be inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1032">
                    <text>GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1033">
                    <text>GadX-dependent activation in Jurkat T-leukemia transfect cells has also been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1034">
                    <text>GadX-dependent activation in T cells of Jurkat transfects is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1035">
                    <text>GadX-dependent activation in T-lycemic cells transfected, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1036">
                    <text>GadX-dependent activation in transfectuously affected T-leukemia cells, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1037">
                    <text>GadX-dependent activation in transiently transfected Jurkat T-cells is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1038">
                    <text>GadX-dependent activation in transiently transfected Jurkat T-cells was also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1039">
                    <text>GadX-dependent activation is a dependent and saturable concentration and can be fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1040">
                    <text>GadX-dependent activation is a dependent and saturable concentration and can be totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1041">
                    <text>GadX-dependent activation is a dependent and saturable concentration and has been totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1042">
                    <text>GadX-dependent activation is a dependent and saturable concentration and is able to be fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1043">
                    <text>GadX-dependent activation is a dependent and saturable concentration and is fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1044">
                    <text>GadX-dependent activation is a dependent and saturable concentration and is observed to be totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1045">
                    <text>GadX-dependent activation is a dependent and saturable concentration and was fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1046">
                    <text>GadX-dependent activation is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1047">
                    <text>GadX-dependent activation is capable of being inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1048">
                    <text>GadX-dependent activation is capable of being inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1049">
                    <text>GadX-dependent activation is concentration-dependent and saturable and is able to be fully inhibited with GadW , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1050">
                    <text>GadX-dependent activation is inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1051">
                    <text>GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1052">
                    <text>GadX-dependent activation is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1053">
                    <text>GadX-dependent activation may have been inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1054">
                    <text>GadX-dependent activation was inhibited by GadW that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1055">
                    <text>GadX-dependent activation was inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1056">
                    <text>GadX-dependent activation was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1057">
                    <text>GadX-dependent activation will be inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1058">
                    <text>GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1059">
                    <text>GadX-dependent are inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1060">
                    <text>GadX-dependent can be inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1061">
                    <text>GadX-dependent has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1062">
                    <text>GadX-dependent in Jurkat T-leukemia transfect cells has also been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1063">
                    <text>GadX-dependent in T cells of Jurkat transfects is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1064">
                    <text>GadX-dependent in T-lycemic cells transfected, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1065">
                    <text>GadX-dependent in transfectuously affected T-leukemia cells, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1066">
                    <text>GadX-dependent in transiently transfected Jurkat T-cells is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1067">
                    <text>GadX-dependent in transiently transfected Jurkat T-cells was also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1068">
                    <text>GadX-dependent is a dependent and saturable concentration and can be fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1069">
                    <text>GadX-dependent is a dependent and saturable concentration and can be totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1070">
                    <text>GadX-dependent is a dependent and saturable concentration and has been totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1071">
                    <text>GadX-dependent is a dependent and saturable concentration and is able to be fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1072">
                    <text>GadX-dependent is a dependent and saturable concentration and is fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1073">
                    <text>GadX-dependent is a dependent and saturable concentration and is observed to be totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1074">
                    <text>GadX-dependent is a dependent and saturable concentration and was fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1075">
                    <text>GadX-dependent is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1076">
                    <text>GadX-dependent is capable of being inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1077">
                    <text>GadX-dependent is capable of being inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1078">
                    <text>GadX-dependent is concentration-dependent and saturable and is able to be fully inhibited with GadW , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1079">
                    <text>GadX-dependent is inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1080">
                    <text>GadX-dependent is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1081">
                    <text>GadX-dependent is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1082">
                    <text>GadX-dependent may have been inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1083">
                    <text>GadX-dependent was inhibited by GadW that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1084">
                    <text>GadX-dependent was inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1085">
                    <text>GadX-dependent was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1086">
                    <text>GadX-dependent will be inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1087">
                    <text>GadX-dependent will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1088">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA can inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1089">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA has inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1090">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA has the ability to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1091">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1092">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA will inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1093">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression can inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1094">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression has inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1095">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression has the ability to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1096">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1097">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression will inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1098">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex can inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1099">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex can inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1100">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex has inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1101">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex has inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1102">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex has the ability to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1103">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex has the ability to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1104">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1105">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex will inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1106">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex will inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1107">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM can inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1108">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM can inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1109">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM has inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1110">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM has inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1111">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM has the ability to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1112">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM has the ability to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1113">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1114">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1115">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM will inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1116">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM will inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1117">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM can inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1118">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM can inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1119">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM has inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1120">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM has inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1121">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM has the ability to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1122">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1123">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1124">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1125">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM will inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1126">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM will inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1127">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM can inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1128">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM has inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1129">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1130">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1131">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM will inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1132">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin can inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1133">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin has inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1134">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin has the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1135">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1136">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin will inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1137">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW can inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1138">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW can inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1139">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW can inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1140">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1141">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1142">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1143">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1144">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has the ability to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1145">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has the ability to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1146">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1147">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1148">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1149">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW will inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1150">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW will inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1151">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW will inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1152">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent activation can be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1153">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1154">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1155">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1156">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent can be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1157">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1158">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1159">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1160">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1161">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression has inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1162">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1163">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1164">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression will inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1165">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression can inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1166">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression has inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1167">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1168">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1169">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression will inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1170">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAR expression can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1171">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAR expression has inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1172">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAR expression has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1173">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAR expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1174">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAR expression will inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1175">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1176">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 can inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1177">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression can inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1178">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression has inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1179">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1180">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1181">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression will inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1182">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 has inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1183">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 has inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1184">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1185">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1186">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1187">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1188">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 will inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1189">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 will inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1190">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1191">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity can be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1192">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity can be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1193">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1194">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1195">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1196">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1197">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1198">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1199">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1200">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1201">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1202">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1203">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1204">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity can be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1205">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity can be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1206">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1207">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1208">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1209">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1210">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1211">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1212">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1213">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1214">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1215">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1216">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1217">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1218">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Roipram can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="1219">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Roipram inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="1220">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Roipram inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="1221">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Roipram inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="1222">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Roipram inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="1223">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I can inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1224">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I has inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1225">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1226">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1227">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I will inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1228">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin can inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1229">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin has inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1230">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin has the ability to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1231">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1232">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin will inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1233">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that activity promotionAp2 can be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1234">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that activity promotionAp2 has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1235">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that activity promotionAp2 is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1236">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that activity promotionAp2 will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1237">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine can inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1238">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine has inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1239">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1240">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1241">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine will inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1242">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding can be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1243">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding can be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1244">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1245">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding has been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1246">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1247">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1248">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1249">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1250">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1251">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1252">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1253">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1254">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1255">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1256">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins can inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1257">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1258">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins has inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1259">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1260">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins has the ability to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1261">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1262">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1263">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1264">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins will inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1265">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins can inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1266">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins has inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1267">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1268">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1269">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins will inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1270">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1271">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1272">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1273">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1274">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1275">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies can inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1276">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies has inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1277">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1278">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1279">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies will inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1280">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies can inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1281">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies has inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1282">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1283">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1284">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies will inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1285">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1286">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1287">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1288">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1289">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1290">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol can inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1291">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol has inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1292">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1293">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1294">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol will inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1295">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1296">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 has inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1297">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1298">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1299">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 will inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1300">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cytotoxicity mediated by NK cells can be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1301">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cytotoxicity mediated by NK cells has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1302">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cytotoxicity mediated by NK cells is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1303">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cytotoxicity mediated by NK cells will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1304">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that depending on GadX can be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1305">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that depending on GadX has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1306">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that depending on GadX is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1307">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that depending on GadX will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1308">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 can be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1309">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 can be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1310">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1311">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1312">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1313">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1314">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1315">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1316">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 can be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1317">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 has been inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1318">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 is inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1319">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1320">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1321">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1322">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1323">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1324">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1325">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1326">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1327">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1328">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1329">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1330">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1331">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1332">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1333">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1334">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1335">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1336">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 can be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1337">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 has been inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1338">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1339">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1340">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1341">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1342">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1343">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1344">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1345">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1346">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1347">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1348">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1349">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1350">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1351">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1352">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that gnAp2 promoting activity can be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1353">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that gnAp2 promoting activity has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1354">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that gnAp2 promoting activity is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1355">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that gnAp2 promoting activity will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1356">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin can inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1357">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin has inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1358">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin has the ability to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1359">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1360">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin will inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1361">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin coated vesicles formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1362">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1363">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1364">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1365">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1366">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1367">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1368">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1369">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1370">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1371">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1372">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1373">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicles formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1374">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1375">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1376">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1377">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1378">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1379">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1380">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1381">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1382">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1383">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1384">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1385">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand has been inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1386">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1387">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand has been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1388">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand has been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1389">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand is inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1390">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1391">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1392">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1393">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand will be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1394">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1395">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1396">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1397">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina can inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1398">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina has inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1399">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina has the ability to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1400">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1401">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina will inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1402">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated can be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1403">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated has been inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1404">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1405">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1406">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="1407">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide can inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1408">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide can inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1409">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide has inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1410">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide has inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1411">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide has the ability to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1412">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide has the ability to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1413">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="1414">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="1415">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1416">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1417">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="1418">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="1419">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide will inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1420">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide will inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1421">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platelet function can be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1422">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platelet function has been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1423">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platelet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1424">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platelet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1425">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platquet function can be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1426">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platquet function has been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1427">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platquet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1428">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platquet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1429">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin can inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1430">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin has inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1431">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1432">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1433">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin will inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1434">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin can inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1435">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin has inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1436">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1437">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1438">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin will inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1439">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin can inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1440">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin has inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1441">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin has the ability to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1442">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1443">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin will inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1444">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected cells can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1445">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected cells inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1446">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected cells inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1447">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1448">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected cells inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1449">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of infected body cells can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1450">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of infected body cells inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1451">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of infected body cells inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1452">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of infected body cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1453">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of infected body cells inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1454">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of the transfected body cells can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1455">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of the transfected body cells inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1456">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of the transfected body cells inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1457">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of the transfected body cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1458">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of the transfected body cells inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="1459">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of transfected cells can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1460">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of transfected cells inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1461">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of transfected cells inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1462">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of transfected cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1463">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of transfected cells inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="1464">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein synthesis can be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1465">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein synthesis has been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1466">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1467">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1468">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 can be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1469">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1470">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1471">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1472">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 can be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1473">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 has been inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1474">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1475">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1476">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1477">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1478">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1479">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1480">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1481">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1482">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has the ability to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1483">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1484">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1485">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I will inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1486">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I will inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1487">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1488">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1489">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1490">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1491">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has the ability to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1492">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1493">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1494">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1495">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I will inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1496">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I will inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1497">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 can be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1498">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 has been inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1499">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 is inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1500">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1501">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 can be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1502">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 has been inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1503">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1504">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1505">
                    <text>Here, we have found that GadX-dependent activation has been inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1506">
                    <text>Here, we have found that GadX-dependent activation is inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1507">
                    <text>Here, we have found that GadX-dependent activation will be inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1508">
                    <text>Here, we have found that GadX-dependent has been inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1509">
                    <text>Here, we have found that GadX-dependent is inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1510">
                    <text>Here, we have found that GadX-dependent will be inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1511">
                    <text>Here, we have found that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1512">
                    <text>Here, we have found that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1513">
                    <text>Here, we have found that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1514">
                    <text>Here, we have found that NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1515">
                    <text>Here, we have found that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1516">
                    <text>Here, we have found that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1517">
                    <text>Here, we have found that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1518">
                    <text>Here, we have found that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1519">
                    <text>Here, we have found that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1520">
                    <text>Here, we have found that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1521">
                    <text>Here, we have found that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1522">
                    <text>Here, we have found that NK-mediated cytotoxicity has been inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1523">
                    <text>Here, we have found that NK-mediated cytotoxicity has been inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1524">
                    <text>Here, we have found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1525">
                    <text>Here, we have found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1526">
                    <text>Here, we have found that NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1527">
                    <text>Here, we have found that NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1528">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1529">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1530">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1531">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1532">
                    <text>Here, we have found that activity promotionAp2 has been inhibited by CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1533">
                    <text>Here, we have found that activity promotionAp2 is inhibited by CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1534">
                    <text>Here, we have found that activity promotionAp2 will be inhibited by CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1535">
                    <text>Here, we have found that binding has been inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1536">
                    <text>Here, we have found that binding has been inhibited by EDTA 10mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1537">
                    <text>Here, we have found that binding is inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1538">
                    <text>Here, we have found that binding is inhibited by EDTA 10mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1539">
                    <text>Here, we have found that binding will be inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1540">
                    <text>Here, we have found that binding will be inhibited by EDTA 10mM, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1541">
                    <text>Here, we have found that cytotoxicity mediated by NK cells has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1542">
                    <text>Here, we have found that cytotoxicity mediated by NK cells is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1543">
                    <text>Here, we have found that cytotoxicity mediated by NK cells will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1544">
                    <text>Here, we have found that depending on GadX has been inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1545">
                    <text>Here, we have found that depending on GadX is inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1546">
                    <text>Here, we have found that depending on GadX will be inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1547">
                    <text>Here, we have found that descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacyttin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1548">
                    <text>Here, we have found that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1549">
                    <text>Here, we have found that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1550">
                    <text>Here, we have found that descending regulation of the phosphorylation status, state5 and state6 has been inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1551">
                    <text>Here, we have found that descending regulation of the phosphorylation status, state5 and state6 is inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1552">
                    <text>Here, we have found that descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1553">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAD-3 co-expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1554">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAR expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1555">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1556">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by co-expression of AAM-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1557">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAD-3 co-expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1558">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1559">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1560">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1561">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1562">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAR expression, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1563">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1564">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1565">
                    <text>Here, we have found that functional activation of an HIV plasmid reporter for p49/p65 has been inhibited by AAM-3 expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1566">
                    <text>Here, we have found that functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1567">
                    <text>Here, we have found that functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1568">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by MAD-3 expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1569">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3 co-expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1570">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1571">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1572">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1573">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1574">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by MAD-3 expression, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1575">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1576">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1577">
                    <text>Here, we have found that gnAp2 promoting activity has been inhibited by CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1578">
                    <text>Here, we have found that gnAp2 promoting activity is inhibited by CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1579">
                    <text>Here, we have found that gnAp2 promoting activity will be inhibited by CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1580">
                    <text>Here, we have found that late clathrin coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1581">
                    <text>Here, we have found that late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1582">
                    <text>Here, we have found that late clathrin coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1583">
                    <text>Here, we have found that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1584">
                    <text>Here, we have found that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1585">
                    <text>Here, we have found that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1586">
                    <text>Here, we have found that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1587">
                    <text>Here, we have found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1588">
                    <text>Here, we have found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1589">
                    <text>Here, we have found that late clathrin-coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1590">
                    <text>Here, we have found that late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1591">
                    <text>Here, we have found that late clathrin-coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1592">
                    <text>Here, we have found that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1593">
                    <text>Here, we have found that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1594">
                    <text>Here, we have found that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1595">
                    <text>Here, we have found that ligand has been inhibited by 10 mM EDTA, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1596">
                    <text>Here, we have found that ligand has been inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1597">
                    <text>Here, we have found that ligand has been inhibited by EDTA 10mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1598">
                    <text>Here, we have found that ligand has been inhibited by EDTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1599">
                    <text>Here, we have found that ligand is inhibited by 10 mM EDTA, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1600">
                    <text>Here, we have found that ligand is inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1601">
                    <text>Here, we have found that ligand is inhibited by EDTA 10mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1602">
                    <text>Here, we have found that ligand is inhibited by EDTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1603">
                    <text>Here, we have found that ligand will be inhibited by 10 mM EDTA, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1604">
                    <text>Here, we have found that ligand will be inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1605">
                    <text>Here, we have found that ligand will be inhibited by EDTA 10mM, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1606">
                    <text>Here, we have found that ligand will be inhibited by EDTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1607">
                    <text>Here, we have found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated has been inhibited by GM132 proteasome inhibitors and laactacytin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1608">
                    <text>Here, we have found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1609">
                    <text>Here, we have found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1610">
                    <text>Here, we have found that platelet function has been inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1611">
                    <text>Here, we have found that platelet function is inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1612">
                    <text>Here, we have found that platelet function will be inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1613">
                    <text>Here, we have found that platquet function has been inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1614">
                    <text>Here, we have found that platquet function is inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1615">
                    <text>Here, we have found that platquet function will be inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1616">
                    <text>Here, we have found that protein synthesis has been inhibited by chloramphenicol, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1617">
                    <text>Here, we have found that protein synthesis is inhibited by chloramphenicol, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1618">
                    <text>Here, we have found that protein synthesis will be inhibited by chloramphenicol, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1619">
                    <text>Here, we have found that reduced regulation of Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacistin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1620">
                    <text>Here, we have found that reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1621">
                    <text>Here, we have found that reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacistin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1622">
                    <text>Here, we have found that regulation of phosphorylated status, stage 5 and stage 6 has been inhibited by an inhibitor of the MG132 protein and lactacittine, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1623">
                    <text>Here, we have found that regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1624">
                    <text>Here, we have found that regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1625">
                    <text>Here, we have found that the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1626">
                    <text>Here, we have found that the glnAp2 promoter activity is inhibited by the CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1627">
                    <text>Here, we have found that the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1628">
                    <text>Here, we have found that the regulation of phosphorylated state, state5 and state6 has been inhibited by a proteasome MG132 inhibitor and lactacitstin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1629">
                    <text>Here, we have found that the regulation of phosphorylated state, state5 and state6 is inhibited by a proteasome MG132 inhibitor and lactacitstin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1630">
                    <text>Here, we have found that the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1631">
                    <text>Here, we have found that the regulation of the phosphorylated state, Stat5 and Stat6 has been inhibited by inhibitors of the MG132 proteasome and lactacyttin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1632">
                    <text>Here, we have found that the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by inhibitors of the MG132 proteasome and lactacyttin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1633">
                    <text>Here, we have found that the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by inhibitors of the MG132 proteasome and lactacyttin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1634">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10 mM EDTA has the ability to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1635">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10 mM EDTA is able to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1636">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10 mM EDTA is observed to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1637">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that AAM-3 expression has the ability to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1638">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that AAM-3 expression is able to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1639">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that AAM-3 expression is observed to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1640">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that CRP-cAMP complex has the ability to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1641">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that CRP-cAMP complex is able to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1642">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that CRP-cAMP complex is observed to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1643">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that DTA of 10 mM has the ability to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1644">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that DTA of 10 mM has the ability to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1645">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that DTA of 10 mM is able to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1646">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that DTA of 10 mM is able to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1647">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that DTA of 10 mM is observed to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1648">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that DTA of 10 mM is observed to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1649">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM has the ability to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1650">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1651">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM is able to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1652">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM is able to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1653">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM is observed to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1654">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1655">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA of 10 mM has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1656">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA of 10 mM is able to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1657">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA of 10 mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1658">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin has the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1659">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin is able to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1660">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin is observed to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1661">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW has the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1662">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW has the ability to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1663">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW has the ability to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1664">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is able to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1665">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is able to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1666">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is able to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1667">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1668">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is observed to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1669">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is observed to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1670">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1671">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1672">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1673">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1674">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1675">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1676">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1677">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1678">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAD-3 co-expression has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1679">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAD-3 co-expression is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1680">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAD-3 co-expression is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1681">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAD-3 expression has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1682">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAD-3 expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1683">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAD-3 expression is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1684">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAR expression has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1685">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAR expression is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1686">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAR expression is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1687">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 co-expression has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1688">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 co-expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1689">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 co-expression is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1690">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1691">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1692">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1693">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1694">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1695">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1696">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1697">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1698">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1699">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1700">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity is able to be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1701">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity is able to be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1702">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1703">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1704">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1705">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1706">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1707">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1708">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1709">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1710">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1711">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1712">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1713">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1714">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1715">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1716">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1717">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1718">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1719">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1720">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1721">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1722">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1723">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1724">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1725">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1726">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1727">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin has the ability to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1728">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin is able to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1729">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin is observed to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1730">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that activity promotionAp2 has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1731">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that activity promotionAp2 is able to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1732">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that activity promotionAp2 is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1733">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that activity promotionAp2 will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1734">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1735">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine is able to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1736">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine is observed to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1737">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1738">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding has been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1739">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding is able to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1740">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding is able to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1741">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1742">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1743">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1744">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1745">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1746">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1747">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1748">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1749">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins has the ability to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1750">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1751">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins is able to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1752">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1753">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins is observed to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1754">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1755">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1756">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1757">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1758">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1759">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1760">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1761">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1762">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1763">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1764">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1765">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1766">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1767">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1768">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1769">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1770">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol is able to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1771">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol is observed to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1772">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that co-expression of AAM-3 has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1773">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that co-expression of AAM-3 is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1774">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that co-expression of AAM-3 is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1775">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cytotoxicity mediated by NK cells has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1776">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cytotoxicity mediated by NK cells is able to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1777">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cytotoxicity mediated by NK cells is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1778">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cytotoxicity mediated by NK cells will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="1779">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that depending on GadX has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1780">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that depending on GadX is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1781">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that depending on GadX is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1782">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that depending on GadX will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1783">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1784">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1785">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 is able to be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1786">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 is able to be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1787">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1788">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1789">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1790">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1791">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 has been inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1792">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 is able to be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1793">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 is inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1794">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1795">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1796">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1797">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1798">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1799">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1800">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1801">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1802">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1803">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1804">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1805">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1806">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1807">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1808">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1809">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1810">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1811">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 has been inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1812">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 is able to be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1813">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1814">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1815">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1816">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1817">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1818">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1819">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1820">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1821">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1822">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1823">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1824">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1825">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1826">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1827">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin has the ability to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1828">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin is able to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1829">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin is observed to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1830">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1831">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin coated vesicles formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1832">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1833">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1834">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1835">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1836">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1837">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1838">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1839">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1840">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1841">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1842">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1843">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicles formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1844">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1845">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1846">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1847">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation is able to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1848">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1849">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1850">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand has been inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1851">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1852">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand has been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1853">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand has been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1854">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is able to be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1855">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is able to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1856">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is able to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1857">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is able to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1858">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1859">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1860">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1861">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1862">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand will be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1863">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1864">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1865">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1866">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina has the ability to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1867">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina is able to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1868">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina is observed to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1869">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated has been inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1870">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated is able to be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1871">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1872">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1873">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide has the ability to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1874">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide has the ability to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1875">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide is able to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1876">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide is able to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1877">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide is observed to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1878">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide is observed to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1879">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function has been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1880">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function is able to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1881">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1882">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="1883">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platquet function has been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1884">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platquet function is able to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1885">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platquet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1886">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platquet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="1887">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1888">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1889">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin is observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1890">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1891">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1892">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin is observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1893">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin has the ability to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1894">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin is able to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1895">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin is observed to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1896">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis has been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1897">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis is able to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1898">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1899">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="1900">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1901">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 is able to be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1902">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1903">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1904">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 has been inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1905">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 is able to be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1906">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1907">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1908">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex has the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1909">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex is able to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1910">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex is observed to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1911">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1912">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has the ability to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1913">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1914">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is able to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1915">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1916">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is observed to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1917">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has the ability to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1918">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1919">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is able to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1920">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1921">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is observed to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="1922">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="1923">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1924">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity is able to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1925">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity is inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1926">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="1927">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 has been inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1928">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 is able to be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1929">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 is inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1930">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1931">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 has been inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1932">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 is able to be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1933">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1934">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="1935">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1936">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibits ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1937">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA is observed to inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1938">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1939">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression inhibits functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1940">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression is observed to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1941">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1942">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1943">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibits activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1944">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibits gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1945">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex is observed to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="1946">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex is observed to inhibit gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="1947">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1948">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1949">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM inhibits binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1950">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM inhibits ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1951">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM is observed to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1952">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM is observed to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1953">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1954">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibited ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1955">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibits binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1956">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibits ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1957">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM is observed to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="1958">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1959">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1960">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibits ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1961">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="1962">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1963">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1964">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin is observed to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="1965">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1966">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1967">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1968">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW inhibits GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1969">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW inhibits GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1970">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW inhibits depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1971">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW is observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="1972">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW is observed to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="1973">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that GadW is observed to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="1974">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1975">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1976">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1977">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1978">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1979">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAD-3 expression is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1980">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAR expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1981">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAR expression inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1982">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAR expression is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1983">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1984">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1985">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1986">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1987">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1988">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1989">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1990">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="1991">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 is observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="1992">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1993">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibits late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1994">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="1995">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1996">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin inhibits the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1997">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin is observed to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="1998">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="1999">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine inhibits regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2000">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine is observed to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2001">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2002">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2003">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2004">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2005">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2006">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2007">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2008">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2009">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins is observed to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2010">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2011">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2012">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2013">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2014">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2015">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2016">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2017">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2018">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2019">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2020">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2021">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies is observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2022">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2023">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2024">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2025">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="2026">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol inhibits protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="2027">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol is observed to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="2028">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2029">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2030">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 is observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2031">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2032">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin inhibits the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2033">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin is observed to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2034">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2035">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina inhibits descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2036">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina is observed to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2037">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2038">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2039">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibits platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2040">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibits platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2041">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nitric oxide is observed to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2042">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nitric oxide is observed to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2043">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2044">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin inhibits descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2045">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin is observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2046">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2047">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin inhibits descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2048">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin is observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2049">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2050">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin inhibits reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2051">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin is observed to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2052">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2053">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2054">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2055">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2056">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2057">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is observed to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2058">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2059">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2060">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2061">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2062">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is observed to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2063">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2064">
                    <text>In this study, we found that GadX-dependent activation will be inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2065">
                    <text>In this study, we found that GadX-dependent will be inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2066">
                    <text>In this study, we found that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2067">
                    <text>In this study, we found that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2068">
                    <text>In this study, we found that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2069">
                    <text>In this study, we found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2070">
                    <text>In this study, we found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2071">
                    <text>In this study, we found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2072">
                    <text>In this study, we found that NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2073">
                    <text>In this study, we found that activity promotionAp2 will be inhibited by CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2074">
                    <text>In this study, we found that binding will be inhibited by DTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2075">
                    <text>In this study, we found that binding will be inhibited by EDTA 10mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2076">
                    <text>In this study, we found that cytotoxicity mediated by NK cells will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2077">
                    <text>In this study, we found that depending on GadX will be inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2078">
                    <text>In this study, we found that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2079">
                    <text>In this study, we found that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2080">
                    <text>In this study, we found that descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2081">
                    <text>In this study, we found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2082">
                    <text>In this study, we found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAR expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2083">
                    <text>In this study, we found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2084">
                    <text>In this study, we found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2085">
                    <text>In this study, we found that functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2086">
                    <text>In this study, we found that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by MAD-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2087">
                    <text>In this study, we found that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2088">
                    <text>In this study, we found that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2089">
                    <text>In this study, we found that gnAp2 promoting activity will be inhibited by CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2090">
                    <text>In this study, we found that late clathrin coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2091">
                    <text>In this study, we found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2092">
                    <text>In this study, we found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2093">
                    <text>In this study, we found that late clathrin-coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2094">
                    <text>In this study, we found that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2095">
                    <text>In this study, we found that ligand will be inhibited by 10 mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2096">
                    <text>In this study, we found that ligand will be inhibited by DTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2097">
                    <text>In this study, we found that ligand will be inhibited by EDTA 10mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2098">
                    <text>In this study, we found that ligand will be inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2099">
                    <text>In this study, we found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2100">
                    <text>In this study, we found that platelet function will be inhibited by nitric oxide, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2101">
                    <text>In this study, we found that platquet function will be inhibited by nitric oxide, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2102">
                    <text>In this study, we found that protein synthesis will be inhibited by chloramphenicol, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="2103">
                    <text>In this study, we found that regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2104">
                    <text>In this study, we found that the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2105">
                    <text>In this study, we found that the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2106">
                    <text>In this study, we found that the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by inhibitors of the MG132 proteasome and lactacyttin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2107">
                    <text>In this work, we found that GadX-dependent activation is inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2108">
                    <text>In this work, we found that GadX-dependent activation was inhibited by GadW, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2109">
                    <text>In this work, we found that GadX-dependent activation was inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2110">
                    <text>In this work, we found that GadX-dependent is inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2111">
                    <text>In this work, we found that GadX-dependent was inhibited by GadW, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2112">
                    <text>In this work, we found that GadX-dependent was inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2113">
                    <text>In this work, we found that NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2114">
                    <text>In this work, we found that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2115">
                    <text>In this work, we found that NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2116">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2117">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2118">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2119">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2120">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2121">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2122">
                    <text>In this work, we found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2123">
                    <text>In this work, we found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2124">
                    <text>In this work, we found that NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2125">
                    <text>In this work, we found that NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2126">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2127">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2128">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2129">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2130">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2131">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2132">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2133">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2134">
                    <text>In this work, we found that activity promotionAp2 is inhibited by CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2135">
                    <text>In this work, we found that activity promotionAp2 was inhibited by CRP-cAMP complex, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2136">
                    <text>In this work, we found that activity promotionAp2 was inhibited by CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2137">
                    <text>In this work, we found that binding is inhibited by DTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2138">
                    <text>In this work, we found that binding is inhibited by EDTA 10mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2139">
                    <text>In this work, we found that binding was inhibited by DTA of 10 mM, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2140">
                    <text>In this work, we found that binding was inhibited by DTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2141">
                    <text>In this work, we found that binding was inhibited by EDTA 10mM, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2142">
                    <text>In this work, we found that binding was inhibited by EDTA 10mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2143">
                    <text>In this work, we found that cytotoxicity mediated by NK cells is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2144">
                    <text>In this work, we found that cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2145">
                    <text>In this work, we found that cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2146">
                    <text>In this work, we found that depending on GadX is inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2147">
                    <text>In this work, we found that depending on GadX was inhibited by GadW, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2148">
                    <text>In this work, we found that depending on GadX was inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2149">
                    <text>In this work, we found that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2150">
                    <text>In this work, we found that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacyttin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2151">
                    <text>In this work, we found that descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacitstin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2152">
                    <text>In this work, we found that descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2153">
                    <text>In this work, we found that descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2154">
                    <text>In this work, we found that descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2155">
                    <text>In this work, we found that descending regulation of the phosphorylation status, state5 and state6 is inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2156">
                    <text>In this work, we found that descending regulation of the phosphorylation status, state5 and state6 was inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2157">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAD-3 co-expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2158">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2159">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2160">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2161">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAD-3 co-expression, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2162">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAD-3 co-expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2163">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2164">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2165">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2166">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2167">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by co-expression of AAM-3, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2168">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by co-expression of AAM-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2169">
                    <text>In this work, we found that functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2170">
                    <text>In this work, we found that functional activation of an HIV plasmid reporter for p49/p65 was inhibited by AAM-3 expression, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2171">
                    <text>In this work, we found that functional activation of an HIV plasmid reporter for p49/p65 was inhibited by AAM-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2172">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2173">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2174">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2175">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 was inhibited by MAD-3 expression, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2176">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 was inhibited by MAD-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2177">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 co-expression, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2178">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 co-expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2179">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2180">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2181">
                    <text>In this work, we found that gnAp2 promoting activity is inhibited by CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2182">
                    <text>In this work, we found that gnAp2 promoting activity was inhibited by CRP-cAMP complex, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2183">
                    <text>In this work, we found that gnAp2 promoting activity was inhibited by CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2184">
                    <text>In this work, we found that late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2185">
                    <text>In this work, we found that late clathrin coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2186">
                    <text>In this work, we found that late clathrin coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2187">
                    <text>In this work, we found that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2188">
                    <text>In this work, we found that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2189">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2190">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2191">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2192">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2193">
                    <text>In this work, we found that late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2194">
                    <text>In this work, we found that late clathrin-coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2195">
                    <text>In this work, we found that late clathrin-coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2196">
                    <text>In this work, we found that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2197">
                    <text>In this work, we found that late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2198">
                    <text>In this work, we found that late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2199">
                    <text>In this work, we found that ligand is inhibited by 10 mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2200">
                    <text>In this work, we found that ligand is inhibited by DTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2201">
                    <text>In this work, we found that ligand is inhibited by EDTA 10mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2202">
                    <text>In this work, we found that ligand is inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2203">
                    <text>In this work, we found that ligand was inhibited by 10 mM EDTA, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2204">
                    <text>In this work, we found that ligand was inhibited by 10 mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2205">
                    <text>In this work, we found that ligand was inhibited by DTA of 10 mM, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2206">
                    <text>In this work, we found that ligand was inhibited by DTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2207">
                    <text>In this work, we found that ligand was inhibited by EDTA 10mM, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2208">
                    <text>In this work, we found that ligand was inhibited by EDTA 10mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2209">
                    <text>In this work, we found that ligand was inhibited by EDTA of 10 mM, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2210">
                    <text>In this work, we found that ligand was inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2211">
                    <text>In this work, we found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2212">
                    <text>In this work, we found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by GM132 proteasome inhibitors and laactacytin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2213">
                    <text>In this work, we found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by GM132 proteasome inhibitors and laactacytin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2214">
                    <text>In this work, we found that platelet function is inhibited by nitric oxide, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2215">
                    <text>In this work, we found that platelet function was inhibited by nitric oxide, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2216">
                    <text>In this work, we found that platelet function was inhibited by nitric oxide, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2217">
                    <text>In this work, we found that platquet function is inhibited by nitric oxide, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2218">
                    <text>In this work, we found that platquet function was inhibited by nitric oxide, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2219">
                    <text>In this work, we found that platquet function was inhibited by nitric oxide, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2220">
                    <text>In this work, we found that protein synthesis is inhibited by chloramphenicol, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="2221">
                    <text>In this work, we found that protein synthesis was inhibited by chloramphenicol, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="2222">
                    <text>In this work, we found that protein synthesis was inhibited by chloramphenicol, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="2223">
                    <text>In this work, we found that reduced regulation of Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacistin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2224">
                    <text>In this work, we found that regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2225">
                    <text>In this work, we found that regulation of phosphorylated status, stage 5 and stage 6 was inhibited by an inhibitor of the MG132 protein and lactacittine, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2226">
                    <text>In this work, we found that regulation of phosphorylated status, stage 5 and stage 6 was inhibited by an inhibitor of the MG132 protein and lactacittine, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2227">
                    <text>In this work, we found that the glnAp2 promoter activity is inhibited by the CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2228">
                    <text>In this work, we found that the glnAp2 promoter activity was inhibited by the CRP-cAMP complex, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2229">
                    <text>In this work, we found that the glnAp2 promoter activity was inhibited by the CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2230">
                    <text>In this work, we found that the regulation of phosphorylated state, state5 and state6 is inhibited by a proteasome MG132 inhibitor and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2231">
                    <text>In this work, we found that the regulation of phosphorylated state, state5 and state6 was inhibited by a proteasome MG132 inhibitor and lactacitstin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2232">
                    <text>In this work, we found that the regulation of phosphorylated state, state5 and state6 was inhibited by a proteasome MG132 inhibitor and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2233">
                    <text>In this work, we found that the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by inhibitors of the MG132 proteasome and lactacyttin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2234">
                    <text>In this work, we found that the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2235">
                    <text>In this work, we found that the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2236">
                    <text>MAD-3 co-expression (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2237">
                    <text>MAD-3 co-expression (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2238">
                    <text>MAD-3 co-expression (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2239">
                    <text>MAD-3 co-expression (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2240">
                    <text>MAD-3 co-expression activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2241">
                    <text>MAD-3 co-expression also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2242">
                    <text>MAD-3 co-expression can fully inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2243">
                    <text>MAD-3 co-expression can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2244">
                    <text>MAD-3 co-expression can totally inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2245">
                    <text>MAD-3 co-expression co-expression also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2246">
                    <text>MAD-3 co-expression fully inhibiting concentration-dependent functional activation of a plasmid HIV reporter by p49/ p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2247">
                    <text>MAD-3 co-expression has also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2248">
                    <text>MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2249">
                    <text>MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2250">
                    <text>MAD-3 co-expression inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2251">
                    <text>MAD-3 co-expression inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2252">
                    <text>MAD-3 co-expression is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2253">
                    <text>MAD-3 co-expression may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in T cells affected by jurkat.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2254">
                    <text>MAD-3 co-expression may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2255">
                    <text>MAD-3 co-expression may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2256">
                    <text>MAD-3 co-expression may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2257">
                    <text>MAD-3 expression (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2258">
                    <text>MAD-3 expression (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2259">
                    <text>MAD-3 expression (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2260">
                    <text>MAD-3 expression (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2261">
                    <text>MAD-3 expression activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2262">
                    <text>MAD-3 expression also has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2263">
                    <text>MAD-3 expression also inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2264">
                    <text>MAD-3 expression also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2265">
                    <text>MAD-3 expression also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2266">
                    <text>MAD-3 expression can fully inhibit functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2267">
                    <text>MAD-3 expression can inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2268">
                    <text>MAD-3 expression can totally inhibit functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2269">
                    <text>MAD-3 expression co-expression also has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2270">
                    <text>MAD-3 expression fully inhibiting concentration-dependent functional activation of an HIV reporter plasmid by p49/p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2271">
                    <text>MAD-3 expression has also inhibited functional activation of an HIV reporter plasmid by p49/p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2272">
                    <text>MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2273">
                    <text>MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2274">
                    <text>MAD-3 expression inhibits functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2275">
                    <text>MAD-3 expression inhibits functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2276">
                    <text>MAD-3 expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2277">
                    <text>MAD-3 expression may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in T cells affected by jurkat.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2278">
                    <text>MAD-3 expression may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2279">
                    <text>MAD-3 expression may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2280">
                    <text>MAD-3 expression may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2281">
                    <text>MAD-3 expression may have inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2282">
                    <text>MAR expression (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2283">
                    <text>MAR expression (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2284">
                    <text>MAR expression (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2285">
                    <text>MAR expression (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2286">
                    <text>MAR expression activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2287">
                    <text>MAR expression also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2288">
                    <text>MAR expression also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2289">
                    <text>MAR expression also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2290">
                    <text>MAR expression also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2291">
                    <text>MAR expression can fully inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2292">
                    <text>MAR expression can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2293">
                    <text>MAR expression can totally inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2294">
                    <text>MAR expression co-expression also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2295">
                    <text>MAR expression fully inhibiting concentration-dependent functional activation of a plasmid HIV reporter by p49/ p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2296">
                    <text>MAR expression has also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2297">
                    <text>MAR expression inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2298">
                    <text>MAR expression inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2299">
                    <text>MAR expression inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2300">
                    <text>MAR expression inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2301">
                    <text>MAR expression is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2302">
                    <text>MAR expression may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in T cells affected by jurkat.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2303">
                    <text>MAR expression may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2304">
                    <text>MAR expression may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2305">
                    <text>MAR expression may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2306">
                    <text>MAR expression may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2307">
                    <text>Mad-3 (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2308">
                    <text>Mad-3 (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2309">
                    <text>Mad-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2310">
                    <text>Mad-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2311">
                    <text>Mad-3 (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2312">
                    <text>Mad-3 (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2313">
                    <text>Mad-3 (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2314">
                    <text>Mad-3 (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2315">
                    <text>Mad-3 activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2316">
                    <text>Mad-3 activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2317">
                    <text>Mad-3 also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2318">
                    <text>Mad-3 also has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2319">
                    <text>Mad-3 also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2320">
                    <text>Mad-3 also inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2321">
                    <text>Mad-3 also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2322">
                    <text>Mad-3 also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2323">
                    <text>Mad-3 also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2324">
                    <text>Mad-3 also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2325">
                    <text>Mad-3 can fully inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2326">
                    <text>Mad-3 can fully inhibit functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2327">
                    <text>Mad-3 can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2328">
                    <text>Mad-3 can inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2329">
                    <text>Mad-3 can totally inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2330">
                    <text>Mad-3 can totally inhibit functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2331">
                    <text>Mad-3 co-expression (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2332">
                    <text>Mad-3 co-expression (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2333">
                    <text>Mad-3 co-expression (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2334">
                    <text>Mad-3 co-expression (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2335">
                    <text>Mad-3 co-expression activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2336">
                    <text>Mad-3 co-expression also has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2337">
                    <text>Mad-3 co-expression also has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2338">
                    <text>Mad-3 co-expression also inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2339">
                    <text>Mad-3 co-expression also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2340">
                    <text>Mad-3 co-expression can fully inhibit functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2341">
                    <text>Mad-3 co-expression can inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2342">
                    <text>Mad-3 co-expression can totally inhibit functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2343">
                    <text>Mad-3 co-expression co-expression also has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2344">
                    <text>Mad-3 co-expression fully inhibiting concentration-dependent functional activation of an HIV reporter plasmid by p49/p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2345">
                    <text>Mad-3 co-expression inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2346">
                    <text>Mad-3 co-expression inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2347">
                    <text>Mad-3 co-expression inhibits functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2348">
                    <text>Mad-3 co-expression inhibits functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2349">
                    <text>Mad-3 co-expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2350">
                    <text>Mad-3 co-expression may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in T cells affected by jurkat.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2351">
                    <text>Mad-3 co-expression may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2352">
                    <text>Mad-3 co-expression may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2353">
                    <text>Mad-3 co-expression may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2354">
                    <text>Mad-3 co-expression may have inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2355">
                    <text>Mad-3 fully inhibiting concentration-dependent functional activation of a plasmid HIV reporter by p49/ p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2356">
                    <text>Mad-3 fully inhibiting concentration-dependent functional activation of an HIV reporter plasmid by p49/p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2357">
                    <text>Mad-3 has also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2358">
                    <text>Mad-3 has also inhibited functional activation of an HIV reporter plasmid by p49/p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2359">
                    <text>Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2360">
                    <text>Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2361">
                    <text>Mad-3 inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2362">
                    <text>Mad-3 inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2363">
                    <text>Mad-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2364">
                    <text>Mad-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2365">
                    <text>Mad-3 inhibits functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2366">
                    <text>Mad-3 inhibits functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2367">
                    <text>Mad-3 is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2368">
                    <text>Mad-3 is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2369">
                    <text>Mad-3 may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in T cells affected by jurkat.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2370">
                    <text>Mad-3 may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2371">
                    <text>Mad-3 may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2372">
                    <text>Mad-3 may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2373">
                    <text>Mad-3 may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2374">
                    <text>Mad-3 may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2375">
                    <text>Mad-3 may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2376">
                    <text>Mad-3 may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2377">
                    <text>Mad-3 may have inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2378">
                    <text>NK cell-mediated cytotoxicity are inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2379">
                    <text>NK cell-mediated cytotoxicity are inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2380">
                    <text>NK cell-mediated cytotoxicity are inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2381">
                    <text>NK cell-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2382">
                    <text>NK cell-mediated cytotoxicity can be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2383">
                    <text>NK cell-mediated cytotoxicity can be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2384">
                    <text>NK cell-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2385">
                    <text>NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2386">
                    <text>NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2387">
                    <text>NK cell-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2388">
                    <text>NK cell-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2389">
                    <text>NK cell-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2390">
                    <text>NK cell-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2391">
                    <text>NK cell-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2392">
                    <text>NK cell-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2393">
                    <text>NK cell-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2394">
                    <text>NK cell-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2395">
                    <text>NK cell-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2396">
                    <text>NK cell-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2397">
                    <text>NK cell-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2398">
                    <text>NK cell-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2399">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2400">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2401">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2402">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2403">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2404">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2405">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2406">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2407">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2408">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2409">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2410">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2411">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2412">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2413">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2414">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2415">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2416">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2417">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2418">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2419">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2420">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2421">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2422">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2423">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2424">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2425">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2426">
                    <text>NK cell-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2427">
                    <text>NK cell-mediated cytotoxicity is able to be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2428">
                    <text>NK cell-mediated cytotoxicity is able to be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2429">
                    <text>NK cell-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2430">
                    <text>NK cell-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2431">
                    <text>NK cell-mediated cytotoxicity is capable of being inhibited by cell surface receptors of immunoglobulin and C-type superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2432">
                    <text>NK cell-mediated cytotoxicity is capable of being inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2433">
                    <text>NK cell-mediated cytotoxicity is capable of being inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2434">
                    <text>NK cell-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2435">
                    <text>NK cell-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors of immunoglobulin and C-type superfamilies , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2436">
                    <text>NK cell-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2437">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2438">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2439">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2440">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2441">
                    <text>NK cell-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2442">
                    <text>NK cell-mediated cytotoxicity is observed to be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2443">
                    <text>NK cell-mediated cytotoxicity is observed to be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2444">
                    <text>NK cell-mediated cytotoxicity may have been inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2445">
                    <text>NK cell-mediated cytotoxicity may have been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2446">
                    <text>NK cell-mediated cytotoxicity may have been inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2447">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2448">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2449">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2450">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2451">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2452">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2453">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2454">
                    <text>NK cell-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2455">
                    <text>NK cell-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2456">
                    <text>NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2457">
                    <text>NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2458">
                    <text>NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2459">
                    <text>NK-mediated cytotoxicity are inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2460">
                    <text>NK-mediated cytotoxicity are inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2461">
                    <text>NK-mediated cytotoxicity are inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2462">
                    <text>NK-mediated cytotoxicity are inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2463">
                    <text>NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2464">
                    <text>NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2465">
                    <text>NK-mediated cytotoxicity can be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2466">
                    <text>NK-mediated cytotoxicity can be inhibited by cellular surface receptors for immunoglobulin and C-type lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2467">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2468">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2469">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2470">
                    <text>NK-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2471">
                    <text>NK-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2472">
                    <text>NK-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2473">
                    <text>NK-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2474">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2475">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2476">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2477">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2478">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2479">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2480">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2481">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2482">
                    <text>NK-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2483">
                    <text>NK-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2484">
                    <text>NK-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2485">
                    <text>NK-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2486">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2487">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2488">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2489">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2490">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2491">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2492">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2493">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2494">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2495">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2496">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2497">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2498">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2499">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2500">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2501">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2502">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2503">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2504">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2505">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2506">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2507">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2508">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2509">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2510">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2511">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2512">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2513">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2514">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2515">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2516">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2517">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2518">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2519">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2520">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2521">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2522">
                    <text>NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2523">
                    <text>NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2524">
                    <text>NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2525">
                    <text>NK-mediated cytotoxicity is able to be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2526">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2527">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2528">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2529">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2530">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2531">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2532">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cellular surface receptors for immunoglobulin and C-type lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2533">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2534">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2535">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2536">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2537">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cellular surface receptors for immunoglobulin and C-type lectin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2538">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2539">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2540">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2541">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2542">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2543">
                    <text>NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2544">
                    <text>NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2545">
                    <text>NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2546">
                    <text>NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2547">
                    <text>NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2548">
                    <text>NK-mediated cytotoxicity is observed to be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2549">
                    <text>NK-mediated cytotoxicity may have been inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2550">
                    <text>NK-mediated cytotoxicity may have been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2551">
                    <text>NK-mediated cytotoxicity may have been inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2552">
                    <text>NK-mediated cytotoxicity may have been inhibited by cellular surface receptors for immunoglobulin and C-type lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2553">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2554">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2555">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2556">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2557">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2558">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2559">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2560">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2561">
                    <text>NK-mediated cytotoxicity was inhibited by cellular surface receptors for immunoglobulin and C-type lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2562">
                    <text>NK-mediated cytotoxicity was inhibited by cellular surface receptors for immunoglobulin and C-type lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2563">
                    <text>NK-mediated cytotoxicity was inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2564">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2565">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2566">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2567">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2568">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2569">
                    <text>NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2570">
                    <text>NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2571">
                    <text>PDE44 cyclic AMP-phosphodiesterases has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2572">
                    <text>PDE44 cyclic AMP-phosphodiesterases is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2573">
                    <text>PDE44 cyclic AMP-phosphodiesterases is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2574">
                    <text>PDE44 cyclic AMP-phosphodiesterases is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2575">
                    <text>PDE44 cyclic AMP-phosphodiesterases was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2576">
                    <text>PDE44 cyclic AMP-specific isoforms has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2577">
                    <text>PDE44 cyclic AMP-specific isoforms is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2578">
                    <text>PDE44 cyclic AMP-specific isoforms is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2579">
                    <text>PDE44 cyclic AMP-specific isoforms is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2580">
                    <text>PDE44 cyclic AMP-specific isoforms was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2581">
                    <text>PDE44 cyclic AMP-specific phosphodiesterase has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2582">
                    <text>PDE44 cyclic AMP-specific phosphodiesterase is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2583">
                    <text>PDE44 cyclic AMP-specific phosphodiesterase is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2584">
                    <text>PDE44 cyclic AMP-specific phosphodiesterase is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2585">
                    <text>PDE44 cyclic AMP-specific phosphodiesterase was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2586">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-phosphodiesterases and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2587">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-phosphodiesterases inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2588">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-phosphodiesterases that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2589">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-phosphodiesterases that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="2590">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific isoforms and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2591">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific isoforms inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2592">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific isoforms that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2593">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific isoforms that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2594">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific phosphodiesterase and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2595">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific phosphodiesterase inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2596">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific phosphodiesterase that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2597">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific phosphodiesterase that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="2598">
                    <text>PDE4C is one of the four mammalian genes that codify both C alpha and C beta isoforms of the catalytic subunit PKA and is inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2599">
                    <text>PDE4C is one of the four mammalian genes that codify both C alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2600">
                    <text>PDE4C is one of the four mammalian genes that codify both C alpha and C beta isoforms of the catalytic subunit PKA that can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2601">
                    <text>PDE4C is one of the four mammalian genes that codify both C alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2602">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit PKA and is inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2603">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2604">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit PKA that can be inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2605">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2606">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA and is inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2607">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA and is inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2608">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA and is inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2609">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA and is inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2610">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2611">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2612">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2613">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2614">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that can be inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2615">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that can be inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2616">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that can be inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2617">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2618">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2619">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2620">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2621">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2622">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and C beta of the catalytic subunit PKA and is inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2623">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and C beta of the catalytic subunit PKA inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2624">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and C beta of the catalytic subunit PKA that can be inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2625">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and C beta of the catalytic subunit PKA that have been inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2626">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and beta C of the catalytic subunit PKA and is inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2627">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and beta C of the catalytic subunit PKA inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2628">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and beta C of the catalytic subunit PKA that can be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2629">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and beta C of the catalytic subunit PKA that have been inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="2630">
                    <text>PDE4C is one of the four mammalian genes that codify depending on sigma (54)-gnAp2 and is inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2631">
                    <text>PDE4C is one of the four mammalian genes that codify depending on sigma (54)-gnAp2 inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2632">
                    <text>PDE4C is one of the four mammalian genes that codify depending on sigma (54)-gnAp2 that can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2633">
                    <text>PDE4C is one of the four mammalian genes that codify depending on sigma (54)-gnAp2 that have been inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2634">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific cyclic PDE4 isoforms inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2635">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific cyclic PDE4 isoforms that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2636">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific cyclic PDE4 isoforms that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2637">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 and is inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2638">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2639">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2640">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2641">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 isoforms coded by PDE4C and is inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2642">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 isoforms coded by PDE4C inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2643">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 isoforms coded by PDE4C that can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2644">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 isoforms coded by PDE4C that have been inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2645">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 that can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2646">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4 that have been inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2647">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4-specific phosphodiesterase isoforms and is inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2648">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4-specific phosphodiesterase isoforms inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2649">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4-specific phosphodiesterase isoforms that can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2650">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4-specific phosphodiesterase isoforms that have been inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2651">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2652">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2653">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2654">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54) - glnAp2 and is inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2655">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54) - glnAp2 inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2656">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54) - glnAp2 that can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2657">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54) - glnAp2 that have been inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2658">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-dependent glnAp2 and is inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2659">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-dependent glnAp2 inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2660">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-dependent glnAp2 that can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2661">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-dependent glnAp2 that have been inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2662">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 and is inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2663">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 dependent and is inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="2664">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 dependent inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="2665">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 dependent that can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="2666">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 dependent that have been inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="2667">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2668">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 that can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2669">
                    <text>PDE4C is one of the four mammalian genes that codify sigma (54)-gnAp2 that have been inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="2670">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit binding.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2671">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit final events of clathrin coated vesicle formation.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="2672">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2673">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit ligand.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2674">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2675">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit binding.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2676">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit final events of clathrin coated vesicle formation.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="2677">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2678">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit ligand.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2679">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2680">
                    <text>Roipram can strongly inhibit multiple PDE4 by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2681">
                    <text>Roipram can strongly inhibit multiple PDE4 isoforms coded by PDE4C by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2682">
                    <text>Roipram can strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2683">
                    <text>Roipram has strongly inhibited multiple PDE4 by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2684">
                    <text>Roipram has strongly inhibited multiple PDE4 isoforms coded by PDE4C by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2685">
                    <text>Roipram has strongly inhibited multiple PDE4-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2686">
                    <text>Roipram has the ability to inhibit phosphorylase-specific multiple PDE4 isoforms coded by PDE4C-isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2687">
                    <text>Roipram has the ability to inhibit phosphorylase-specific multiple PDE4-specific phosphodiesterase isoforms-isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2688">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4 by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2689">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4 by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2690">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4 isoforms coded by PDE4C by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2691">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4 isoforms coded by PDE4C by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2692">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2693">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2694">
                    <text>Roipram inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="2695">
                    <text>Roipram inhibited multiple PDE4 coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2696">
                    <text>Roipram inhibited multiple PDE4 isoforms coded by PDE4C coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2697">
                    <text>Roipram inhibited multiple PDE4-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2698">
                    <text>Roipram inhibits multiple PDE4 codified by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2699">
                    <text>Roipram inhibits multiple PDE4 isoforms coded by PDE4C codified by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2700">
                    <text>Roipram inhibits multiple PDE4-specific phosphodiesterase isoforms codified by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2701">
                    <text>Roipram is able to inhibit multiple PDE4 coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2702">
                    <text>Roipram is able to inhibit multiple PDE4 isoforms coded by PDE4C coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2703">
                    <text>Roipram is able to inhibit multiple PDE4-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2704">
                    <text>Roipram is able to inhibit multiple PDE4-specific phosphodiesterase isoforms.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2705">
                    <text>Roipram is able to inhibit multiple PDE4.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2706">
                    <text>Roipram is able to strongly inhibit multiple PDE4 by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2707">
                    <text>Roipram is able to strongly inhibit multiple PDE4 isoforms coded by PDE4C by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2708">
                    <text>Roipram is able to strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2709">
                    <text>Roipram may have strongly inhibited multiple PDE4 by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2710">
                    <text>Roipram may have strongly inhibited multiple PDE4 isoforms coded by PDE4C by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2711">
                    <text>Roipram may have strongly inhibited multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2712">
                    <text>Roipram may inhibit multiple PDE4 coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2713">
                    <text>Roipram may inhibit multiple PDE4 isoforms coded by PDE4C coded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2714">
                    <text>Roipram strongly inhibited multiple PDE4 by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2715">
                    <text>Roipram strongly inhibited multiple PDE4 isoforms coded by PDE4C by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2716">
                    <text>Roipram strongly inhibited multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2717">
                    <text>Roipram strongly inhibits multiple PDE4 by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2718">
                    <text>Roipram strongly inhibits multiple PDE4 isoforms coded by PDE4C by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2719">
                    <text>Roipram strongly inhibits multiple PDE4-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2720">
                    <text>Roipram will strongly inhibit multiple PDE4 by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="2721">
                    <text>Roipram will strongly inhibit multiple PDE4 isoforms coded by PDE4C by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="2722">
                    <text>Roipram will strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="2723">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2724">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2725">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I (NO) inhibiting late events of clathrin-coated vesicles formation activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2726">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I (NO) inhibiting late events of clathrin-coated vesicles formation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2727">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2728">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I also has the ability to inhibit late events of clathrin-coated vesicles formation in transient transfected T-cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2729">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I also inhibited late events of clathrin-coated vesicles formation in transfected T-leukemia cells transfected.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2730">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I also inhibits late events of clathrin-coated vesicles formation in transient transfected T-cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2731">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I also inhibits late events of clathrin-coated vesicles formation in transiently transfected T-leukemia cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2732">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I can fully inhibit late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2733">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I can inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2734">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I can totally inhibit late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2735">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I co-expression also has the ability to inhibit late events of clathrin-coated vesicles formation in T-leukemia transnetly affected cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2736">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I fully inhibiting concentration-dependent late events of clathrin-coated vesicles formation and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2737">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I has also inhibited late events of clathrin-coated vesicles formation in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2738">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2739">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2740">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibits late events of clathrin-coated vesicles formation activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2741">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibits late events of clathrin-coated vesicles formation activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2742">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2743">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may also have inhibited late events of clathrin-coated vesicles formation in T cells affected by jurkat.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2744">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may also have inhibited late events of clathrin-coated vesicles formation in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2745">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may have completely inhibited late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2746">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may have completely inhibited late events of clathrin-coated vesicles formation which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2747">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may have inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2748">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit binding.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2749">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit final events of clathrin coated vesicle formation.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="2750">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2751">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit ligand.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2752">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2753">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then GadX-dependent activation was inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2754">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then GadX-dependent was inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2755">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2756">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2757">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2758">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2759">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2760">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2761">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2762">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then activity promotionAp2 was inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2763">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then binding was inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2764">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then binding was inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2765">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then cytotoxicity mediated by NK cells was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2766">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then depending on GadX was inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2767">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2768">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2769">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 was inhibited by 50 mg/ml mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2770">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2771">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2772">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2773">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2774">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was inhibited by 50 mg/ml AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2775">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2776">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2777">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2778">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then gnAp2 promoting activity was inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2779">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late clathrin coated vesicles formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2780">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2781">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2782">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late clathrin-coated vesicles formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2783">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2784">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then ligand was inhibited by 50 mg/ml 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2785">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then ligand was inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2786">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then ligand was inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2787">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then ligand was inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2788">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by 50 mg/ml GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2789">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then platelet function was inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2790">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then platquet function was inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2791">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2792">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 was inhibited by 50 mg/ml an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2793">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then the glnAp2 promoter activity was inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2794">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was inhibited by 50 mg/ml a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2795">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by 50 mg/ml inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2796">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation has been inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2797">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation was about to be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2798">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation was inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2799">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation will be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2800">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent has been inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2801">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent was about to be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2802">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent was inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2803">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent will be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2804">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2805">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2806">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2807">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2808">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2809">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2810">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2811">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2812">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2813">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2814">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2815">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2816">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2817">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2818">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2819">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2820">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2821">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2822">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2823">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2824">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2825">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2826">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2827">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2828">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2829">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2830">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2831">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2832">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then activity promotionAp2 has been inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2833">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then activity promotionAp2 was about to be inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2834">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then activity promotionAp2 was inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2835">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then activity promotionAp2 will be inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2836">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding has been inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2837">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding has been inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2838">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding was about to be inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2839">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding was about to be inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2840">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding was inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2841">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding was inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2842">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding will be inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2843">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding will be inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2844">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then cytotoxicity mediated by NK cells has been inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2845">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then cytotoxicity mediated by NK cells was about to be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2846">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then cytotoxicity mediated by NK cells was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2847">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then cytotoxicity mediated by NK cells will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2848">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then depending on GadX has been inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2849">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then depending on GadX was about to be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2850">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then depending on GadX was inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2851">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then depending on GadX will be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2852">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 has been inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2853">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 has been inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2854">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was about to be inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2855">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was about to be inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2856">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2857">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2858">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 will be inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2859">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 will be inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2860">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 has been inhibited by 50 mg/ml mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2861">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 was about to be inhibited by 50 mg/ml mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2862">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 was inhibited by 50 mg/ml mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2863">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 will be inhibited by 50 mg/ml mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2864">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by 50 mg/ml MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2865">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by 50 mg/ml MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2866">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2867">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by 50 mg/ml co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2868">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2869">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2870">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2871">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2872">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2873">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2874">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2875">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2876">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2877">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2878">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2879">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2880">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 has been inhibited by 50 mg/ml AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2881">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was about to be inhibited by 50 mg/ml AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2882">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was inhibited by 50 mg/ml AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2883">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by 50 mg/ml AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2884">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by 50 mg/ml MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2885">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by 50 mg/ml Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2886">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2887">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was about to be inhibited by 50 mg/ml MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2888">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was about to be inhibited by 50 mg/ml Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2889">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was about to be inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2890">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2891">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2892">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2893">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2894">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2895">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2896">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then gnAp2 promoting activity has been inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2897">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then gnAp2 promoting activity was about to be inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2898">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then gnAp2 promoting activity was inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2899">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then gnAp2 promoting activity will be inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2900">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin coated vesicles formation events has been inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2901">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin coated vesicles formation events was about to be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2902">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin coated vesicles formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2903">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin coated vesicles formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2904">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events has been inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2905">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events has been inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2906">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2907">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2908">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2909">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2910">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2911">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2912">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicles formation events has been inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2913">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicles formation events was about to be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2914">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicles formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2915">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicles formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2916">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation has been inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2917">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation was about to be inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2918">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2919">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation will be inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2920">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand has been inhibited by 50 mg/ml 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2921">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand has been inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2922">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand has been inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2923">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand has been inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2924">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2925">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2926">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2927">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2928">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was inhibited by 50 mg/ml 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2929">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2930">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2931">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2932">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand will be inhibited by 50 mg/ml 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2933">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand will be inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2934">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand will be inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2935">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand will be inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2936">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated has been inhibited by 50 mg/ml GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2937">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated was about to be inhibited by 50 mg/ml GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2938">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by 50 mg/ml GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2939">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by 50 mg/ml GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="2940">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function has been inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2941">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function was about to be inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2942">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function was inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2943">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function will be inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="2944">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platquet function has been inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2945">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platquet function was about to be inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2946">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platquet function was inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2947">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then platquet function will be inhibited by 50 mg/ml nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="2948">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 has been inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2949">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was about to be inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2950">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2951">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2952">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 has been inhibited by 50 mg/ml an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2953">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 was about to be inhibited by 50 mg/ml an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2954">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 was inhibited by 50 mg/ml an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2955">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by 50 mg/ml an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="2956">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity has been inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2957">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity was about to be inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2958">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity was inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2959">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity will be inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="2960">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 has been inhibited by 50 mg/ml a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2961">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was about to be inhibited by 50 mg/ml a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2962">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was inhibited by 50 mg/ml a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2963">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 will be inhibited by 50 mg/ml a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2964">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 has been inhibited by 50 mg/ml inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2965">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 was about to be inhibited by 50 mg/ml inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2966">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by 50 mg/ml inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2967">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by 50 mg/ml inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="2968">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then GadX-dependent activation will be inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="2969">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then GadX-dependent will be inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="2970">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2971">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2972">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2973">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2974">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2975">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2976">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="2977">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then activity promotionAp2 will be inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="2978">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then binding will be inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2979">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then binding will be inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="2980">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then cytotoxicity mediated by NK cells will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="2981">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then depending on GadX will be inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="2982">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then descendant regulation of phosphorylation state, state5 and state6 will be inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2983">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then descendant regulation of phosphorylation state, state5 and state6 will be inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2984">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then descending regulation of the phosphorylation status, state5 and state6 will be inhibited by 50 mg/ml of mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="2985">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml of MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2986">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml of MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2987">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2988">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml of co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="2989">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by 50 mg/ml of AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2990">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml of MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2991">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml of Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2992">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="2993">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then gnAp2 promoting activity will be inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="2994">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin coated vesicles formation events will be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2995">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2996">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="2997">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin-coated vesicles formation events will be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="2998">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late events of clathrin-coated vesicles formation will be inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="2999">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then ligand will be inhibited by 50 mg/ml of 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3000">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then ligand will be inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3001">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then ligand will be inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3002">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then ligand will be inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3003">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by 50 mg/ml of GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3004">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then platelet function will be inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="3005">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then platquet function will be inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="3006">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by 50 mg/ml of proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3007">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by 50 mg/ml of an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3008">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then the glnAp2 promoter activity will be inhibited by 50 mg/ml of the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3009">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then the regulation of phosphorylated state, state5 and state6 will be inhibited by 50 mg/ml of a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3010">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by 50 mg/ml of inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3011">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml 10 mM EDTA to inhibiting ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3012">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml AAM-3 expression to inhibiting functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3013">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml CRP-cAMP complex to inhibiting activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3014">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml CRP-cAMP complex to inhibiting gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="3015">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml DTA of 10 mM to inhibiting binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3016">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml DTA of 10 mM to inhibiting ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3017">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml EDTA 10mM to inhibiting binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3018">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml EDTA 10mM to inhibiting ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3019">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml EDTA of 10 mM to inhibiting ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3020">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml GM132 proteasome inhibitors and laactacytin to inhibiting negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3021">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml GadW to inhibiting GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="3022">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml GadW to inhibiting GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="3023">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml GadW to inhibiting depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="3024">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml MAD-3 co-expression to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3025">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml MAD-3 expression to inhibiting functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3026">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml MAR expression to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3027">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml Mad-3 co-expression to inhibiting functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3028">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml Mad-3 to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3029">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml Mad-3 to inhibiting functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3030">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I to inhibiting late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="3031">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml a proteasome MG132 inhibitor and lactacitstin to inhibiting the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3032">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml an inhibitor of the MG132 protein and lactacittine to inhibiting regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3033">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin and C-type lectin superfamilies to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3034">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3035">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins to inhibiting cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3036">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins to inhibiting NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3037">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for the superfamilies of immunoglobulin and type C lectin to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3038">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies to inhibiting NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3039">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies to inhibiting NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3040">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cellular surface receptors for immunoglobulin and C-type lectin to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3041">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml co-expression of AAM-3 to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3042">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml inhibitors of the MG132 proteasome and lactacyttin to inhibiting the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3043">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml mainly the inhibitors of the MG132 proteasome and lactacittina to inhibiting descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3044">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml nitric oxide to inhibiting platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="3045">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml nitric oxide to inhibiting platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="3046">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml primary proteasome inhibitors MG132 and lactacitstin to inhibiting descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3047">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml primary proteasome inhibitors MG132 and lactacyttin to inhibiting descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3048">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml proteasome inhibitors MG132 and lactacistin to inhibiting reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3049">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml the CRP-cAMP complex to inhibiting the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3050">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3051">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I to inhibiting late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3052">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I to inhibiting late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3053">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3054">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of 10 mM EDTA to inhibiting ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3055">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of AAM-3 expression to inhibiting functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3056">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of CRP-cAMP complex to inhibiting activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3057">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of CRP-cAMP complex to inhibiting gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="3058">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of DTA of 10 mM to inhibiting binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3059">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of DTA of 10 mM to inhibiting ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3060">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of EDTA 10mM to inhibiting binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3061">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of EDTA 10mM to inhibiting ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3062">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of EDTA of 10 mM to inhibiting ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3063">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of GM132 proteasome inhibitors and laactacytin to inhibiting negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3064">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of GadW to inhibiting GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="3065">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of GadW to inhibiting GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="3066">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of GadW to inhibiting depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="3067">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of MAD-3 co-expression to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3068">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of MAD-3 expression to inhibiting functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3069">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of MAR expression to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3070">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of Mad-3 co-expression to inhibiting functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3071">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of Mad-3 to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3072">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of Mad-3 to inhibiting functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3073">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I to inhibiting late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="3074">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of a proteasome MG132 inhibitor and lactacitstin to inhibiting the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3075">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of an inhibitor of the MG132 protein and lactacittine to inhibiting regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3076">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3077">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3078">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins to inhibiting cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3079">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and type C lectins to inhibiting NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3080">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for the superfamilies of immunoglobulin and type C lectin to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3081">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies to inhibiting NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3082">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors of immunoglobulin and Clectin superfamilies to inhibiting NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3083">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cellular surface receptors for immunoglobulin and C-type lectin to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3084">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of co-expression of AAM-3 to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3085">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of inhibitors of the MG132 proteasome and lactacyttin to inhibiting the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3086">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of mainly the inhibitors of the MG132 proteasome and lactacittina to inhibiting descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3087">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of nitric oxide to inhibiting platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="3088">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of nitric oxide to inhibiting platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="3089">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of primary proteasome inhibitors MG132 and lactacitstin to inhibiting descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3090">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of primary proteasome inhibitors MG132 and lactacyttin to inhibiting descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3091">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of proteasome inhibitors MG132 and lactacistin to inhibiting reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3092">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of the CRP-cAMP complex to inhibiting the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3093">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3094">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I to inhibiting late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3095">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I to inhibiting late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3096">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3097">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then GadX-dependent activation was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="3098">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then GadX-dependent was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="3099">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3100">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3101">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3102">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3103">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3104">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3105">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3106">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then activity promotionAp2 was inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3107">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then binding was inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3108">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then binding was inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3109">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then cytotoxicity mediated by NK cells was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3110">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then depending on GadX was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="3111">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3112">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3113">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 was inhibited by 50 mg/ml of mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3114">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3115">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3116">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3117">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3118">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was inhibited by 50 mg/ml of AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3119">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml of MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3120">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml of Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3121">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3122">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then gnAp2 promoting activity was inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="3123">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin coated vesicles formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3124">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3125">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3126">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin-coated vesicles formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3127">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="3128">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then ligand was inhibited by 50 mg/ml of 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3129">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then ligand was inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3130">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then ligand was inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3131">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then ligand was inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3132">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by 50 mg/ml of GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3133">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then platelet function was inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="3134">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then platquet function was inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="3135">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was inhibited by 50 mg/ml of proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3136">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 was inhibited by 50 mg/ml of an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3137">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then the glnAp2 promoter activity was inhibited by 50 mg/ml of the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3138">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was inhibited by 50 mg/ml of a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3139">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by 50 mg/ml of inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3140">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then GadX-dependent activation is inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="3141">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then GadX-dependent activation was about to be inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="3142">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then GadX-dependent activation was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="3143">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then GadX-dependent is inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="3144">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then GadX-dependent was about to be inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="3145">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then GadX-dependent was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="3146">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3147">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3148">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3149">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3150">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3151">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3152">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3153">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3154">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3155">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3156">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3157">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3158">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity is inhibited by 50 mg/ml of cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3159">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3160">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3161">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3162">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3163">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3164">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3165">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3166">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3167">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then activity promotionAp2 is inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3168">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then activity promotionAp2 was about to be inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3169">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then activity promotionAp2 was inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3170">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding is inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3171">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding is inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3172">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding was about to be inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3173">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding was about to be inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3174">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding was inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3175">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding was inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3176">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then cytotoxicity mediated by NK cells is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3177">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then cytotoxicity mediated by NK cells was about to be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3178">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then cytotoxicity mediated by NK cells was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3179">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then depending on GadX is inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="3180">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then depending on GadX was about to be inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="3181">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then depending on GadX was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="3182">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 is inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3183">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 is inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3184">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was about to be inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3185">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was about to be inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3186">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3187">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3188">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 is inhibited by 50 mg/ml of mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3189">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 was about to be inhibited by 50 mg/ml of mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3190">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then descending regulation of the phosphorylation status, state5 and state6 was inhibited by 50 mg/ml of mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3191">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by 50 mg/ml of MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3192">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by 50 mg/ml of MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3193">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3194">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by 50 mg/ml of co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3195">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml of MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3196">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml of MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3197">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3198">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml of co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3199">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3200">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3201">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3202">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="3203">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 is inhibited by 50 mg/ml of AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3204">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was about to be inhibited by 50 mg/ml of AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3205">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was inhibited by 50 mg/ml of AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3206">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 is inhibited by 50 mg/ml of MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3207">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 is inhibited by 50 mg/ml of Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3208">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 is inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3209">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was about to be inhibited by 50 mg/ml of MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3210">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was about to be inhibited by 50 mg/ml of Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3211">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was about to be inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3212">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml of MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3213">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml of Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3214">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="3215">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then gnAp2 promoting activity is inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="3216">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then gnAp2 promoting activity was about to be inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="3217">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then gnAp2 promoting activity was inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="3218">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin coated vesicles formation events is inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3219">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin coated vesicles formation events was about to be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3220">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin coated vesicles formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3221">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events is inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3222">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events is inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3223">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3224">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3225">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3226">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="3227">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicles formation events is inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3228">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicles formation events was about to be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3229">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicles formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="3230">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation is inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="3231">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation was about to be inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="3232">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="3233">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand is inhibited by 50 mg/ml of 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3234">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand is inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3235">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand is inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3236">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand is inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3237">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml of 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3238">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3239">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3240">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3241">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was inhibited by 50 mg/ml of 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3242">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3243">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3244">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3245">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by 50 mg/ml of GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3246">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated was about to be inhibited by 50 mg/ml of GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3247">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by 50 mg/ml of GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3248">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then platelet function is inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="3249">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then platelet function was about to be inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="3250">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then platelet function was inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="3251">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then platquet function is inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="3252">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then platquet function was about to be inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="3253">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then platquet function was inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="3254">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 is inhibited by 50 mg/ml of proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3255">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was about to be inhibited by 50 mg/ml of proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3256">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was inhibited by 50 mg/ml of proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3257">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 is inhibited by 50 mg/ml of an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3258">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 was about to be inhibited by 50 mg/ml of an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3259">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then regulation of phosphorylated status, stage 5 and stage 6 was inhibited by 50 mg/ml of an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3260">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the glnAp2 promoter activity is inhibited by 50 mg/ml of the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3261">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the glnAp2 promoter activity was about to be inhibited by 50 mg/ml of the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3262">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the glnAp2 promoter activity was inhibited by 50 mg/ml of the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3263">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 is inhibited by 50 mg/ml of a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3264">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was about to be inhibited by 50 mg/ml of a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3265">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was inhibited by 50 mg/ml of a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3266">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by 50 mg/ml of inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3267">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 was about to be inhibited by 50 mg/ml of inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3268">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by 50 mg/ml of inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="3269">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit binding involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3270">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit late events of clathrin-coated vesicles formation involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="3271">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit ligand involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3272">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="3273">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit the regulation of phosphorylated state, state5 and state6 involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3274">
                    <text>This synthetic peptide binding to P can inhibit is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="3275">
                    <text>This synthetic peptide binding to P can inhibit its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="3276">
                    <text>This synthetic peptide binding to P may have inhibited is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="3277">
                    <text>This synthetic peptide binding to P may have inhibited its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="3278">
                    <text>This synthetic peptide binds to P and is able to inhibit is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="3279">
                    <text>This synthetic peptide binds to P to inhibit is binds to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="3280">
                    <text>This synthetic peptide binds to P to inhibit its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="3281">
                    <text>This synthetic peptide that binds to P may have inhibited its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="3282">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and PDE44 cyclic AMP-phosphodiesterases are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3283">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and PDE44 cyclic AMP-phosphodiesterases can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3284">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and PDE44 cyclic AMP-specific isoforms are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3285">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and PDE44 cyclic AMP-specific isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3286">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and PDE44 cyclic AMP-specific phosphodiesterase are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3287">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and PDE44 cyclic AMP-specific phosphodiesterase can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3288">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3289">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3290">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3291">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3292">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3293">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3294">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3295">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3296">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3297">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3298">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3299">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the isoforms C alpha and C beta of the catalytic subunit PKA can be inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3300">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the isoforms C alpha and beta C of the catalytic subunit PKA are inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3301">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the isoforms C alpha and beta C of the catalytic subunit PKA can be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3302">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and depending on sigma (54)-gnAp2 are inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3303">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and depending on sigma (54)-gnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3304">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple AMP-specific cyclic PDE4 isoforms are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3305">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple AMP-specific cyclic PDE4 isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3306">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 are inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3307">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3308">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3309">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3310">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 isoforms coded by PDE4C are inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3311">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 isoforms coded by PDE4C can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3312">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4-specific phosphodiesterase isoforms are inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3313">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4-specific phosphodiesterase isoforms can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3314">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3315">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3316">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54) - glnAp2 are inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3317">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54) - glnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3318">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54)-dependent glnAp2 are inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3319">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54)-dependent glnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3320">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54)-gnAp2 are inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3321">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54)-gnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3322">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54)-gnAp2 dependent are inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3323">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and sigma (54)-gnAp2 dependent can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3324">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and CRP-cAMP is able to inhibit depending on sigma (54)-gnAp2 equally.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3325">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and CRP-cAMP is able to inhibit sigma (54) - glnAp2 equally.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3326">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and CRP-cAMP is able to inhibit sigma (54)-dependent glnAp2 equally.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3327">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and CRP-cAMP is able to inhibit sigma (54)-gnAp2 dependent equally.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3328">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and CRP-cAMP is able to inhibit sigma (54)-gnAp2 equally.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3329">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and Roipram is able to inhibit multiple PDE4 equally.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3330">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and Roipram is able to inhibit multiple PDE4 isoforms coded by PDE4C equally.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3331">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and Roipram is able to inhibit multiple PDE4-specific phosphodiesterase isoforms equally.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3332">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from the transcedit body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3333">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transcedit body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3334">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transcent body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3335">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transfect body cells is able to inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3336">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transfected body cells is able to inhibit both C alpha and C beta isoforms of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3337">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transfected body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3338">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts of the transfected body cells is able to inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3339">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit PDE44 cyclic AMP-phosphodiesterases equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3340">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit PDE44 cyclic AMP-specific isoforms equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3341">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit PDE44 cyclic AMP-specific phosphodiesterase equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3342">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit multiple AMP-specific cyclic PDE4 isoforms equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3343">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3344">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3345">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that CRP-cAMP could have inhibited depending on sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3346">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that CRP-cAMP could have inhibited sigma (54) - glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3347">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that CRP-cAMP could have inhibited sigma (54)-dependent glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3348">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that CRP-cAMP could have inhibited sigma (54)-gnAp2 dependent with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3349">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that CRP-cAMP could have inhibited sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3350">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that Roipram could have inhibited multiple PDE4 isoforms coded by PDE4C with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3351">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that Roipram could have inhibited multiple PDE4 with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3352">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that Roipram could have inhibited multiple PDE4-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3353">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from the transcedit body cells could have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3354">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transcedit body cells could have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3355">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transcent body cells could have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3356">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transfect body cells could have inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3357">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transfected body cells could have inhibited both C alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3358">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts of the transfected body cells could have inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3359">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts of transcedural body cells could have inhibited both alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3360">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited PDE44 cyclic AMP-phosphodiesterases with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3361">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited PDE44 cyclic AMP-specific isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3362">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited PDE44 cyclic AMP-specific phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3363">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited multiple AMP-specific cyclic PDE4 isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3364">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3365">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3366">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and CRP-cAMP can inhibit depending on sigma (54)-gnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3367">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and CRP-cAMP can inhibit sigma (54) - glnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3368">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and CRP-cAMP can inhibit sigma (54)-dependent glnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3369">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and CRP-cAMP can inhibit sigma (54)-gnAp2 dependent equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3370">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and CRP-cAMP can inhibit sigma (54)-gnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3371">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and Roipram can inhibit multiple PDE4 equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3372">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and Roipram can inhibit multiple PDE4 isoforms coded by PDE4C equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3373">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and Roipram can inhibit multiple PDE4-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3374">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from the transcedit body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3375">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transcent body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3376">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transfect body cells can inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3377">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transfected body cells can inhibit both C alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3378">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transfected body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3379">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts of the transfected body cells can inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3380">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts of transcedural body cells can inhibit both alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3381">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit PDE44 cyclic AMP-phosphodiesterases equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3382">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit PDE44 cyclic AMP-specific isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3383">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit PDE44 cyclic AMP-specific phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3384">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit multiple AMP-specific cyclic PDE4 isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3385">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3386">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3387">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that CRP-cAMP has inhibited depending on sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3388">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that CRP-cAMP has inhibited sigma (54) - glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3389">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that CRP-cAMP has inhibited sigma (54)-dependent glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3390">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that CRP-cAMP has inhibited sigma (54)-gnAp2 dependent with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3391">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that CRP-cAMP has inhibited sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3392">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that Roipram has inhibited multiple PDE4 isoforms coded by PDE4C with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3393">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that Roipram has inhibited multiple PDE4 with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3394">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that Roipram has inhibited multiple PDE4-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3395">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from the transcedit body cells has inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3396">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transcedit body cells has inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3397">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transfect body cells has inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3398">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transfected body cells has inhibited both C alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3399">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transfected body cells has inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3400">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts of the transfected body cells has inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3401">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts of transcedural body cells has inhibited both alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3402">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited PDE44 cyclic AMP-phosphodiesterases with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3403">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited PDE44 cyclic AMP-specific isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3404">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited PDE44 cyclic AMP-specific phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3405">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited multiple AMP-specific cyclic PDE4 isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3406">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3407">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3408">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that CRP-cAMP inhibits depending on sigma (54)-gnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3409">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that CRP-cAMP inhibits sigma (54) - glnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3410">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that CRP-cAMP inhibits sigma (54)-dependent glnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3411">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that CRP-cAMP inhibits sigma (54)-gnAp2 dependent equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3412">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that CRP-cAMP inhibits sigma (54)-gnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3413">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that Roipram inhibits multiple PDE4 equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3414">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that Roipram inhibits multiple PDE4 isoforms coded by PDE4C equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3415">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that Roipram inhibits multiple PDE4-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3416">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transcedit body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3417">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transcent body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3418">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transfect body cells inhibits both the isoforms C alpha and beta C of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3419">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transfected body cells inhibits both C alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3420">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transfected body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3421">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts of the transfected body cells inhibits both the isoforms C alpha and C beta of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3422">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts of transcedural body cells inhibits both alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3423">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits PDE44 cyclic AMP-phosphodiesterases equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3424">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits PDE44 cyclic AMP-specific isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3425">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits PDE44 cyclic AMP-specific phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3426">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits multiple AMP-specific cyclic PDE4 isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3427">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3428">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3429">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and PDE44 cyclic AMP-phosphodiesterases are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3430">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and PDE44 cyclic AMP-phosphodiesterases can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3431">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and PDE44 cyclic AMP-specific isoforms are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3432">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and PDE44 cyclic AMP-specific isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3433">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and PDE44 cyclic AMP-specific phosphodiesterase are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3434">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and PDE44 cyclic AMP-specific phosphodiesterase can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3435">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both C alpha and C beta isoforms of the catalytic subunit PKA are observed to be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3436">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both C alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3437">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both alpha and C beta isoforms of the catalytic subunit PKA are observed to be inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3438">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3439">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA are observed to be inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3440">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA are observed to be inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3441">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA are observed to be inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3442">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA are observed to be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3443">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3444">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3445">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3446">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3447">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the isoforms C alpha and beta C of the catalytic subunit PKA are observed to be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3448">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the isoforms C alpha and beta C of the catalytic subunit PKA can be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3449">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and depending on sigma (54)-gnAp2 are observed to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3450">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and depending on sigma (54)-gnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3451">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple AMP-specific cyclic PDE4 isoforms are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3452">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple AMP-specific cyclic PDE4 isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3453">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4 are observed to be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3454">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4 can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3455">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3456">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3457">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4 isoforms coded by PDE4C are observed to be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3458">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4 isoforms coded by PDE4C can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3459">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4-specific phosphodiesterase isoforms are observed to be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3460">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4-specific phosphodiesterase isoforms can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3461">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3462">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3463">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54) - glnAp2 are observed to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3464">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54) - glnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3465">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54)-dependent glnAp2 are observed to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3466">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54)-dependent glnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3467">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54)-gnAp2 are observed to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3468">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54)-gnAp2 can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3469">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54)-gnAp2 dependent are observed to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3470">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54)-gnAp2 dependent can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3471">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="3472">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="3473">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="3474">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3475">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3476">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3477">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="3478">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="3479">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="3480">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3481">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3482">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3483">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and CRP-cAMP can inhibit depending on sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3484">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and CRP-cAMP can inhibit sigma (54) - glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3485">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and CRP-cAMP can inhibit sigma (54)-dependent glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3486">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and CRP-cAMP can inhibit sigma (54)-gnAp2 dependent with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3487">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and CRP-cAMP can inhibit sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3488">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and Roipram can inhibit multiple PDE4 isoforms coded by PDE4C with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3489">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and Roipram can inhibit multiple PDE4 with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3490">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and Roipram can inhibit multiple PDE4-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3491">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from the transcedit body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3492">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transcedit body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3493">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transcent body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3494">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfected body cells can inhibit both C alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3495">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfected body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3496">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts of the transfected body cells can inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3497">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts of transcedural body cells can inhibit both alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3498">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit PDE44 cyclic AMP-phosphodiesterases with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3499">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit PDE44 cyclic AMP-specific isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3500">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit PDE44 cyclic AMP-specific phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3501">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit multiple AMP-specific cyclic PDE4 isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3502">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3503">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3504">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that CRP-cAMP is capable of inhibiting depending on sigma (54)-gnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3505">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that CRP-cAMP is capable of inhibiting sigma (54) - glnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3506">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that CRP-cAMP is capable of inhibiting sigma (54)-dependent glnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3507">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that CRP-cAMP is capable of inhibiting sigma (54)-gnAp2 dependent equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3508">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that CRP-cAMP is capable of inhibiting sigma (54)-gnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3509">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that Roipram is capable of inhibiting multiple PDE4 equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3510">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that Roipram is capable of inhibiting multiple PDE4 isoforms coded by PDE4C equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3511">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that Roipram is capable of inhibiting multiple PDE4-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3512">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from the transcedit body cells is capable of inhibiting both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3513">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transcedit body cells is capable of inhibiting both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3514">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transfect body cells is capable of inhibiting both the isoforms C alpha and beta C of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3515">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transfected body cells is capable of inhibiting both C alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3516">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transfected body cells is capable of inhibiting both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3517">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts of the transfected body cells is capable of inhibiting both the isoforms C alpha and C beta of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3518">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts of transcedural body cells is capable of inhibiting both alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3519">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting PDE44 cyclic AMP-phosphodiesterases equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3520">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting PDE44 cyclic AMP-specific isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3521">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting PDE44 cyclic AMP-specific phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3522">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting multiple AMP-specific cyclic PDE4 isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3523">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3524">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3525">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that CRP-cAMP may have inhibited depending on sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3526">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that CRP-cAMP may have inhibited sigma (54) - glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3527">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that CRP-cAMP may have inhibited sigma (54)-dependent glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3528">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that CRP-cAMP may have inhibited sigma (54)-gnAp2 dependent with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3529">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that CRP-cAMP may have inhibited sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3530">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that Roipram may have inhibited multiple PDE4 isoforms coded by PDE4C with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3531">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that Roipram may have inhibited multiple PDE4 with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3532">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that Roipram may have inhibited multiple PDE4-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3533">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from the transcedit body cells may have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3534">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transcedit body cells may have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3535">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transcent body cells may have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3536">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfected body cells may have inhibited both C alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3537">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfected body cells may have inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3538">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts of the transfected body cells may have inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3539">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts of transcedural body cells may have inhibited both alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3540">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited PDE44 cyclic AMP-phosphodiesterases with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3541">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited PDE44 cyclic AMP-specific isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3542">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited PDE44 cyclic AMP-specific phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3543">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited multiple AMP-specific cyclic PDE4 isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3544">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3545">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3546">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="3547">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="3548">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="3549">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3550">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3551">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3552">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="3553">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="3554">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="3555">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3556">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3557">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3558">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and PDE44 cyclic AMP-phosphodiesterases will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3559">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and PDE44 cyclic AMP-specific isoforms will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3560">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and PDE44 cyclic AMP-specific phosphodiesterase will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3561">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both C alpha and C beta isoforms of the catalytic subunit PKA will be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3562">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both alpha and C beta isoforms of the catalytic subunit PKA will be inhibited by protein extracts of transcedural body cells.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3563">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the alpha and C beta isoforms of the catalytic subunit PKA will be inhibited by protein extracts from the transcedit body cells.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3564">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the alpha and C beta isoforms of the catalytic subunit PKA will be inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3565">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the alpha and C beta isoforms of the catalytic subunit PKA will be inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3566">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the alpha and C beta isoforms of the catalytic subunit PKA will be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3567">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the isoforms C alpha and beta C of the catalytic subunit PKA will be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3568">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and depending on sigma (54)-gnAp2 will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3569">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple AMP-specific cyclic PDE4 isoforms will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3570">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3571">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple PDE4 isoforms coded by PDE4C will be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3572">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple PDE4 will be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3573">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple PDE4-specific phosphodiesterase isoforms will be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3574">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3575">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and sigma (54) - glnAp2 will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3576">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and sigma (54)-dependent glnAp2 will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3577">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and sigma (54)-gnAp2 dependent will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3578">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and sigma (54)-gnAp2 will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3579">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="3580">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="3581">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="3582">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3583">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3584">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3585">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="3586">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="3587">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="3588">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3589">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3590">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3591">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="3592">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="3593">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="3594">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3595">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="3596">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="3597">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and CRP-cAMP inhibited depending on sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3598">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and CRP-cAMP inhibited sigma (54) - glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3599">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and CRP-cAMP inhibited sigma (54)-dependent glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3600">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and CRP-cAMP inhibited sigma (54)-gnAp2 dependent with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="3601">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and CRP-cAMP inhibited sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="3602">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and Roipram inhibited multiple PDE4 isoforms coded by PDE4C with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="3603">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and Roipram inhibited multiple PDE4 with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="3604">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and Roipram inhibited multiple PDE4-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3605">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from the transcedit body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3606">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transcedit body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3607">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transcent body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3608">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transfected body cells inhibited both C alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3609">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transfected body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3610">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts of the transfected body cells inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3611">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts of transcedural body cells inhibited both alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3612">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited PDE44 cyclic AMP-phosphodiesterases with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="3613">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited PDE44 cyclic AMP-specific isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3614">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited PDE44 cyclic AMP-specific phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="3615">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited multiple AMP-specific cyclic PDE4 isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3616">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3617">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="3618">
                    <text>a proteasome MG132 inhibitor and lactacitstin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3619">
                    <text>a proteasome MG132 inhibitor and lactacitstin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3620">
                    <text>a proteasome MG132 inhibitor and lactacitstin (NO) inhibiting the regulation of phosphorylated state, state5 and state6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3621">
                    <text>a proteasome MG132 inhibitor and lactacitstin (NO) inhibiting the regulation of phosphorylated state, state5 and state6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3622">
                    <text>a proteasome MG132 inhibitor and lactacitstin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3623">
                    <text>a proteasome MG132 inhibitor and lactacitstin also has the ability to inhibit the regulation of phosphorylated state, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3624">
                    <text>a proteasome MG132 inhibitor and lactacitstin also inhibited the regulation of phosphorylated state, state5 and state6 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3625">
                    <text>a proteasome MG132 inhibitor and lactacitstin also inhibits the regulation of phosphorylated state, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3626">
                    <text>a proteasome MG132 inhibitor and lactacitstin also inhibits the regulation of phosphorylated state, state5 and state6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3627">
                    <text>a proteasome MG132 inhibitor and lactacitstin can fully inhibit the regulation of phosphorylated state, state5 and state6 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3628">
                    <text>a proteasome MG132 inhibitor and lactacitstin can inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3629">
                    <text>a proteasome MG132 inhibitor and lactacitstin can totally inhibit the regulation of phosphorylated state, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3630">
                    <text>a proteasome MG132 inhibitor and lactacitstin co-expression also has the ability to inhibit the regulation of phosphorylated state, state5 and state6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3631">
                    <text>a proteasome MG132 inhibitor and lactacitstin fully inhibiting concentration-dependent the regulation of phosphorylated state, state5 and state6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3632">
                    <text>a proteasome MG132 inhibitor and lactacitstin has also inhibited the regulation of phosphorylated state, state5 and state6 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3633">
                    <text>a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3634">
                    <text>a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3635">
                    <text>a proteasome MG132 inhibitor and lactacitstin inhibits the regulation of phosphorylated state, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3636">
                    <text>a proteasome MG132 inhibitor and lactacitstin inhibits the regulation of phosphorylated state, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3637">
                    <text>a proteasome MG132 inhibitor and lactacitstin is able to inhibit the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3638">
                    <text>a proteasome MG132 inhibitor and lactacitstin may also have inhibited the regulation of phosphorylated state, state5 and state6 in T cells affected by jurkat.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3639">
                    <text>a proteasome MG132 inhibitor and lactacitstin may also have inhibited the regulation of phosphorylated state, state5 and state6 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3640">
                    <text>a proteasome MG132 inhibitor and lactacitstin may have completely inhibited the regulation of phosphorylated state, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3641">
                    <text>a proteasome MG132 inhibitor and lactacitstin may have completely inhibited the regulation of phosphorylated state, state5 and state6 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="3642">
                    <text>activity promotionAp2 are inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3643">
                    <text>activity promotionAp2 can be inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3644">
                    <text>activity promotionAp2 has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3645">
                    <text>activity promotionAp2 in Jurkat T-leukemia transfect cells has also been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3646">
                    <text>activity promotionAp2 in T cells of Jurkat transfects is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3647">
                    <text>activity promotionAp2 in T-lycemic cells transfected, wil is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3648">
                    <text>activity promotionAp2 in transfectuously affected T-leukemia cells, wil is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3649">
                    <text>activity promotionAp2 in transiently transfected Jurkat T-cells is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3650">
                    <text>activity promotionAp2 in transiently transfected Jurkat T-cells was also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3651">
                    <text>activity promotionAp2 is a dependent and saturable concentration and can be fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3652">
                    <text>activity promotionAp2 is a dependent and saturable concentration and can be totally inhibited with CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3653">
                    <text>activity promotionAp2 is a dependent and saturable concentration and has been totally inhibited with CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3654">
                    <text>activity promotionAp2 is a dependent and saturable concentration and is able to be fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3655">
                    <text>activity promotionAp2 is a dependent and saturable concentration and is fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3656">
                    <text>activity promotionAp2 is a dependent and saturable concentration and is observed to be totally inhibited with CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3657">
                    <text>activity promotionAp2 is a dependent and saturable concentration and was fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3658">
                    <text>activity promotionAp2 is able to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3659">
                    <text>activity promotionAp2 is capable of being inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3660">
                    <text>activity promotionAp2 is capable of being inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3661">
                    <text>activity promotionAp2 is concentration-dependent and saturable and is able to be fully inhibited with CRP-cAMP complex , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3662">
                    <text>activity promotionAp2 is inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3663">
                    <text>activity promotionAp2 is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3664">
                    <text>activity promotionAp2 is observed to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3665">
                    <text>activity promotionAp2 may have been inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3666">
                    <text>activity promotionAp2 was inhibited by CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3667">
                    <text>activity promotionAp2 was inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3668">
                    <text>activity promotionAp2 was inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3669">
                    <text>activity promotionAp2 will be inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3670">
                    <text>activity promotionAp2 will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="3671">
                    <text>an inhibitor of the MG132 protein and lactacittine (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3672">
                    <text>an inhibitor of the MG132 protein and lactacittine (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3673">
                    <text>an inhibitor of the MG132 protein and lactacittine (NO) inhibiting regulation of phosphorylated status, stage 5 and stage 6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3674">
                    <text>an inhibitor of the MG132 protein and lactacittine (NO) inhibiting regulation of phosphorylated status, stage 5 and stage 6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3675">
                    <text>an inhibitor of the MG132 protein and lactacittine activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3676">
                    <text>an inhibitor of the MG132 protein and lactacittine also has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6 in transient transfected T-cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3677">
                    <text>an inhibitor of the MG132 protein and lactacittine also inhibited regulation of phosphorylated status, stage 5 and stage 6 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3678">
                    <text>an inhibitor of the MG132 protein and lactacittine also inhibits regulation of phosphorylated status, stage 5 and stage 6 in transient transfected T-cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3679">
                    <text>an inhibitor of the MG132 protein and lactacittine also inhibits regulation of phosphorylated status, stage 5 and stage 6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3680">
                    <text>an inhibitor of the MG132 protein and lactacittine can fully inhibit regulation of phosphorylated status, stage 5 and stage 6 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3681">
                    <text>an inhibitor of the MG132 protein and lactacittine can inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3682">
                    <text>an inhibitor of the MG132 protein and lactacittine can totally inhibit regulation of phosphorylated status, stage 5 and stage 6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3683">
                    <text>an inhibitor of the MG132 protein and lactacittine co-expression also has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3684">
                    <text>an inhibitor of the MG132 protein and lactacittine fully inhibiting concentration-dependent regulation of phosphorylated status, stage 5 and stage 6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3685">
                    <text>an inhibitor of the MG132 protein and lactacittine has also inhibited regulation of phosphorylated status, stage 5 and stage 6 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3686">
                    <text>an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3687">
                    <text>an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3688">
                    <text>an inhibitor of the MG132 protein and lactacittine inhibits regulation of phosphorylated status, stage 5 and stage 6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3689">
                    <text>an inhibitor of the MG132 protein and lactacittine inhibits regulation of phosphorylated status, stage 5 and stage 6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3690">
                    <text>an inhibitor of the MG132 protein and lactacittine may also have inhibited regulation of phosphorylated status, stage 5 and stage 6 in T cells affected by jurkat.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3691">
                    <text>an inhibitor of the MG132 protein and lactacittine may also have inhibited regulation of phosphorylated status, stage 5 and stage 6 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3692">
                    <text>an inhibitor of the MG132 protein and lactacittine may have completely inhibited regulation of phosphorylated status, stage 5 and stage 6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3693">
                    <text>an inhibitor of the MG132 protein and lactacittine may have completely inhibited regulation of phosphorylated status, stage 5 and stage 6 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3694">
                    <text>an inhibitor of the MG132 protein and lactacittine may have inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="3695">
                    <text>another protein binding to phosphatase can inhibit function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="3696">
                    <text>another protein binding to phosphatase can inhibit the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="3697">
                    <text>another protein binding to phosphatase may have inhibited function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="3698">
                    <text>another protein binding to phosphatase may have inhibited the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="3699">
                    <text>another protein binds to phosphatase and is able to inhibit function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="3700">
                    <text>another protein binds to phosphatase and is able to inhibit the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="3701">
                    <text>another protein binds to phosphatase to inhibit function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="3702">
                    <text>another protein binds to phosphatase to inhibit the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="3703">
                    <text>another protein that binds to phosphatase may have inhibited function and location of phosphatases.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="3704">
                    <text>another protein that binds to phosphatase may have inhibited the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="3705">
                    <text>binding are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3706">
                    <text>binding are inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3707">
                    <text>binding are inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3708">
                    <text>binding can be inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3709">
                    <text>binding can be inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3710">
                    <text>binding has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3711">
                    <text>binding has been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3712">
                    <text>binding in Jurkat T-leukemia transfect cells has also been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3713">
                    <text>binding in Jurkat T-leukemia transfect cells has also been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3714">
                    <text>binding in T cells of Jurkat transfects is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3715">
                    <text>binding in T cells of Jurkat transfects is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3716">
                    <text>binding in T-lycemic cells transfected, wil is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3717">
                    <text>binding in T-lycemic cells transfected, wil is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3718">
                    <text>binding in transfectuously affected T-leukemia cells, wil is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3719">
                    <text>binding in transfectuously affected T-leukemia cells, wil is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3720">
                    <text>binding in transiently transfected Jurkat T-cells is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3721">
                    <text>binding in transiently transfected Jurkat T-cells is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3722">
                    <text>binding in transiently transfected Jurkat T-cells was also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3723">
                    <text>binding in transiently transfected Jurkat T-cells was also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3724">
                    <text>binding is a dependent and saturable concentration and can be fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3725">
                    <text>binding is a dependent and saturable concentration and can be fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3726">
                    <text>binding is a dependent and saturable concentration and can be totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3727">
                    <text>binding is a dependent and saturable concentration and has been totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3728">
                    <text>binding is a dependent and saturable concentration and is able to be fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3729">
                    <text>binding is a dependent and saturable concentration and is able to be fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3730">
                    <text>binding is a dependent and saturable concentration and is fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3731">
                    <text>binding is a dependent and saturable concentration and is fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3732">
                    <text>binding is a dependent and saturable concentration and is observed to be totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3733">
                    <text>binding is a dependent and saturable concentration and was fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3734">
                    <text>binding is a dependent and saturable concentration and was fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3735">
                    <text>binding is able to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3736">
                    <text>binding is able to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3737">
                    <text>binding is capable of being inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3738">
                    <text>binding is capable of being inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3739">
                    <text>binding is capable of being inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3740">
                    <text>binding is capable of being inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3741">
                    <text>binding is concentration-dependent and saturable and is able to be fully inhibited with DTA of 10 mM , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3742">
                    <text>binding is concentration-dependent and saturable and is able to be fully inhibited with EDTA 10mM , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3743">
                    <text>binding is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3744">
                    <text>binding is inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3745">
                    <text>binding is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3746">
                    <text>binding is inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3747">
                    <text>binding is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3748">
                    <text>binding is observed to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3749">
                    <text>binding is observed to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3750">
                    <text>binding may have been inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3751">
                    <text>binding may have been inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3752">
                    <text>binding was inhibited by DTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3753">
                    <text>binding was inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3754">
                    <text>binding was inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3755">
                    <text>binding was inhibited by EDTA 10mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3756">
                    <text>binding was inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3757">
                    <text>binding was inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3758">
                    <text>binding were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3759">
                    <text>binding will be inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3760">
                    <text>binding will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3761">
                    <text>binding will be inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3762">
                    <text>binding will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="3763">
                    <text>both C alpha and C beta isoforms of the catalytic subunit PKA has been strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3764">
                    <text>both C alpha and C beta isoforms of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from transfected body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3765">
                    <text>both C alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transfected body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3766">
                    <text>both C alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3767">
                    <text>both C alpha and C beta isoforms of the catalytic subunit PKA was strongly inhibited by protein extracts from transfected body cells 21 times.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3768">
                    <text>both alpha and C beta isoforms of the catalytic subunit PKA has been strongly inhibited by protein extracts of transcedural body cells, by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3769">
                    <text>both alpha and C beta isoforms of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts of transcedural body cells, by 21-folds.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3770">
                    <text>both alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts of transcedural body cells by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3771">
                    <text>both alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts of transcedural body cells, by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3772">
                    <text>both alpha and C beta isoforms of the catalytic subunit PKA was strongly inhibited by protein extracts of transcedural body cells 21 times.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3773">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA has been strongly inhibited by protein extracts from the transcedit body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3774">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA has been strongly inhibited by protein extracts from transcedit body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3775">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA has been strongly inhibited by protein extracts from transcent body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3776">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA has been strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3777">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from the transcedit body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3778">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from transcedit body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3779">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from transcent body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3780">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from transfected body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3781">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from the transcedit body cells by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3782">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from the transcedit body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3783">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transcedit body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3784">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transcedit body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3785">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transcent body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3786">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transcent body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3787">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transfected body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3788">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3789">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA was strongly inhibited by protein extracts from the transcedit body cells 21 times.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3790">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA was strongly inhibited by protein extracts from transcedit body cells 21 times.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3791">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA was strongly inhibited by protein extracts from transcent body cells 21 times.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3792">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA was strongly inhibited by protein extracts from transfected body cells 21 times.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3793">
                    <text>both the isoforms C alpha and C beta of the catalytic subunit PKA has been strongly inhibited by protein extracts of the transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3794">
                    <text>both the isoforms C alpha and C beta of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts of the transfected body cells, by 21-folds.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3795">
                    <text>both the isoforms C alpha and C beta of the catalytic subunit PKA is strongly inhibited by protein extracts of the transfected body cells by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3796">
                    <text>both the isoforms C alpha and C beta of the catalytic subunit PKA is strongly inhibited by protein extracts of the transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3797">
                    <text>both the isoforms C alpha and C beta of the catalytic subunit PKA was strongly inhibited by protein extracts of the transfected body cells 21 times.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3798">
                    <text>both the isoforms C alpha and beta C of the catalytic subunit PKA has been strongly inhibited by protein extracts from transfect body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3799">
                    <text>both the isoforms C alpha and beta C of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from transfect body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3800">
                    <text>both the isoforms C alpha and beta C of the catalytic subunit PKA is strongly inhibited by protein extracts from transfect body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3801">
                    <text>both the isoforms C alpha and beta C of the catalytic subunit PKA is strongly inhibited by protein extracts from transfect body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3802">
                    <text>both the isoforms C alpha and beta C of the catalytic subunit PKA was strongly inhibited by protein extracts from transfect body cells 21 times.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="3803">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3804">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3805">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3806">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3807">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3808">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies also has the ability to inhibit NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3809">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3810">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3811">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3812">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies can fully inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3813">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3814">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3815">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies co-expression also has the ability to inhibit NK-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3816">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3817">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies has also inhibited NK-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3818">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3819">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3820">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3821">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3822">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3823">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3824">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3825">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3826">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3827">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3828">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3829">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3830">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3831">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3832">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3833">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3834">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) inhibiting cytotoxicity mediated by NK cells activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3835">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) inhibiting cytotoxicity mediated by NK cells activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3836">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3837">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3838">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also has the ability to inhibit NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3839">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also has the ability to inhibit cytotoxicity mediated by NK cells in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3840">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3841">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also inhibited cytotoxicity mediated by NK cells in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3842">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3843">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3844">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also inhibits cytotoxicity mediated by NK cells in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3845">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also inhibits cytotoxicity mediated by NK cells in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3846">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins can fully inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3847">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins can fully inhibit cytotoxicity mediated by NK cells that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3848">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3849">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins can inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3850">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3851">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins can totally inhibit cytotoxicity mediated by NK cells that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3852">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins co-expression also has the ability to inhibit NK-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3853">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins co-expression also has the ability to inhibit cytotoxicity mediated by NK cells in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3854">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3855">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins fully inhibiting concentration-dependent cytotoxicity mediated by NK cells and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3856">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins has also inhibited NK-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3857">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins has also inhibited cytotoxicity mediated by NK cells in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3858">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3859">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3860">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited cytotoxicity mediated by NK cells activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3861">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited cytotoxicity mediated by NK cells activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3862">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3863">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3864">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits cytotoxicity mediated by NK cells activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3865">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits cytotoxicity mediated by NK cells activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3866">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3867">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins is able to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3868">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3869">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3870">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may also have inhibited cytotoxicity mediated by NK cells in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3871">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may also have inhibited cytotoxicity mediated by NK cells in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3872">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3873">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3874">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may have completely inhibited cytotoxicity mediated by NK cells that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3875">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may have completely inhibited cytotoxicity mediated by NK cells which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3876">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3877">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may have inhibited cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="3878">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3879">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3880">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins (NO) inhibiting NK cell-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3881">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins (NO) inhibiting NK cell-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3882">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3883">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins also has the ability to inhibit NK cell-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3884">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins also inhibited NK cell-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3885">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins also inhibits NK cell-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3886">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins also inhibits NK cell-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3887">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins can fully inhibit NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3888">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins can inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3889">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins can totally inhibit NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3890">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins co-expression also has the ability to inhibit NK cell-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3891">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins fully inhibiting concentration-dependent NK cell-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3892">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins has also inhibited NK cell-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3893">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins inhibited NK cell-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3894">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins inhibited NK cell-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3895">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins inhibits NK cell-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3896">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins inhibits NK cell-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3897">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3898">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins may also have inhibited NK cell-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3899">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins may also have inhibited NK cell-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3900">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins may have completely inhibited NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3901">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins may have completely inhibited NK cell-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3902">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins may have inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3903">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3904">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3905">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3906">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3907">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3908">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin also has the ability to inhibit NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3909">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3910">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3911">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3912">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin can fully inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3913">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3914">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3915">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin co-expression also has the ability to inhibit NK-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3916">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3917">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin has also inhibited NK-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3918">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3919">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3920">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3921">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3922">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3923">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3924">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3925">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3926">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3927">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3928">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3929">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3930">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies (NO) inhibiting NK cell-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3931">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies (NO) inhibiting NK cell-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3932">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3933">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies also has the ability to inhibit NK cell-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3934">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies also inhibited NK cell-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3935">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies also inhibits NK cell-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3936">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies also inhibits NK cell-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3937">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies can fully inhibit NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3938">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies can inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3939">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies can totally inhibit NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3940">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies co-expression also has the ability to inhibit NK cell-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3941">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies fully inhibiting concentration-dependent NK cell-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3942">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies has also inhibited NK cell-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3943">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies inhibited NK cell-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3944">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies inhibited NK cell-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3945">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies inhibits NK cell-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3946">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies inhibits NK cell-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3947">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3948">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies may also have inhibited NK cell-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3949">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies may also have inhibited NK cell-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3950">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies may have completely inhibited NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3951">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies may have completely inhibited NK cell-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3952">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies may have inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3953">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3954">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3955">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies (NO) inhibiting NK cell-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3956">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies (NO) inhibiting NK cell-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3957">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3958">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies also has the ability to inhibit NK cell-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3959">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies also inhibited NK cell-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3960">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies also inhibits NK cell-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3961">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies also inhibits NK cell-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3962">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies can fully inhibit NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3963">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies can inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3964">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies can totally inhibit NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3965">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies co-expression also has the ability to inhibit NK cell-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3966">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies fully inhibiting concentration-dependent NK cell-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3967">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies has also inhibited NK cell-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3968">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies inhibited NK cell-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3969">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies inhibited NK cell-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3970">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies inhibits NK cell-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3971">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies inhibits NK cell-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3972">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3973">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies may also have inhibited NK cell-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3974">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies may also have inhibited NK cell-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3975">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies may have completely inhibited NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3976">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies may have completely inhibited NK cell-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3977">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies may have inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3978">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3979">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3980">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3981">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3982">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3983">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin also has the ability to inhibit NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3984">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3985">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3986">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3987">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin can fully inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3988">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3989">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3990">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin co-expression also has the ability to inhibit NK-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3991">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3992">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin has also inhibited NK-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3993">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3994">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3995">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3996">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3997">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3998">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="3999">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="4000">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="4001">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="4002">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="4003">
                    <text>chloramphenicol (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4004">
                    <text>chloramphenicol (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4005">
                    <text>chloramphenicol (NO) inhibiting protein synthesis activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4006">
                    <text>chloramphenicol (NO) inhibiting protein synthesis activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4007">
                    <text>chloramphenicol activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4008">
                    <text>chloramphenicol also has the ability to inhibit protein synthesis in transient transfected T-cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4009">
                    <text>chloramphenicol also inhibited protein synthesis in transfected T-leukemia cells transfected.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4010">
                    <text>chloramphenicol also inhibits protein synthesis in transient transfected T-cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4011">
                    <text>chloramphenicol also inhibits protein synthesis in transiently transfected T-leukemia cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4012">
                    <text>chloramphenicol can fully inhibit protein synthesis that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4013">
                    <text>chloramphenicol can inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4014">
                    <text>chloramphenicol can totally inhibit protein synthesis that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4015">
                    <text>chloramphenicol co-expression also has the ability to inhibit protein synthesis in T-leukemia transnetly affected cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4016">
                    <text>chloramphenicol fully inhibiting concentration-dependent protein synthesis and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4017">
                    <text>chloramphenicol has also inhibited protein synthesis in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4018">
                    <text>chloramphenicol inhibited protein synthesis activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4019">
                    <text>chloramphenicol inhibited protein synthesis activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4020">
                    <text>chloramphenicol inhibits protein synthesis activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4021">
                    <text>chloramphenicol inhibits protein synthesis activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4022">
                    <text>chloramphenicol is able to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4023">
                    <text>chloramphenicol may also have inhibited protein synthesis in T cells affected by jurkat.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4024">
                    <text>chloramphenicol may also have inhibited protein synthesis in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4025">
                    <text>chloramphenicol may have completely inhibited protein synthesis that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4026">
                    <text>chloramphenicol may have completely inhibited protein synthesis which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4027">
                    <text>chloramphenicol may have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="4028">
                    <text>co-expression of AAM-3 (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4029">
                    <text>co-expression of AAM-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4030">
                    <text>co-expression of AAM-3 (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4031">
                    <text>co-expression of AAM-3 (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4032">
                    <text>co-expression of AAM-3 activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4033">
                    <text>co-expression of AAM-3 also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4034">
                    <text>co-expression of AAM-3 also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4035">
                    <text>co-expression of AAM-3 also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4036">
                    <text>co-expression of AAM-3 also inhibits functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4037">
                    <text>co-expression of AAM-3 can fully inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4038">
                    <text>co-expression of AAM-3 can inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4039">
                    <text>co-expression of AAM-3 can totally inhibit functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4040">
                    <text>co-expression of AAM-3 co-expression also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4041">
                    <text>co-expression of AAM-3 fully inhibiting concentration-dependent functional activation of a plasmid HIV reporter by p49/ p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4042">
                    <text>co-expression of AAM-3 has also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4043">
                    <text>co-expression of AAM-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4044">
                    <text>co-expression of AAM-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4045">
                    <text>co-expression of AAM-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4046">
                    <text>co-expression of AAM-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4047">
                    <text>co-expression of AAM-3 is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4048">
                    <text>co-expression of AAM-3 may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in T cells affected by jurkat.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4049">
                    <text>co-expression of AAM-3 may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4050">
                    <text>co-expression of AAM-3 may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4051">
                    <text>co-expression of AAM-3 may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4052">
                    <text>co-expression of AAM-3 may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4053">
                    <text>cytotoxicity mediated by NK cells are inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4054">
                    <text>cytotoxicity mediated by NK cells can be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4055">
                    <text>cytotoxicity mediated by NK cells has been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4056">
                    <text>cytotoxicity mediated by NK cells in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4057">
                    <text>cytotoxicity mediated by NK cells in T cells of Jurkat transfects is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4058">
                    <text>cytotoxicity mediated by NK cells in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4059">
                    <text>cytotoxicity mediated by NK cells in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4060">
                    <text>cytotoxicity mediated by NK cells in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4061">
                    <text>cytotoxicity mediated by NK cells in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4062">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4063">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4064">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4065">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4066">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4067">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4068">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and was fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4069">
                    <text>cytotoxicity mediated by NK cells is able to be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4070">
                    <text>cytotoxicity mediated by NK cells is capable of being inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4071">
                    <text>cytotoxicity mediated by NK cells is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4072">
                    <text>cytotoxicity mediated by NK cells is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4073">
                    <text>cytotoxicity mediated by NK cells is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4074">
                    <text>cytotoxicity mediated by NK cells may have been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4075">
                    <text>cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4076">
                    <text>cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4077">
                    <text>cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4078">
                    <text>cytotoxicity mediated by NK cells will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4079">
                    <text>cytotoxicity mediated by NK cells will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="4080">
                    <text>depending on GadX are inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4081">
                    <text>depending on GadX can be inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4082">
                    <text>depending on GadX has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4083">
                    <text>depending on GadX in Jurkat T-leukemia transfect cells has also been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4084">
                    <text>depending on GadX in T cells of Jurkat transfects is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4085">
                    <text>depending on GadX in T-lycemic cells transfected, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4086">
                    <text>depending on GadX in transfectuously affected T-leukemia cells, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4087">
                    <text>depending on GadX in transiently transfected Jurkat T-cells is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4088">
                    <text>depending on GadX in transiently transfected Jurkat T-cells was also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4089">
                    <text>depending on GadX is a dependent and saturable concentration and can be fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4090">
                    <text>depending on GadX is a dependent and saturable concentration and can be totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4091">
                    <text>depending on GadX is a dependent and saturable concentration and has been totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4092">
                    <text>depending on GadX is a dependent and saturable concentration and is able to be fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4093">
                    <text>depending on GadX is a dependent and saturable concentration and is fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4094">
                    <text>depending on GadX is a dependent and saturable concentration and is observed to be totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4095">
                    <text>depending on GadX is a dependent and saturable concentration and was fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4096">
                    <text>depending on GadX is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4097">
                    <text>depending on GadX is capable of being inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4098">
                    <text>depending on GadX is capable of being inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4099">
                    <text>depending on GadX is concentration-dependent and saturable and is able to be fully inhibited with GadW , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4100">
                    <text>depending on GadX is inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4101">
                    <text>depending on GadX is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4102">
                    <text>depending on GadX is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4103">
                    <text>depending on GadX may have been inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4104">
                    <text>depending on GadX was inhibited by GadW that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4105">
                    <text>depending on GadX was inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4106">
                    <text>depending on GadX was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4107">
                    <text>depending on GadX will be inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4108">
                    <text>depending on GadX will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="4109">
                    <text>depending on sigma (54)-gnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="4110">
                    <text>depending on sigma (54)-gnAp2 is observed to be strongly inhibited by CRP-cAMP, by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="4111">
                    <text>depending on sigma (54)-gnAp2 is strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="4112">
                    <text>depending on sigma (54)-gnAp2 was strongly inhibited by CRP-cAMP 21 times.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="4113">
                    <text>descendant regulation of phosphorylation state, state5 and state6 are inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4114">
                    <text>descendant regulation of phosphorylation state, state5 and state6 are inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4115">
                    <text>descendant regulation of phosphorylation state, state5 and state6 can be inhibited by primary proteasome inhibitors MG132 and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4116">
                    <text>descendant regulation of phosphorylation state, state5 and state6 can be inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4117">
                    <text>descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4118">
                    <text>descendant regulation of phosphorylation state, state5 and state6 has been inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4119">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in Jurkat T-leukemia transfect cells has also been inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4120">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in Jurkat T-leukemia transfect cells has also been inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4121">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in T cells of Jurkat transfects is also inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4122">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in T cells of Jurkat transfects is also inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4123">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in T-lycemic cells transfected, wil is also inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4124">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in T-lycemic cells transfected, wil is also inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4125">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in transfectuously affected T-leukemia cells, wil is also inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4126">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in transfectuously affected T-leukemia cells, wil is also inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4127">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in transiently transfected Jurkat T-cells is also inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4128">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in transiently transfected Jurkat T-cells is also inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4129">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in transiently transfected Jurkat T-cells was also inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4130">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in transiently transfected Jurkat T-cells was also inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4131">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and can be fully inhibited with primary proteasome inhibitors MG132 and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4132">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and can be fully inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4133">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and can be totally inhibited with primary proteasome inhibitors MG132 and lactacitstin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4134">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and can be totally inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4135">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and has been totally inhibited with primary proteasome inhibitors MG132 and lactacitstin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4136">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and has been totally inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4137">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and is able to be fully inhibited with primary proteasome inhibitors MG132 and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4138">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and is able to be fully inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4139">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and is fully inhibited with primary proteasome inhibitors MG132 and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4140">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and is fully inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4141">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and is observed to be totally inhibited with primary proteasome inhibitors MG132 and lactacitstin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4142">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and is observed to be totally inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4143">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and was fully inhibited with primary proteasome inhibitors MG132 and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4144">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and was fully inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4145">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is able to be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4146">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is able to be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4147">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is capable of being inhibited by primary proteasome inhibitors MG132 and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4148">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is capable of being inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4149">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is capable of being inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4150">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is capable of being inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4151">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is concentration-dependent and saturable and is able to be fully inhibited with primary proteasome inhibitors MG132 and lactacitstin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4152">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is concentration-dependent and saturable and is able to be fully inhibited with primary proteasome inhibitors MG132 and lactacyttin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4153">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4154">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4155">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4156">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4157">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is observed to be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4158">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is observed to be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4159">
                    <text>descendant regulation of phosphorylation state, state5 and state6 may have been inhibited by primary proteasome inhibitors MG132 and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4160">
                    <text>descendant regulation of phosphorylation state, state5 and state6 may have been inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4161">
                    <text>descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacitstin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4162">
                    <text>descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4163">
                    <text>descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4164">
                    <text>descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4165">
                    <text>descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4166">
                    <text>descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4167">
                    <text>descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4168">
                    <text>descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4169">
                    <text>descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4170">
                    <text>descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4171">
                    <text>descending regulation of the phosphorylation status, state5 and state6 are inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4172">
                    <text>descending regulation of the phosphorylation status, state5 and state6 can be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4173">
                    <text>descending regulation of the phosphorylation status, state5 and state6 has been inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4174">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in Jurkat T-leukemia transfect cells has also been inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4175">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in T cells of Jurkat transfects is also inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4176">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in T-lycemic cells transfected, wil is also inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4177">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in transfectuously affected T-leukemia cells, wil is also inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4178">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in transiently transfected Jurkat T-cells is also inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4179">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in transiently transfected Jurkat T-cells was also inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4180">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and can be fully inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4181">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and can be totally inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4182">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and has been totally inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4183">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and is able to be fully inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4184">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and is fully inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4185">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and is observed to be totally inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4186">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and was fully inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4187">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is able to be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4188">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is capable of being inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4189">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is capable of being inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4190">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is concentration-dependent and saturable and is able to be fully inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4191">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4192">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4193">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is observed to be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4194">
                    <text>descending regulation of the phosphorylation status, state5 and state6 may have been inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4195">
                    <text>descending regulation of the phosphorylation status, state5 and state6 was inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4196">
                    <text>descending regulation of the phosphorylation status, state5 and state6 was inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4197">
                    <text>descending regulation of the phosphorylation status, state5 and state6 was inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4198">
                    <text>descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4199">
                    <text>descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4200">
                    <text>final events of clathrin coated vesicle formation are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="4201">
                    <text>final events of clathrin coated vesicle formation is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="4202">
                    <text>final events of clathrin coated vesicle formation were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">final events of clathrin coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="4203">
                    <text>function and location of phosphatases would be inhibited if phosphatase were associated with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphatases</arg>
                </example>
                <example src="PERMUTATE" no="4204">
                    <text>function and location of phosphateases will be inhibited if phosphatase is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="4205">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 are inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4206">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 are inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4207">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 are inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4208">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 are inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4209">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by MAD-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4210">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by MAR expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4211">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4212">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 can be inhibited by co-expression of AAM-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4213">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4214">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4215">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4216">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4217">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat T-leukemia transfect cells has also been inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4218">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat T-leukemia transfect cells has also been inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4219">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat T-leukemia transfect cells has also been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4220">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat T-leukemia transfect cells has also been inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4221">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T cells of Jurkat transfects is also inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4222">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T cells of Jurkat transfects is also inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4223">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T cells of Jurkat transfects is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4224">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T cells of Jurkat transfects is also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4225">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T-lycemic cells transfected, wil is also inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4226">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T-lycemic cells transfected, wil is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4227">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T-lycemic cells transfected, wil is also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4228">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transfectuously affected T-leukemia cells, wil is also inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4229">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transfectuously affected T-leukemia cells, wil is also inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4230">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transfectuously affected T-leukemia cells, wil is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4231">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transfectuously affected T-leukemia cells, wil is also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4232">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells is also inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4233">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells is also inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4234">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4235">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells was also inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4236">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells was also inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4237">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells was also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4238">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be fully inhibited with MAD-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4239">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be fully inhibited with MAR expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4240">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4241">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be fully inhibited with co-expression of AAM-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4242">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be totally inhibited with MAD-3 co-expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4243">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be totally inhibited with MAR expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4244">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be totally inhibited with Mad-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4245">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be totally inhibited with co-expression of AAM-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4246">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and has been totally inhibited with MAD-3 co-expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4247">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and has been totally inhibited with MAR expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4248">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and has been totally inhibited with Mad-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4249">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and has been totally inhibited with co-expression of AAM-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4250">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is able to be fully inhibited with MAD-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4251">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is able to be fully inhibited with MAR expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4252">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is able to be fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4253">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is able to be fully inhibited with co-expression of AAM-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4254">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is fully inhibited with MAD-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4255">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is fully inhibited with MAR expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4256">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4257">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is fully inhibited with co-expression of AAM-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4258">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is observed to be totally inhibited with MAD-3 co-expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4259">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is observed to be totally inhibited with MAR expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4260">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is observed to be totally inhibited with Mad-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4261">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is observed to be totally inhibited with co-expression of AAM-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4262">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and was fully inhibited with MAD-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4263">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and was fully inhibited with MAR expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4264">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and was fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4265">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and was fully inhibited with co-expression of AAM-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4266">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4267">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4268">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4269">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4270">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by MAD-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4271">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4272">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by MAR expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4273">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4274">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4275">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4276">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by co-expression of AAM-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4277">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is capable of being inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4278">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is concentration-dependent and saturable and is able to be fully inhibited with MAD-3 co-expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4279">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is concentration-dependent and saturable and is able to be fully inhibited with MAR expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4280">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is concentration-dependent and saturable and is able to be fully inhibited with Mad-3 , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4281">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is concentration-dependent and saturable and is able to be fully inhibited with co-expression of AAM-3 , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4282">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAD-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4283">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4284">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4285">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4286">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4287">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4288">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4289">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4290">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4291">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4292">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4293">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is observed to be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4294">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 may have been inhibited by MAD-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4295">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 may have been inhibited by MAR expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4296">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 may have been inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4297">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 may have been inhibited by co-expression of AAM-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4298">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAD-3 co-expression that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4299">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAD-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4300">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4301">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4302">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4303">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4304">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4305">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4306">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4307">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by co-expression of AAM-3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4308">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by co-expression of AAM-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4309">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4310">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4311">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4312">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAR expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4313">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4314">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4315">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4316">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4317">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="4318">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 are inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4319">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 can be inhibited by AAM-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4320">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 has been inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4321">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 in Jurkat T-leukemia transfect cells has also been inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4322">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 in T-lycemic cells transfected, wil is also inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4323">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 in transfectuously affected T-leukemia cells, wil is also inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4324">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 in transiently transfected Jurkat T-cells is also inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4325">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 in transiently transfected Jurkat T-cells was also inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4326">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is a dependent and saturable concentration and can be fully inhibited with AAM-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4327">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is a dependent and saturable concentration and can be totally inhibited with AAM-3 expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4328">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is a dependent and saturable concentration and has been totally inhibited with AAM-3 expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4329">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is a dependent and saturable concentration and is able to be fully inhibited with AAM-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4330">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is a dependent and saturable concentration and is fully inhibited with AAM-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4331">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is a dependent and saturable concentration and is observed to be totally inhibited with AAM-3 expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4332">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is a dependent and saturable concentration and was fully inhibited with AAM-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4333">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is able to be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4334">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is capable of being inhibited by AAM-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4335">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is capable of being inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4336">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is concentration-dependent and saturable and is able to be fully inhibited with AAM-3 expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4337">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4338">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4339">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 is observed to be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4340">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 may have been inhibited by AAM-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4341">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 was inhibited by AAM-3 expression that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4342">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 was inhibited by AAM-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4343">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 was inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4344">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4345">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4346">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 are inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4347">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 are inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4348">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 are inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4349">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by MAD-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4350">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by Mad-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4351">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4352">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4353">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4354">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4355">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in Jurkat T-leukemia transfect cells has also been inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4356">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in Jurkat T-leukemia transfect cells has also been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4357">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in T cells of Jurkat transfects is also inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4358">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in T cells of Jurkat transfects is also inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4359">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in T cells of Jurkat transfects is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4360">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in T-lycemic cells transfected, wil is also inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4361">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in T-lycemic cells transfected, wil is also inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4362">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in T-lycemic cells transfected, wil is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4363">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transfectuously affected T-leukemia cells, wil is also inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4364">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transfectuously affected T-leukemia cells, wil is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4365">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-cells is also inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4366">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-cells is also inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4367">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-cells is also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4368">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-cells was also inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4369">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-cells was also inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4370">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-cells was also inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4371">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and can be fully inhibited with MAD-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4372">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and can be fully inhibited with Mad-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4373">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and can be fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4374">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and can be totally inhibited with MAD-3 expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4375">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and can be totally inhibited with Mad-3 co-expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4376">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and can be totally inhibited with Mad-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4377">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and has been totally inhibited with MAD-3 expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4378">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and has been totally inhibited with Mad-3 co-expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4379">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and has been totally inhibited with Mad-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4380">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is able to be fully inhibited with MAD-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4381">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is able to be fully inhibited with Mad-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4382">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is able to be fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4383">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is fully inhibited with MAD-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4384">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is fully inhibited with Mad-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4385">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4386">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is observed to be totally inhibited with MAD-3 expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4387">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is observed to be totally inhibited with Mad-3 co-expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4388">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and is observed to be totally inhibited with Mad-3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4389">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and was fully inhibited with MAD-3 expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4390">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and was fully inhibited with Mad-3 co-expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4391">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is a dependent and saturable concentration and was fully inhibited with Mad-3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4392">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4393">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4394">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4395">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is capable of being inhibited by MAD-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4396">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is capable of being inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4397">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is capable of being inhibited by Mad-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4398">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is capable of being inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4399">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is capable of being inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4400">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is capable of being inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4401">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is concentration-dependent and saturable and is able to be fully inhibited with MAD-3 expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4402">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is concentration-dependent and saturable and is able to be fully inhibited with Mad-3 , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4403">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is concentration-dependent and saturable and is able to be fully inhibited with Mad-3 co-expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4404">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4405">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4406">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4407">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4408">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4409">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4410">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4411">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4412">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4413">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 may have been inhibited by MAD-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4414">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 may have been inhibited by Mad-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4415">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 may have been inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4416">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by MAD-3 expression that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4417">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by MAD-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4418">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4419">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 co-expression that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4420">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4421">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4422">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4423">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4424">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4425">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by MAD-3 expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4426">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4427">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4428">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4429">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4430">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="4431">
                    <text>gnAp2 promoting activity are inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4432">
                    <text>gnAp2 promoting activity can be inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4433">
                    <text>gnAp2 promoting activity has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4434">
                    <text>gnAp2 promoting activity in Jurkat T-leukemia transfect cells has also been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4435">
                    <text>gnAp2 promoting activity in T cells of Jurkat transfects is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4436">
                    <text>gnAp2 promoting activity in T-lycemic cells transfected, wil is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4437">
                    <text>gnAp2 promoting activity in transfectuously affected T-leukemia cells, wil is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4438">
                    <text>gnAp2 promoting activity in transiently transfected Jurkat T-cells is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4439">
                    <text>gnAp2 promoting activity in transiently transfected Jurkat T-cells was also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4440">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and can be fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4441">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and can be totally inhibited with CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4442">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and has been totally inhibited with CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4443">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and is able to be fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4444">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and is fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4445">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and is observed to be totally inhibited with CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4446">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and was fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4447">
                    <text>gnAp2 promoting activity is able to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4448">
                    <text>gnAp2 promoting activity is capable of being inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4449">
                    <text>gnAp2 promoting activity is capable of being inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4450">
                    <text>gnAp2 promoting activity is concentration-dependent and saturable and is able to be fully inhibited with CRP-cAMP complex , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4451">
                    <text>gnAp2 promoting activity is inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4452">
                    <text>gnAp2 promoting activity is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4453">
                    <text>gnAp2 promoting activity is observed to be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4454">
                    <text>gnAp2 promoting activity may have been inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4455">
                    <text>gnAp2 promoting activity was inhibited by CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4456">
                    <text>gnAp2 promoting activity was inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4457">
                    <text>gnAp2 promoting activity was inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4458">
                    <text>gnAp2 promoting activity will be inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4459">
                    <text>gnAp2 promoting activity will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="4460">
                    <text>inhibitors of the MG132 proteasome and lactacyttin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4461">
                    <text>inhibitors of the MG132 proteasome and lactacyttin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4462">
                    <text>inhibitors of the MG132 proteasome and lactacyttin (NO) inhibiting the regulation of the phosphorylated state, Stat5 and Stat6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4463">
                    <text>inhibitors of the MG132 proteasome and lactacyttin (NO) inhibiting the regulation of the phosphorylated state, Stat5 and Stat6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4464">
                    <text>inhibitors of the MG132 proteasome and lactacyttin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4465">
                    <text>inhibitors of the MG132 proteasome and lactacyttin also has the ability to inhibit the regulation of the phosphorylated state, Stat5 and Stat6 in transient transfected T-cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4466">
                    <text>inhibitors of the MG132 proteasome and lactacyttin also inhibited the regulation of the phosphorylated state, Stat5 and Stat6 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4467">
                    <text>inhibitors of the MG132 proteasome and lactacyttin also inhibits the regulation of the phosphorylated state, Stat5 and Stat6 in transient transfected T-cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4468">
                    <text>inhibitors of the MG132 proteasome and lactacyttin also inhibits the regulation of the phosphorylated state, Stat5 and Stat6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4469">
                    <text>inhibitors of the MG132 proteasome and lactacyttin can fully inhibit the regulation of the phosphorylated state, Stat5 and Stat6 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4470">
                    <text>inhibitors of the MG132 proteasome and lactacyttin can totally inhibit the regulation of the phosphorylated state, Stat5 and Stat6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4471">
                    <text>inhibitors of the MG132 proteasome and lactacyttin co-expression also has the ability to inhibit the regulation of the phosphorylated state, Stat5 and Stat6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4472">
                    <text>inhibitors of the MG132 proteasome and lactacyttin fully inhibiting concentration-dependent the regulation of the phosphorylated state, Stat5 and Stat6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4473">
                    <text>inhibitors of the MG132 proteasome and lactacyttin has also inhibited the regulation of the phosphorylated state, Stat5 and Stat6 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4474">
                    <text>inhibitors of the MG132 proteasome and lactacyttin inhibited the regulation of the phosphorylated state, Stat5 and Stat6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4475">
                    <text>inhibitors of the MG132 proteasome and lactacyttin inhibited the regulation of the phosphorylated state, Stat5 and Stat6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4476">
                    <text>inhibitors of the MG132 proteasome and lactacyttin inhibits the regulation of the phosphorylated state, Stat5 and Stat6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4477">
                    <text>inhibitors of the MG132 proteasome and lactacyttin inhibits the regulation of the phosphorylated state, Stat5 and Stat6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4478">
                    <text>inhibitors of the MG132 proteasome and lactacyttin is able to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4479">
                    <text>inhibitors of the MG132 proteasome and lactacyttin may also have inhibited the regulation of the phosphorylated state, Stat5 and Stat6 in T cells affected by jurkat.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4480">
                    <text>inhibitors of the MG132 proteasome and lactacyttin may also have inhibited the regulation of the phosphorylated state, Stat5 and Stat6 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4481">
                    <text>inhibitors of the MG132 proteasome and lactacyttin may have completely inhibited the regulation of the phosphorylated state, Stat5 and Stat6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4482">
                    <text>inhibitors of the MG132 proteasome and lactacyttin may have completely inhibited the regulation of the phosphorylated state, Stat5 and Stat6 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4483">
                    <text>inhibitors of the MG132 proteasome and lactacyttin may have inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="4484">
                    <text>is binds to C3b would be inhibited if P were associated with This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">is binds to C3b</arg>
                </example>
                <example src="PERMUTATE" no="4485">
                    <text>its C3b binding would be inhibited if P were associated with This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="4486">
                    <text>its binding to C3b would be inhibited if P were associated with this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="4487">
                    <text>its function or location will be inhibited if phosphatase is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4488">
                    <text>its function or location will be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4489">
                    <text>its function or location will be inhibited if phosphatease is associated with other proteins.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4490">
                    <text>its function or location would be inhibited if phosphatase were associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4491">
                    <text>its function or location would be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4492">
                    <text>its function or location would be inhibited if phosphatease is associated with other proteins.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4493">
                    <text>its function or location would be inhibited if phosphatease were associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4494">
                    <text>its function or location would be inhibited if phosphatease were associated with other proteins.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4495">
                    <text>late clathrin coated vesicles formation events are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4496">
                    <text>late clathrin coated vesicles formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4497">
                    <text>late clathrin coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4498">
                    <text>late clathrin coated vesicles formation events in Jurkat T-leukemia transfect cells has also been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4499">
                    <text>late clathrin coated vesicles formation events in T cells of Jurkat transfects is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4500">
                    <text>late clathrin coated vesicles formation events in T-lycemic cells transfected, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4501">
                    <text>late clathrin coated vesicles formation events in transfectuously affected T-leukemia cells, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4502">
                    <text>late clathrin coated vesicles formation events in transiently transfected Jurkat T-cells is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4503">
                    <text>late clathrin coated vesicles formation events in transiently transfected Jurkat T-cells was also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4504">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and can be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4505">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and can be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4506">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and has been totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4507">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4508">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and is fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4509">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and is observed to be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4510">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and was fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4511">
                    <text>late clathrin coated vesicles formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4512">
                    <text>late clathrin coated vesicles formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4513">
                    <text>late clathrin coated vesicles formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4514">
                    <text>late clathrin coated vesicles formation events is concentration-dependent and saturable and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4515">
                    <text>late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4516">
                    <text>late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4517">
                    <text>late clathrin coated vesicles formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4518">
                    <text>late clathrin coated vesicles formation events may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4519">
                    <text>late clathrin coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4520">
                    <text>late clathrin coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4521">
                    <text>late clathrin coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4522">
                    <text>late clathrin coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4523">
                    <text>late clathrin-coated vesicle formation events are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4524">
                    <text>late clathrin-coated vesicle formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4525">
                    <text>late clathrin-coated vesicle formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4526">
                    <text>late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4527">
                    <text>late clathrin-coated vesicle formation events in Jurkat T-leukemia transfect cells has also been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4528">
                    <text>late clathrin-coated vesicle formation events in Jurkat T-leukemia transfect cells has also been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4529">
                    <text>late clathrin-coated vesicle formation events in T cells of Jurkat transfects is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4530">
                    <text>late clathrin-coated vesicle formation events in T cells of Jurkat transfects is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4531">
                    <text>late clathrin-coated vesicle formation events in T-lycemic cells transfected, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4532">
                    <text>late clathrin-coated vesicle formation events in T-lycemic cells transfected, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4533">
                    <text>late clathrin-coated vesicle formation events in transfectuously affected T-leukemia cells, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4534">
                    <text>late clathrin-coated vesicle formation events in transfectuously affected T-leukemia cells, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4535">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4536">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4537">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells was also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4538">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells was also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4539">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4540">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4541">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4542">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4543">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and has been totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4544">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and has been totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4545">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4546">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4547">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4548">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4549">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is observed to be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4550">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is observed to be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4551">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and was fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4552">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and was fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4553">
                    <text>late clathrin-coated vesicle formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4554">
                    <text>late clathrin-coated vesicle formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4555">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4556">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4557">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4558">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4559">
                    <text>late clathrin-coated vesicle formation events is concentration-dependent and saturable and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4560">
                    <text>late clathrin-coated vesicle formation events is concentration-dependent and saturable and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4561">
                    <text>late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4562">
                    <text>late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4563">
                    <text>late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4564">
                    <text>late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4565">
                    <text>late clathrin-coated vesicle formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4566">
                    <text>late clathrin-coated vesicle formation events may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4567">
                    <text>late clathrin-coated vesicle formation events may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4568">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4569">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4570">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4571">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4572">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4573">
                    <text>late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4574">
                    <text>late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4575">
                    <text>late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4576">
                    <text>late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="4577">
                    <text>late clathrin-coated vesicles formation events are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4578">
                    <text>late clathrin-coated vesicles formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4579">
                    <text>late clathrin-coated vesicles formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4580">
                    <text>late clathrin-coated vesicles formation events in Jurkat T-leukemia transfect cells has also been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4581">
                    <text>late clathrin-coated vesicles formation events in T cells of Jurkat transfects is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4582">
                    <text>late clathrin-coated vesicles formation events in T-lycemic cells transfected, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4583">
                    <text>late clathrin-coated vesicles formation events in transfectuously affected T-leukemia cells, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4584">
                    <text>late clathrin-coated vesicles formation events in transiently transfected Jurkat T-cells is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4585">
                    <text>late clathrin-coated vesicles formation events in transiently transfected Jurkat T-cells was also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4586">
                    <text>late clathrin-coated vesicles formation events is a dependent and saturable concentration and can be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4587">
                    <text>late clathrin-coated vesicles formation events is a dependent and saturable concentration and can be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4588">
                    <text>late clathrin-coated vesicles formation events is a dependent and saturable concentration and has been totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4589">
                    <text>late clathrin-coated vesicles formation events is a dependent and saturable concentration and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4590">
                    <text>late clathrin-coated vesicles formation events is a dependent and saturable concentration and is fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4591">
                    <text>late clathrin-coated vesicles formation events is a dependent and saturable concentration and is observed to be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4592">
                    <text>late clathrin-coated vesicles formation events is a dependent and saturable concentration and was fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4593">
                    <text>late clathrin-coated vesicles formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4594">
                    <text>late clathrin-coated vesicles formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4595">
                    <text>late clathrin-coated vesicles formation events is concentration-dependent and saturable and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4596">
                    <text>late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4597">
                    <text>late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4598">
                    <text>late clathrin-coated vesicles formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4599">
                    <text>late clathrin-coated vesicles formation events may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4600">
                    <text>late clathrin-coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4601">
                    <text>late clathrin-coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4602">
                    <text>late clathrin-coated vesicles formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4603">
                    <text>late clathrin-coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4604">
                    <text>late clathrin-coated vesicles formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="4605">
                    <text>late events of clathrin-coated vesicles formation are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4606">
                    <text>late events of clathrin-coated vesicles formation can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4607">
                    <text>late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4608">
                    <text>late events of clathrin-coated vesicles formation in Jurkat T-leukemia transfect cells has also been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4609">
                    <text>late events of clathrin-coated vesicles formation in T cells of Jurkat transfects is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4610">
                    <text>late events of clathrin-coated vesicles formation in T-lycemic cells transfected, wil is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4611">
                    <text>late events of clathrin-coated vesicles formation in transfectuously affected T-leukemia cells, wil is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4612">
                    <text>late events of clathrin-coated vesicles formation in transiently transfected Jurkat T-cells is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4613">
                    <text>late events of clathrin-coated vesicles formation in transiently transfected Jurkat T-cells was also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4614">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and can be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4615">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and can be totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4616">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and has been totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4617">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and is able to be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4618">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and is fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4619">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and is observed to be totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4620">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and was fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4621">
                    <text>late events of clathrin-coated vesicles formation is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4622">
                    <text>late events of clathrin-coated vesicles formation is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4623">
                    <text>late events of clathrin-coated vesicles formation is concentration-dependent and saturable and is able to be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4624">
                    <text>late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4625">
                    <text>late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4626">
                    <text>late events of clathrin-coated vesicles formation is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4627">
                    <text>late events of clathrin-coated vesicles formation may have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4628">
                    <text>late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4629">
                    <text>late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4630">
                    <text>late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="4631">
                    <text>ligand are inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4632">
                    <text>ligand are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4633">
                    <text>ligand are inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4634">
                    <text>ligand are inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4635">
                    <text>ligand are inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4636">
                    <text>ligand can be inhibited by 10 mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4637">
                    <text>ligand can be inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4638">
                    <text>ligand can be inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4639">
                    <text>ligand can be inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4640">
                    <text>ligand has been inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4641">
                    <text>ligand has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4642">
                    <text>ligand has been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4643">
                    <text>ligand has been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4644">
                    <text>ligand in Jurkat T-leukemia transfect cells has also been inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4645">
                    <text>ligand in Jurkat T-leukemia transfect cells has also been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4646">
                    <text>ligand in Jurkat T-leukemia transfect cells has also been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4647">
                    <text>ligand in Jurkat T-leukemia transfect cells has also been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4648">
                    <text>ligand in T cells of Jurkat transfects is also inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4649">
                    <text>ligand in T cells of Jurkat transfects is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4650">
                    <text>ligand in T cells of Jurkat transfects is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4651">
                    <text>ligand in T cells of Jurkat transfects is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4652">
                    <text>ligand in T-lycemic cells transfected, wil is also inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4653">
                    <text>ligand in T-lycemic cells transfected, wil is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4654">
                    <text>ligand in T-lycemic cells transfected, wil is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4655">
                    <text>ligand in T-lycemic cells transfected, wil is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4656">
                    <text>ligand in transfectuously affected T-leukemia cells, wil is also inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4657">
                    <text>ligand in transfectuously affected T-leukemia cells, wil is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4658">
                    <text>ligand in transfectuously affected T-leukemia cells, wil is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4659">
                    <text>ligand in transfectuously affected T-leukemia cells, wil is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4660">
                    <text>ligand in transiently transfected Jurkat T-cells is also inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4661">
                    <text>ligand in transiently transfected Jurkat T-cells is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4662">
                    <text>ligand in transiently transfected Jurkat T-cells is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4663">
                    <text>ligand in transiently transfected Jurkat T-cells is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4664">
                    <text>ligand in transiently transfected Jurkat T-cells was also inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4665">
                    <text>ligand in transiently transfected Jurkat T-cells was also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4666">
                    <text>ligand in transiently transfected Jurkat T-cells was also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4667">
                    <text>ligand in transiently transfected Jurkat T-cells was also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4668">
                    <text>ligand is a dependent and saturable concentration and can be fully inhibited with 10 mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4669">
                    <text>ligand is a dependent and saturable concentration and can be fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4670">
                    <text>ligand is a dependent and saturable concentration and can be fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4671">
                    <text>ligand is a dependent and saturable concentration and can be totally inhibited with 10 mM EDTA, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4672">
                    <text>ligand is a dependent and saturable concentration and can be totally inhibited with DTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4673">
                    <text>ligand is a dependent and saturable concentration and can be totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4674">
                    <text>ligand is a dependent and saturable concentration and can be totally inhibited with EDTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4675">
                    <text>ligand is a dependent and saturable concentration and has been totally inhibited with 10 mM EDTA, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4676">
                    <text>ligand is a dependent and saturable concentration and has been totally inhibited with DTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4677">
                    <text>ligand is a dependent and saturable concentration and has been totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4678">
                    <text>ligand is a dependent and saturable concentration and has been totally inhibited with EDTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4679">
                    <text>ligand is a dependent and saturable concentration and is able to be fully inhibited with 10 mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4680">
                    <text>ligand is a dependent and saturable concentration and is able to be fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4681">
                    <text>ligand is a dependent and saturable concentration and is able to be fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4682">
                    <text>ligand is a dependent and saturable concentration and is fully inhibited with 10 mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4683">
                    <text>ligand is a dependent and saturable concentration and is fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4684">
                    <text>ligand is a dependent and saturable concentration and is fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4685">
                    <text>ligand is a dependent and saturable concentration and is observed to be totally inhibited with 10 mM EDTA, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4686">
                    <text>ligand is a dependent and saturable concentration and is observed to be totally inhibited with DTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4687">
                    <text>ligand is a dependent and saturable concentration and is observed to be totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4688">
                    <text>ligand is a dependent and saturable concentration and is observed to be totally inhibited with EDTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4689">
                    <text>ligand is a dependent and saturable concentration and was fully inhibited with 10 mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4690">
                    <text>ligand is a dependent and saturable concentration and was fully inhibited with EDTA 10mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4691">
                    <text>ligand is a dependent and saturable concentration and was fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4692">
                    <text>ligand is able to be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4693">
                    <text>ligand is able to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4694">
                    <text>ligand is able to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4695">
                    <text>ligand is able to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4696">
                    <text>ligand is capable of being inhibited by 10 mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4697">
                    <text>ligand is capable of being inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4698">
                    <text>ligand is capable of being inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4699">
                    <text>ligand is capable of being inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4700">
                    <text>ligand is capable of being inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4701">
                    <text>ligand is capable of being inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4702">
                    <text>ligand is capable of being inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4703">
                    <text>ligand is capable of being inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4704">
                    <text>ligand is concentration-dependent and saturable and is able to be fully inhibited with DTA of 10 mM , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4705">
                    <text>ligand is concentration-dependent and saturable and is able to be fully inhibited with EDTA 10mM , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4706">
                    <text>ligand is concentration-dependent and saturable and is able to be fully inhibited with EDTA of 10 mM , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4707">
                    <text>ligand is inhibited by 10 mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4708">
                    <text>ligand is inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4709">
                    <text>ligand is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4710">
                    <text>ligand is inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4711">
                    <text>ligand is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4712">
                    <text>ligand is inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4713">
                    <text>ligand is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4714">
                    <text>ligand is inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4715">
                    <text>ligand is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4716">
                    <text>ligand is observed to be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4717">
                    <text>ligand is observed to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4718">
                    <text>ligand is observed to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4719">
                    <text>ligand is observed to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4720">
                    <text>ligand may have been inhibited by 10 mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4721">
                    <text>ligand may have been inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4722">
                    <text>ligand may have been inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4723">
                    <text>ligand may have been inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4724">
                    <text>ligand was inhibited by 10 mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4725">
                    <text>ligand was inhibited by 10 mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4726">
                    <text>ligand was inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4727">
                    <text>ligand was inhibited by DTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4728">
                    <text>ligand was inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4729">
                    <text>ligand was inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4730">
                    <text>ligand was inhibited by EDTA 10mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4731">
                    <text>ligand was inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4732">
                    <text>ligand was inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4733">
                    <text>ligand was inhibited by EDTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4734">
                    <text>ligand was inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4735">
                    <text>ligand was inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4736">
                    <text>ligand were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4737">
                    <text>ligand will be inhibited by 10 mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4738">
                    <text>ligand will be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4739">
                    <text>ligand will be inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4740">
                    <text>ligand will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4741">
                    <text>ligand will be inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4742">
                    <text>ligand will be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4743">
                    <text>ligand will be inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4744">
                    <text>ligand will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4745">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4746">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4747">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina (NO) inhibiting descending regulation of the phosphorylation status, state5 and state6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4748">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina (NO) inhibiting descending regulation of the phosphorylation status, state5 and state6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4749">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4750">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina also has the ability to inhibit descending regulation of the phosphorylation status, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4751">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina also inhibited descending regulation of the phosphorylation status, state5 and state6 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4752">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina also inhibits descending regulation of the phosphorylation status, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4753">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina also inhibits descending regulation of the phosphorylation status, state5 and state6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4754">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina can fully inhibit descending regulation of the phosphorylation status, state5 and state6 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4755">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina can inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4756">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina can totally inhibit descending regulation of the phosphorylation status, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4757">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina co-expression also has the ability to inhibit descending regulation of the phosphorylation status, state5 and state6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4758">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina fully inhibiting concentration-dependent descending regulation of the phosphorylation status, state5 and state6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4759">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina has also inhibited descending regulation of the phosphorylation status, state5 and state6 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4760">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4761">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4762">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina inhibits descending regulation of the phosphorylation status, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4763">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina inhibits descending regulation of the phosphorylation status, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4764">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina is able to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4765">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina may also have inhibited descending regulation of the phosphorylation status, state5 and state6 in T cells affected by jurkat.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4766">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina may also have inhibited descending regulation of the phosphorylation status, state5 and state6 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4767">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina may have completely inhibited descending regulation of the phosphorylation status, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4768">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina may have completely inhibited descending regulation of the phosphorylation status, state5 and state6 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4769">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina may have inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4770">
                    <text>multiple AMP-specific cyclic PDE4 isoforms has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4771">
                    <text>multiple AMP-specific cyclic PDE4 isoforms is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4772">
                    <text>multiple AMP-specific cyclic PDE4 isoforms is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4773">
                    <text>multiple AMP-specific cyclic PDE4 isoforms is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4774">
                    <text>multiple AMP-specific cyclic PDE4 isoforms was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4775">
                    <text>multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4776">
                    <text>multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4777">
                    <text>multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4778">
                    <text>multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4779">
                    <text>multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4780">
                    <text>multiple PDE4 has been strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="4781">
                    <text>multiple PDE4 is observed to be strongly inhibited by Roipram, by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="4782">
                    <text>multiple PDE4 is strongly inhibited by Roipram by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="4783">
                    <text>multiple PDE4 is strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="4784">
                    <text>multiple PDE4 isoforms coded by PDE4C has been strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="4785">
                    <text>multiple PDE4 isoforms coded by PDE4C is observed to be strongly inhibited by Roipram, by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="4786">
                    <text>multiple PDE4 isoforms coded by PDE4C is strongly inhibited by Roipram by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="4787">
                    <text>multiple PDE4 isoforms coded by PDE4C is strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="4788">
                    <text>multiple PDE4 isoforms coded by PDE4C was strongly inhibited by Roipram 21 times.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="4789">
                    <text>multiple PDE4 was strongly inhibited by Roipram 21 times.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="4790">
                    <text>multiple PDE4-specific phosphodiesterase isoforms has been strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4791">
                    <text>multiple PDE4-specific phosphodiesterase isoforms is observed to be strongly inhibited by Roipram, by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4792">
                    <text>multiple PDE4-specific phosphodiesterase isoforms is strongly inhibited by Roipram by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4793">
                    <text>multiple PDE4-specific phosphodiesterase isoforms is strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4794">
                    <text>multiple PDE4-specific phosphodiesterase isoforms was strongly inhibited by Roipram 21 times.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4795">
                    <text>multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4796">
                    <text>multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4797">
                    <text>multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4798">
                    <text>multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4799">
                    <text>multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="4800">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4801">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated are inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4802">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated can be inhibited by GM132 proteasome inhibitors and laactacytin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4803">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated has been inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4804">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated in Jurkat T-leukemia transfect cells has also been inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4805">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated in T cells of Jurkat transfects is also inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4806">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated in T-lycemic cells transfected, wil is also inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4807">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transfectuously affected T-leukemia cells, wil is also inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4808">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transiently transfected Jurkat T-cells is also inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4809">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transiently transfected Jurkat T-cells was also inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4810">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and can be fully inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4811">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and can be totally inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4812">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and has been totally inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4813">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and is able to be fully inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4814">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and is fully inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4815">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and is observed to be totally inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4816">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and was fully inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4817">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is able to be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4818">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is capable of being inhibited by GM132 proteasome inhibitors and laactacytin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4819">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is capable of being inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4820">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is concentration-dependent and saturable and is able to be fully inhibited with GM132 proteasome inhibitors and laactacytin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4821">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4822">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4823">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4824">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is observed to be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4825">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated may have been inhibited by GM132 proteasome inhibitors and laactacytin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4826">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by GM132 proteasome inhibitors and laactacytin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4827">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by GM132 proteasome inhibitors and laactacytin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4828">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated was inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4829">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4830">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4831">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="4832">
                    <text>nitric oxide (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4833">
                    <text>nitric oxide (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4834">
                    <text>nitric oxide (NO) inhibiting platquet function activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4835">
                    <text>nitric oxide (NO) inhibiting platquet function activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4836">
                    <text>nitric oxide activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4837">
                    <text>nitric oxide also has the ability to inhibit platelet function in transient transfected T-cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4838">
                    <text>nitric oxide also has the ability to inhibit platquet function in transient transfected T-cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4839">
                    <text>nitric oxide also inhibited platelet function in transfected T-leukemia cells transfected.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4840">
                    <text>nitric oxide also inhibited platquet function in transfected T-leukemia cells transfected.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4841">
                    <text>nitric oxide also inhibits platelet function in transient transfected T-cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4842">
                    <text>nitric oxide also inhibits platelet function in transiently transfected T-leukemia cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4843">
                    <text>nitric oxide also inhibits platquet function in transient transfected T-cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4844">
                    <text>nitric oxide also inhibits platquet function in transiently transfected T-leukemia cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4845">
                    <text>nitric oxide can fully inhibit platelet function that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4846">
                    <text>nitric oxide can fully inhibit platquet function that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4847">
                    <text>nitric oxide can inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4848">
                    <text>nitric oxide can inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4849">
                    <text>nitric oxide can totally inhibit platelet function that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4850">
                    <text>nitric oxide can totally inhibit platquet function that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4851">
                    <text>nitric oxide co-expression also has the ability to inhibit platelet function in T-leukemia transnetly affected cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4852">
                    <text>nitric oxide co-expression also has the ability to inhibit platquet function in T-leukemia transnetly affected cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4853">
                    <text>nitric oxide fully inhibiting concentration-dependent platelet function and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4854">
                    <text>nitric oxide fully inhibiting concentration-dependent platquet function and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4855">
                    <text>nitric oxide has also inhibited platelet function in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4856">
                    <text>nitric oxide has also inhibited platquet function in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4857">
                    <text>nitric oxide has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="4858">
                    <text>nitric oxide inhibited platelet function activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4859">
                    <text>nitric oxide inhibited platquet function activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4860">
                    <text>nitric oxide inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="4861">
                    <text>nitric oxide inhibits platelet function activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4862">
                    <text>nitric oxide inhibits platquet function activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4863">
                    <text>nitric oxide is able to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4864">
                    <text>nitric oxide is able to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4865">
                    <text>nitric oxide may also have inhibited platelet function in T cells affected by jurkat.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4866">
                    <text>nitric oxide may also have inhibited platelet function in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4867">
                    <text>nitric oxide may also have inhibited platquet function in T cells affected by jurkat.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4868">
                    <text>nitric oxide may also have inhibited platquet function in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4869">
                    <text>nitric oxide may have completely inhibited platelet function that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4870">
                    <text>nitric oxide may have completely inhibited platelet function which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4871">
                    <text>nitric oxide may have completely inhibited platquet function that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4872">
                    <text>nitric oxide may have completely inhibited platquet function which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4873">
                    <text>nitric oxide may have inhibited platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4874">
                    <text>nitric oxide may have inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4875">
                    <text>other protein binding to phosphatase can inhibit function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="4876">
                    <text>other protein binding to phosphatase can inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4877">
                    <text>other protein binding to phosphatase can inhibit the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4878">
                    <text>other protein binding to phosphatase may have inhibited function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="4879">
                    <text>other protein binding to phosphatase may have inhibited its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4880">
                    <text>other protein binding to phosphatase may have inhibited the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4881">
                    <text>other protein binding to phosphatease can inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4882">
                    <text>other protein binding to phosphatease can inhibit the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="4883">
                    <text>other protein binding to phosphatease can inhibit the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4884">
                    <text>other protein binding to phosphatease may have inhibited its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4885">
                    <text>other protein binding to phosphatease may have inhibited the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="4886">
                    <text>other protein binding to phosphatease may have inhibited the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4887">
                    <text>other protein binds to phosphatase and is able to inhibit function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="4888">
                    <text>other protein binds to phosphatase and is able to inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4889">
                    <text>other protein binds to phosphatase and is able to inhibit the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4890">
                    <text>other protein binds to phosphatase to inhibit function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="4891">
                    <text>other protein binds to phosphatase to inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4892">
                    <text>other protein binds to phosphatase to inhibit the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4893">
                    <text>other protein binds to phosphatease and is able to inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4894">
                    <text>other protein binds to phosphatease and is able to inhibit the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="4895">
                    <text>other protein binds to phosphatease and is able to inhibit the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4896">
                    <text>other protein binds to phosphatease to inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4897">
                    <text>other protein binds to phosphatease to inhibit the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="4898">
                    <text>other protein binds to phosphatease to inhibit the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4899">
                    <text>other protein that binds to phosphatase may have inhibited function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="4900">
                    <text>other protein that binds to phosphatase may have inhibited its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4901">
                    <text>other protein that binds to phosphatase may have inhibited the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4902">
                    <text>other protein that binds to phosphatease may have inhibited its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4903">
                    <text>other protein that binds to phosphatease may have inhibited the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="4904">
                    <text>other protein that binds to phosphatease may have inhibited the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="4905">
                    <text>other proteins binding to phosphatease can inhibit its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4906">
                    <text>other proteins binding to phosphatease may have inhibited its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4907">
                    <text>other proteins binds to phosphatease and is able to inhibit its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4908">
                    <text>other proteins binds to phosphatease to inhibit its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4909">
                    <text>other proteins that binds to phosphatease may have inhibited its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="4910">
                    <text>platelet function are inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4911">
                    <text>platelet function has been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4912">
                    <text>platelet function in Jurkat T-leukemia transfect cells has also been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4913">
                    <text>platelet function in T cells of Jurkat transfects is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4914">
                    <text>platelet function in T-lycemic cells transfected, wil is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4915">
                    <text>platelet function in transfectuously affected T-leukemia cells, wil is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4916">
                    <text>platelet function in transiently transfected Jurkat T-cells is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4917">
                    <text>platelet function in transiently transfected Jurkat T-cells was also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4918">
                    <text>platelet function is a dependent and saturable concentration and can be fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4919">
                    <text>platelet function is a dependent and saturable concentration and can be totally inhibited with nitric oxide, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4920">
                    <text>platelet function is a dependent and saturable concentration and has been totally inhibited with nitric oxide, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4921">
                    <text>platelet function is a dependent and saturable concentration and is able to be fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4922">
                    <text>platelet function is a dependent and saturable concentration and is fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4923">
                    <text>platelet function is a dependent and saturable concentration and is observed to be totally inhibited with nitric oxide, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4924">
                    <text>platelet function is a dependent and saturable concentration and was fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4925">
                    <text>platelet function is able to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4926">
                    <text>platelet function is capable of being inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4927">
                    <text>platelet function is concentration-dependent and saturable and is able to be fully inhibited with nitric oxide , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4928">
                    <text>platelet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4929">
                    <text>platelet function is observed to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4930">
                    <text>platelet function was inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4931">
                    <text>platelet function was inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4932">
                    <text>platelet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="4933">
                    <text>platquet function are inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4934">
                    <text>platquet function can be inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4935">
                    <text>platquet function has been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4936">
                    <text>platquet function in Jurkat T-leukemia transfect cells has also been inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4937">
                    <text>platquet function in T cells of Jurkat transfects is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4938">
                    <text>platquet function in T-lycemic cells transfected, wil is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4939">
                    <text>platquet function in transfectuously affected T-leukemia cells, wil is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4940">
                    <text>platquet function in transiently transfected Jurkat T-cells is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4941">
                    <text>platquet function in transiently transfected Jurkat T-cells was also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4942">
                    <text>platquet function is a dependent and saturable concentration and can be fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4943">
                    <text>platquet function is a dependent and saturable concentration and can be totally inhibited with nitric oxide, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4944">
                    <text>platquet function is a dependent and saturable concentration and has been totally inhibited with nitric oxide, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4945">
                    <text>platquet function is a dependent and saturable concentration and is able to be fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4946">
                    <text>platquet function is a dependent and saturable concentration and is fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4947">
                    <text>platquet function is a dependent and saturable concentration and is observed to be totally inhibited with nitric oxide, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4948">
                    <text>platquet function is a dependent and saturable concentration and was fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4949">
                    <text>platquet function is able to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4950">
                    <text>platquet function is capable of being inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4951">
                    <text>platquet function is capable of being inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4952">
                    <text>platquet function is concentration-dependent and saturable and is able to be fully inhibited with nitric oxide , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4953">
                    <text>platquet function is inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4954">
                    <text>platquet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4955">
                    <text>platquet function is observed to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4956">
                    <text>platquet function may have been inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4957">
                    <text>platquet function was inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4958">
                    <text>platquet function was inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4959">
                    <text>platquet function will be inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4960">
                    <text>platquet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="4961">
                    <text>primary proteasome inhibitors MG132 and lactacitstin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4962">
                    <text>primary proteasome inhibitors MG132 and lactacitstin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4963">
                    <text>primary proteasome inhibitors MG132 and lactacitstin (NO) inhibiting descendant regulation of phosphorylation state, state5 and state6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4964">
                    <text>primary proteasome inhibitors MG132 and lactacitstin (NO) inhibiting descendant regulation of phosphorylation state, state5 and state6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4965">
                    <text>primary proteasome inhibitors MG132 and lactacitstin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4966">
                    <text>primary proteasome inhibitors MG132 and lactacitstin also has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4967">
                    <text>primary proteasome inhibitors MG132 and lactacitstin also inhibited descendant regulation of phosphorylation state, state5 and state6 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4968">
                    <text>primary proteasome inhibitors MG132 and lactacitstin also inhibits descendant regulation of phosphorylation state, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4969">
                    <text>primary proteasome inhibitors MG132 and lactacitstin also inhibits descendant regulation of phosphorylation state, state5 and state6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4970">
                    <text>primary proteasome inhibitors MG132 and lactacitstin can fully inhibit descendant regulation of phosphorylation state, state5 and state6 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4971">
                    <text>primary proteasome inhibitors MG132 and lactacitstin can inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4972">
                    <text>primary proteasome inhibitors MG132 and lactacitstin can totally inhibit descendant regulation of phosphorylation state, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4973">
                    <text>primary proteasome inhibitors MG132 and lactacitstin co-expression also has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4974">
                    <text>primary proteasome inhibitors MG132 and lactacitstin fully inhibiting concentration-dependent descendant regulation of phosphorylation state, state5 and state6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4975">
                    <text>primary proteasome inhibitors MG132 and lactacitstin has also inhibited descendant regulation of phosphorylation state, state5 and state6 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4976">
                    <text>primary proteasome inhibitors MG132 and lactacitstin inhibited descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4977">
                    <text>primary proteasome inhibitors MG132 and lactacitstin inhibited descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4978">
                    <text>primary proteasome inhibitors MG132 and lactacitstin inhibits descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4979">
                    <text>primary proteasome inhibitors MG132 and lactacitstin inhibits descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4980">
                    <text>primary proteasome inhibitors MG132 and lactacitstin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4981">
                    <text>primary proteasome inhibitors MG132 and lactacitstin may also have inhibited descendant regulation of phosphorylation state, state5 and state6 in T cells affected by jurkat.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4982">
                    <text>primary proteasome inhibitors MG132 and lactacitstin may also have inhibited descendant regulation of phosphorylation state, state5 and state6 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4983">
                    <text>primary proteasome inhibitors MG132 and lactacitstin may have completely inhibited descendant regulation of phosphorylation state, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4984">
                    <text>primary proteasome inhibitors MG132 and lactacitstin may have completely inhibited descendant regulation of phosphorylation state, state5 and state6 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4985">
                    <text>primary proteasome inhibitors MG132 and lactacitstin may have inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4986">
                    <text>primary proteasome inhibitors MG132 and lactacyttin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4987">
                    <text>primary proteasome inhibitors MG132 and lactacyttin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4988">
                    <text>primary proteasome inhibitors MG132 and lactacyttin (NO) inhibiting descendant regulation of phosphorylation state, state5 and state6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4989">
                    <text>primary proteasome inhibitors MG132 and lactacyttin (NO) inhibiting descendant regulation of phosphorylation state, state5 and state6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4990">
                    <text>primary proteasome inhibitors MG132 and lactacyttin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4991">
                    <text>primary proteasome inhibitors MG132 and lactacyttin also has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4992">
                    <text>primary proteasome inhibitors MG132 and lactacyttin also inhibited descendant regulation of phosphorylation state, state5 and state6 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4993">
                    <text>primary proteasome inhibitors MG132 and lactacyttin also inhibits descendant regulation of phosphorylation state, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4994">
                    <text>primary proteasome inhibitors MG132 and lactacyttin also inhibits descendant regulation of phosphorylation state, state5 and state6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4995">
                    <text>primary proteasome inhibitors MG132 and lactacyttin can fully inhibit descendant regulation of phosphorylation state, state5 and state6 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4996">
                    <text>primary proteasome inhibitors MG132 and lactacyttin can inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4997">
                    <text>primary proteasome inhibitors MG132 and lactacyttin can totally inhibit descendant regulation of phosphorylation state, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4998">
                    <text>primary proteasome inhibitors MG132 and lactacyttin co-expression also has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="4999">
                    <text>primary proteasome inhibitors MG132 and lactacyttin fully inhibiting concentration-dependent descendant regulation of phosphorylation state, state5 and state6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5000">
                    <text>primary proteasome inhibitors MG132 and lactacyttin has also inhibited descendant regulation of phosphorylation state, state5 and state6 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5001">
                    <text>primary proteasome inhibitors MG132 and lactacyttin inhibited descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5002">
                    <text>primary proteasome inhibitors MG132 and lactacyttin inhibited descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5003">
                    <text>primary proteasome inhibitors MG132 and lactacyttin inhibits descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5004">
                    <text>primary proteasome inhibitors MG132 and lactacyttin inhibits descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5005">
                    <text>primary proteasome inhibitors MG132 and lactacyttin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5006">
                    <text>primary proteasome inhibitors MG132 and lactacyttin may also have inhibited descendant regulation of phosphorylation state, state5 and state6 in T cells affected by jurkat.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5007">
                    <text>primary proteasome inhibitors MG132 and lactacyttin may also have inhibited descendant regulation of phosphorylation state, state5 and state6 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5008">
                    <text>primary proteasome inhibitors MG132 and lactacyttin may have completely inhibited descendant regulation of phosphorylation state, state5 and state6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5009">
                    <text>primary proteasome inhibitors MG132 and lactacyttin may have completely inhibited descendant regulation of phosphorylation state, state5 and state6 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5010">
                    <text>primary proteasome inhibitors MG132 and lactacyttin may have inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5011">
                    <text>proteasome inhibitors MG132 and lactacistin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5012">
                    <text>proteasome inhibitors MG132 and lactacistin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5013">
                    <text>proteasome inhibitors MG132 and lactacistin (NO) inhibiting reduced regulation of Stat4, Stat5 and Stat6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5014">
                    <text>proteasome inhibitors MG132 and lactacistin (NO) inhibiting reduced regulation of Stat4, Stat5 and Stat6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5015">
                    <text>proteasome inhibitors MG132 and lactacistin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5016">
                    <text>proteasome inhibitors MG132 and lactacistin also has the ability to inhibit reduced regulation of Stat4, Stat5 and Stat6 in transient transfected T-cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5017">
                    <text>proteasome inhibitors MG132 and lactacistin also inhibited reduced regulation of Stat4, Stat5 and Stat6 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5018">
                    <text>proteasome inhibitors MG132 and lactacistin also inhibits reduced regulation of Stat4, Stat5 and Stat6 in transient transfected T-cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5019">
                    <text>proteasome inhibitors MG132 and lactacistin also inhibits reduced regulation of Stat4, Stat5 and Stat6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5020">
                    <text>proteasome inhibitors MG132 and lactacistin can fully inhibit reduced regulation of Stat4, Stat5 and Stat6 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5021">
                    <text>proteasome inhibitors MG132 and lactacistin can inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5022">
                    <text>proteasome inhibitors MG132 and lactacistin can totally inhibit reduced regulation of Stat4, Stat5 and Stat6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5023">
                    <text>proteasome inhibitors MG132 and lactacistin co-expression also has the ability to inhibit reduced regulation of Stat4, Stat5 and Stat6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5024">
                    <text>proteasome inhibitors MG132 and lactacistin fully inhibiting concentration-dependent reduced regulation of Stat4, Stat5 and Stat6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5025">
                    <text>proteasome inhibitors MG132 and lactacistin has also inhibited reduced regulation of Stat4, Stat5 and Stat6 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5026">
                    <text>proteasome inhibitors MG132 and lactacistin inhibited reduced regulation of Stat4, Stat5 and Stat6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5027">
                    <text>proteasome inhibitors MG132 and lactacistin inhibited reduced regulation of Stat4, Stat5 and Stat6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5028">
                    <text>proteasome inhibitors MG132 and lactacistin inhibits reduced regulation of Stat4, Stat5 and Stat6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5029">
                    <text>proteasome inhibitors MG132 and lactacistin inhibits reduced regulation of Stat4, Stat5 and Stat6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5030">
                    <text>proteasome inhibitors MG132 and lactacistin is able to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5031">
                    <text>proteasome inhibitors MG132 and lactacistin may also have inhibited reduced regulation of Stat4, Stat5 and Stat6 in T cells affected by jurkat.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5032">
                    <text>proteasome inhibitors MG132 and lactacistin may also have inhibited reduced regulation of Stat4, Stat5 and Stat6 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5033">
                    <text>proteasome inhibitors MG132 and lactacistin may have completely inhibited reduced regulation of Stat4, Stat5 and Stat6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5034">
                    <text>proteasome inhibitors MG132 and lactacistin may have completely inhibited reduced regulation of Stat4, Stat5 and Stat6 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5035">
                    <text>proteasome inhibitors MG132 and lactacistin may have inhibited reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5036">
                    <text>protein extracts from the transcedit body cells can strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5037">
                    <text>protein extracts from the transcedit body cells has strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5038">
                    <text>protein extracts from the transcedit body cells has the ability to inhibit phosphorylase-specific both the alpha and C beta isoforms of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5039">
                    <text>protein extracts from the transcedit body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5040">
                    <text>protein extracts from the transcedit body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5041">
                    <text>protein extracts from the transcedit body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5042">
                    <text>protein extracts from the transcedit body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5043">
                    <text>protein extracts from the transcedit body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5044">
                    <text>protein extracts from the transcedit body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5045">
                    <text>protein extracts from the transcedit body cells is able to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5046">
                    <text>protein extracts from the transcedit body cells may have strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5047">
                    <text>protein extracts from the transcedit body cells may inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5048">
                    <text>protein extracts from the transcedit body cells strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5049">
                    <text>protein extracts from the transcedit body cells strongly inhibits both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5050">
                    <text>protein extracts from the transcedit body cells will strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5051">
                    <text>protein extracts from transcedit body cells can strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5052">
                    <text>protein extracts from transcedit body cells has strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5053">
                    <text>protein extracts from transcedit body cells has the ability to inhibit phosphorylase-specific both the alpha and C beta isoforms of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5054">
                    <text>protein extracts from transcedit body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5055">
                    <text>protein extracts from transcedit body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5056">
                    <text>protein extracts from transcedit body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5057">
                    <text>protein extracts from transcedit body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5058">
                    <text>protein extracts from transcedit body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5059">
                    <text>protein extracts from transcedit body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5060">
                    <text>protein extracts from transcedit body cells is able to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5061">
                    <text>protein extracts from transcedit body cells may have strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5062">
                    <text>protein extracts from transcedit body cells may inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5063">
                    <text>protein extracts from transcedit body cells strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5064">
                    <text>protein extracts from transcedit body cells strongly inhibits both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5065">
                    <text>protein extracts from transcedit body cells will strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5066">
                    <text>protein extracts from transcent body cells can strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5067">
                    <text>protein extracts from transcent body cells has strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5068">
                    <text>protein extracts from transcent body cells has the ability to inhibit phosphorylase-specific both the alpha and C beta isoforms of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5069">
                    <text>protein extracts from transcent body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5070">
                    <text>protein extracts from transcent body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5071">
                    <text>protein extracts from transcent body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5072">
                    <text>protein extracts from transcent body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5073">
                    <text>protein extracts from transcent body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5074">
                    <text>protein extracts from transcent body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5075">
                    <text>protein extracts from transcent body cells is able to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5076">
                    <text>protein extracts from transcent body cells may have strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5077">
                    <text>protein extracts from transcent body cells may inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5078">
                    <text>protein extracts from transcent body cells strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5079">
                    <text>protein extracts from transcent body cells strongly inhibits both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5080">
                    <text>protein extracts from transcent body cells will strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5081">
                    <text>protein extracts from transfect body cells can strongly inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5082">
                    <text>protein extracts from transfect body cells has strongly inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5083">
                    <text>protein extracts from transfect body cells has the ability to inhibit phosphorylase-specific both the isoforms C alpha and beta C of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5084">
                    <text>protein extracts from transfect body cells has the ability to strongly inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5085">
                    <text>protein extracts from transfect body cells has the ability to strongly inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5086">
                    <text>protein extracts from transfect body cells inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5087">
                    <text>protein extracts from transfect body cells inhibits both the isoforms C alpha and beta C of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5088">
                    <text>protein extracts from transfect body cells is able to inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5089">
                    <text>protein extracts from transfect body cells is able to inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5090">
                    <text>protein extracts from transfect body cells is able to strongly inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5091">
                    <text>protein extracts from transfect body cells may have strongly inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5092">
                    <text>protein extracts from transfect body cells may inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5093">
                    <text>protein extracts from transfect body cells strongly inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5094">
                    <text>protein extracts from transfect body cells strongly inhibits both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5095">
                    <text>protein extracts from transfect body cells will strongly inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5096">
                    <text>protein extracts from transfected body cells can strongly inhibit both C alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5097">
                    <text>protein extracts from transfected body cells can strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5098">
                    <text>protein extracts from transfected body cells has strongly inhibited both C alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5099">
                    <text>protein extracts from transfected body cells has strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5100">
                    <text>protein extracts from transfected body cells has the ability to inhibit phosphorylase-specific both C alpha and C beta isoforms of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5101">
                    <text>protein extracts from transfected body cells has the ability to inhibit phosphorylase-specific both the alpha and C beta isoforms of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5102">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both C alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5103">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both C alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5104">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5105">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5106">
                    <text>protein extracts from transfected body cells inhibited both C alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5107">
                    <text>protein extracts from transfected body cells inhibited both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5108">
                    <text>protein extracts from transfected body cells inhibits both C alpha and C beta isoforms of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5109">
                    <text>protein extracts from transfected body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5110">
                    <text>protein extracts from transfected body cells is able to inhibit both C alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5111">
                    <text>protein extracts from transfected body cells is able to inhibit both C alpha and C beta isoforms of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5112">
                    <text>protein extracts from transfected body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5113">
                    <text>protein extracts from transfected body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5114">
                    <text>protein extracts from transfected body cells is able to strongly inhibit both C alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5115">
                    <text>protein extracts from transfected body cells is able to strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5116">
                    <text>protein extracts from transfected body cells may have strongly inhibited both C alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5117">
                    <text>protein extracts from transfected body cells may have strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5118">
                    <text>protein extracts from transfected body cells may inhibit both C alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5119">
                    <text>protein extracts from transfected body cells may inhibit both the alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5120">
                    <text>protein extracts from transfected body cells strongly inhibited both C alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5121">
                    <text>protein extracts from transfected body cells strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5122">
                    <text>protein extracts from transfected body cells strongly inhibits both C alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5123">
                    <text>protein extracts from transfected body cells strongly inhibits both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5124">
                    <text>protein extracts from transfected body cells will strongly inhibit both C alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5125">
                    <text>protein extracts from transfected body cells will strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5126">
                    <text>protein extracts from transfected cells has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="5127">
                    <text>protein extracts from transfected cells inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="5128">
                    <text>protein extracts from transfected cells inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="5129">
                    <text>protein extracts of infected body cells has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="5130">
                    <text>protein extracts of infected body cells inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="5131">
                    <text>protein extracts of infected body cells inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="5132">
                    <text>protein extracts of the transfected body cells can strongly inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5133">
                    <text>protein extracts of the transfected body cells has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="5134">
                    <text>protein extracts of the transfected body cells has strongly inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5135">
                    <text>protein extracts of the transfected body cells has the ability to inhibit phosphorylase-specific both the isoforms C alpha and C beta of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5136">
                    <text>protein extracts of the transfected body cells has the ability to strongly inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5137">
                    <text>protein extracts of the transfected body cells has the ability to strongly inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5138">
                    <text>protein extracts of the transfected body cells inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="5139">
                    <text>protein extracts of the transfected body cells inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5140">
                    <text>protein extracts of the transfected body cells inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="5141">
                    <text>protein extracts of the transfected body cells inhibits both the isoforms C alpha and C beta of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5142">
                    <text>protein extracts of the transfected body cells is able to inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5143">
                    <text>protein extracts of the transfected body cells is able to inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5144">
                    <text>protein extracts of the transfected body cells is able to strongly inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5145">
                    <text>protein extracts of the transfected body cells may have strongly inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5146">
                    <text>protein extracts of the transfected body cells may inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5147">
                    <text>protein extracts of the transfected body cells strongly inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5148">
                    <text>protein extracts of the transfected body cells strongly inhibits both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5149">
                    <text>protein extracts of the transfected body cells will strongly inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5150">
                    <text>protein extracts of transcedural body cells can strongly inhibit both alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5151">
                    <text>protein extracts of transcedural body cells has strongly inhibited both alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5152">
                    <text>protein extracts of transcedural body cells has the ability to inhibit phosphorylase-specific both alpha and C beta isoforms of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5153">
                    <text>protein extracts of transcedural body cells has the ability to strongly inhibit both alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5154">
                    <text>protein extracts of transcedural body cells has the ability to strongly inhibit both alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5155">
                    <text>protein extracts of transcedural body cells inhibited both alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5156">
                    <text>protein extracts of transcedural body cells inhibits both alpha and C beta isoforms of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5157">
                    <text>protein extracts of transcedural body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5158">
                    <text>protein extracts of transcedural body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5159">
                    <text>protein extracts of transcedural body cells is able to strongly inhibit both alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5160">
                    <text>protein extracts of transcedural body cells may have strongly inhibited both alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5161">
                    <text>protein extracts of transcedural body cells may inhibit both alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5162">
                    <text>protein extracts of transcedural body cells strongly inhibited both alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5163">
                    <text>protein extracts of transcedural body cells strongly inhibits both alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5164">
                    <text>protein extracts of transcedural body cells will strongly inhibit both alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="5165">
                    <text>protein extracts of transfected cells has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="5166">
                    <text>protein extracts of transfected cells inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="5167">
                    <text>protein extracts of transfected cells inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="5168">
                    <text>protein synthesis are inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5169">
                    <text>protein synthesis can be inhibited by chloramphenicol which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5170">
                    <text>protein synthesis has been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5171">
                    <text>protein synthesis in Jurkat T-leukemia transfect cells has also been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5172">
                    <text>protein synthesis in T cells of Jurkat transfects is also inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5173">
                    <text>protein synthesis in T-lycemic cells transfected, wil is also inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5174">
                    <text>protein synthesis in transfectuously affected T-leukemia cells, wil is also inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5175">
                    <text>protein synthesis in transiently transfected Jurkat T-cells is also inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5176">
                    <text>protein synthesis in transiently transfected Jurkat T-cells was also inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5177">
                    <text>protein synthesis is a dependent and saturable concentration and can be fully inhibited with chloramphenicol, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5178">
                    <text>protein synthesis is a dependent and saturable concentration and can be totally inhibited with chloramphenicol, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5179">
                    <text>protein synthesis is a dependent and saturable concentration and has been totally inhibited with chloramphenicol, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5180">
                    <text>protein synthesis is a dependent and saturable concentration and is able to be fully inhibited with chloramphenicol, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5181">
                    <text>protein synthesis is a dependent and saturable concentration and is fully inhibited with chloramphenicol, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5182">
                    <text>protein synthesis is a dependent and saturable concentration and is observed to be totally inhibited with chloramphenicol, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5183">
                    <text>protein synthesis is a dependent and saturable concentration and was fully inhibited with chloramphenicol, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5184">
                    <text>protein synthesis is able to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5185">
                    <text>protein synthesis is capable of being inhibited by chloramphenicol which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5186">
                    <text>protein synthesis is capable of being inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5187">
                    <text>protein synthesis is concentration-dependent and saturable and is able to be fully inhibited with chloramphenicol , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5188">
                    <text>protein synthesis is inhibited by chloramphenicol which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5189">
                    <text>protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5190">
                    <text>protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5191">
                    <text>protein synthesis may have been inhibited by chloramphenicol which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5192">
                    <text>protein synthesis was inhibited by chloramphenicol that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5193">
                    <text>protein synthesis was inhibited by chloramphenicol which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5194">
                    <text>protein synthesis was inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5195">
                    <text>protein synthesis will be inhibited by chloramphenicol which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5196">
                    <text>protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5197">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 are inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5198">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 can be inhibited by proteasome inhibitors MG132 and lactacistin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5199">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5200">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 in Jurkat T-leukemia transfect cells has also been inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5201">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 in T cells of Jurkat transfects is also inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5202">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 in T-lycemic cells transfected, wil is also inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5203">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 in transfectuously affected T-leukemia cells, wil is also inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5204">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 in transiently transfected Jurkat T-cells is also inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5205">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 in transiently transfected Jurkat T-cells was also inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5206">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and can be fully inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5207">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and can be totally inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5208">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and has been totally inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5209">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and is able to be fully inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5210">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and is fully inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5211">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and is observed to be totally inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5212">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and was fully inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5213">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is able to be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5214">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is capable of being inhibited by proteasome inhibitors MG132 and lactacistin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5215">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is capable of being inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5216">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is concentration-dependent and saturable and is able to be fully inhibited with proteasome inhibitors MG132 and lactacistin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5217">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5218">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5219">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is observed to be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5220">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 may have been inhibited by proteasome inhibitors MG132 and lactacistin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5221">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacistin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5222">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacistin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5223">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5224">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacistin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5225">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5226">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 are inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5227">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 can be inhibited by an inhibitor of the MG132 protein and lactacittine which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5228">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 has been inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5229">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 in Jurkat T-leukemia transfect cells has also been inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5230">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 in T cells of Jurkat transfects is also inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5231">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 in T-lycemic cells transfected, wil is also inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5232">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 in transfectuously affected T-leukemia cells, wil is also inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5233">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 in transiently transfected Jurkat T-cells is also inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5234">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 in transiently transfected Jurkat T-cells was also inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5235">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and can be fully inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5236">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and can be totally inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5237">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and has been totally inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5238">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and is able to be fully inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5239">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and is fully inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5240">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and is observed to be totally inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5241">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and was fully inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5242">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is able to be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5243">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is capable of being inhibited by an inhibitor of the MG132 protein and lactacittine which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5244">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is capable of being inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5245">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is concentration-dependent and saturable and is able to be fully inhibited with an inhibitor of the MG132 protein and lactacittine , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5246">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5247">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5248">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is observed to be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5249">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 may have been inhibited by an inhibitor of the MG132 protein and lactacittine which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5250">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 was inhibited by an inhibitor of the MG132 protein and lactacittine that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5251">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 was inhibited by an inhibitor of the MG132 protein and lactacittine which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5252">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 was inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5253">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5254">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="5255">
                    <text>rolipram can strongly inhibit PDE44 cyclic AMP-phosphodiesterases by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5256">
                    <text>rolipram can strongly inhibit PDE44 cyclic AMP-specific isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5257">
                    <text>rolipram can strongly inhibit PDE44 cyclic AMP-specific phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5258">
                    <text>rolipram can strongly inhibit multiple AMP-specific cyclic PDE4 isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5259">
                    <text>rolipram can strongly inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5260">
                    <text>rolipram can strongly inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5261">
                    <text>rolipram has strongly inhibited PDE44 cyclic AMP-phosphodiesterases by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5262">
                    <text>rolipram has strongly inhibited PDE44 cyclic AMP-specific isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5263">
                    <text>rolipram has strongly inhibited PDE44 cyclic AMP-specific phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5264">
                    <text>rolipram has strongly inhibited multiple AMP-specific cyclic PDE4 isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5265">
                    <text>rolipram has strongly inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5266">
                    <text>rolipram has strongly inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5267">
                    <text>rolipram has the ability to inhibit phosphorylase-specific PDE44 cyclic AMP-phosphodiesterases-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5268">
                    <text>rolipram has the ability to inhibit phosphorylase-specific PDE44 cyclic AMP-specific isoforms-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5269">
                    <text>rolipram has the ability to inhibit phosphorylase-specific PDE44 cyclic AMP-specific phosphodiesterase-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5270">
                    <text>rolipram has the ability to inhibit phosphorylase-specific multiple AMP-specific cyclic PDE4 isoforms-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5271">
                    <text>rolipram has the ability to inhibit phosphorylase-specific multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5272">
                    <text>rolipram has the ability to inhibit phosphorylase-specific multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5273">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-phosphodiesterases by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5274">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-phosphodiesterases by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5275">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-specific isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5276">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-specific isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5277">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-specific phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5278">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-specific phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5279">
                    <text>rolipram has the ability to strongly inhibit multiple AMP-specific cyclic PDE4 isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5280">
                    <text>rolipram has the ability to strongly inhibit multiple AMP-specific cyclic PDE4 isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5281">
                    <text>rolipram has the ability to strongly inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5282">
                    <text>rolipram has the ability to strongly inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5283">
                    <text>rolipram has the ability to strongly inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5284">
                    <text>rolipram has the ability to strongly inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5285">
                    <text>rolipram inhibited PDE44 cyclic AMP-phosphodiesterases coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5286">
                    <text>rolipram inhibited PDE44 cyclic AMP-specific phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5287">
                    <text>rolipram inhibited multiple AMP-specific cyclic PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5288">
                    <text>rolipram inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5289">
                    <text>rolipram inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5290">
                    <text>rolipram inhibits PDE44 cyclic AMP-specific isoforms codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5291">
                    <text>rolipram inhibits PDE44 cyclic AMP-specific phosphodiesterase codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5292">
                    <text>rolipram inhibits multiple AMP-specific cyclic PDE4 isoforms codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5293">
                    <text>rolipram inhibits multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5294">
                    <text>rolipram inhibits multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5295">
                    <text>rolipram is able to inhibit PDE44 cyclic AMP-phosphodiesterases coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5296">
                    <text>rolipram is able to inhibit PDE44 cyclic AMP-phosphodiesterases.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5297">
                    <text>rolipram is able to inhibit PDE44 cyclic AMP-specific isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5298">
                    <text>rolipram is able to inhibit PDE44 cyclic AMP-specific isoforms.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5299">
                    <text>rolipram is able to inhibit PDE44 cyclic AMP-specific phosphodiesterase.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5300">
                    <text>rolipram is able to inhibit multiple AMP-specific cyclic PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5301">
                    <text>rolipram is able to inhibit multiple AMP-specific cyclic PDE4 isoforms.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5302">
                    <text>rolipram is able to inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5303">
                    <text>rolipram is able to inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5304">
                    <text>rolipram is able to inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5305">
                    <text>rolipram is able to inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5306">
                    <text>rolipram is able to strongly inhibit PDE44 cyclic AMP-phosphodiesterases by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5307">
                    <text>rolipram is able to strongly inhibit PDE44 cyclic AMP-specific isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5308">
                    <text>rolipram is able to strongly inhibit PDE44 cyclic AMP-specific phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5309">
                    <text>rolipram is able to strongly inhibit multiple AMP-specific cyclic PDE4 isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5310">
                    <text>rolipram is able to strongly inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5311">
                    <text>rolipram is able to strongly inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5312">
                    <text>rolipram may have strongly inhibited PDE44 cyclic AMP-phosphodiesterases by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5313">
                    <text>rolipram may have strongly inhibited PDE44 cyclic AMP-specific isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5314">
                    <text>rolipram may have strongly inhibited PDE44 cyclic AMP-specific phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5315">
                    <text>rolipram may have strongly inhibited multiple AMP-specific cyclic PDE4 isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5316">
                    <text>rolipram may have strongly inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5317">
                    <text>rolipram may have strongly inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5318">
                    <text>rolipram may inhibit PDE44 cyclic AMP-phosphodiesterases coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5319">
                    <text>rolipram may inhibit PDE44 cyclic AMP-specific isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5320">
                    <text>rolipram may inhibit PDE44 cyclic AMP-specific phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5321">
                    <text>rolipram may inhibit multiple AMP-specific cyclic PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5322">
                    <text>rolipram may inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5323">
                    <text>rolipram may inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5324">
                    <text>rolipram strongly inhibited PDE44 cyclic AMP-phosphodiesterases by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5325">
                    <text>rolipram strongly inhibited PDE44 cyclic AMP-specific isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5326">
                    <text>rolipram strongly inhibited PDE44 cyclic AMP-specific phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5327">
                    <text>rolipram strongly inhibited multiple AMP-specific cyclic PDE4 isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5328">
                    <text>rolipram strongly inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5329">
                    <text>rolipram strongly inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5330">
                    <text>rolipram strongly inhibits PDE44 cyclic AMP-phosphodiesterases by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5331">
                    <text>rolipram strongly inhibits PDE44 cyclic AMP-specific isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5332">
                    <text>rolipram strongly inhibits PDE44 cyclic AMP-specific phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5333">
                    <text>rolipram strongly inhibits multiple AMP-specific cyclic PDE4 isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5334">
                    <text>rolipram strongly inhibits multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5335">
                    <text>rolipram strongly inhibits multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5336">
                    <text>rolipram will strongly inhibit PDE44 cyclic AMP-phosphodiesterases by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="5337">
                    <text>rolipram will strongly inhibit PDE44 cyclic AMP-specific isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5338">
                    <text>rolipram will strongly inhibit PDE44 cyclic AMP-specific phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="5339">
                    <text>rolipram will strongly inhibit multiple AMP-specific cyclic PDE4 isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5340">
                    <text>rolipram will strongly inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5341">
                    <text>rolipram will strongly inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="5342">
                    <text>sigma (54) - glnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5343">
                    <text>sigma (54) - glnAp2 is observed to be strongly inhibited by CRP-cAMP, by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5344">
                    <text>sigma (54) - glnAp2 is strongly inhibited by CRP-cAMP by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5345">
                    <text>sigma (54) - glnAp2 is strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5346">
                    <text>sigma (54)-dependent glnAp2 is strongly inhibited by CRP-cAMP by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5347">
                    <text>sigma (54)-dependent glnAp2 was strongly inhibited by CRP-cAMP 21 times.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5348">
                    <text>sigma (54)-gnAp2 dependent has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="5349">
                    <text>sigma (54)-gnAp2 dependent is observed to be strongly inhibited by CRP-cAMP, by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="5350">
                    <text>sigma (54)-gnAp2 dependent is strongly inhibited by CRP-cAMP by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="5351">
                    <text>sigma (54)-gnAp2 dependent is strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="5352">
                    <text>sigma (54)-gnAp2 dependent was strongly inhibited by CRP-cAMP 21 times.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="5353">
                    <text>sigma (54)-gnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5354">
                    <text>sigma (54)-gnAp2 is observed to be strongly inhibited by CRP-cAMP, by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5355">
                    <text>sigma (54)-gnAp2 is strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5356">
                    <text>sigma (54)-gnAp2 was strongly inhibited by CRP-cAMP 21 times.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="5357">
                    <text>the CRP-cAMP complex (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5358">
                    <text>the CRP-cAMP complex (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5359">
                    <text>the CRP-cAMP complex (NO) inhibiting the glnAp2 promoter activity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5360">
                    <text>the CRP-cAMP complex (NO) inhibiting the glnAp2 promoter activity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5361">
                    <text>the CRP-cAMP complex activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5362">
                    <text>the CRP-cAMP complex also has the ability to inhibit the glnAp2 promoter activity in transient transfected T-cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5363">
                    <text>the CRP-cAMP complex also inhibited the glnAp2 promoter activity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5364">
                    <text>the CRP-cAMP complex also inhibits the glnAp2 promoter activity in transient transfected T-cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5365">
                    <text>the CRP-cAMP complex also inhibits the glnAp2 promoter activity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5366">
                    <text>the CRP-cAMP complex can fully inhibit the glnAp2 promoter activity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5367">
                    <text>the CRP-cAMP complex can inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5368">
                    <text>the CRP-cAMP complex can totally inhibit the glnAp2 promoter activity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5369">
                    <text>the CRP-cAMP complex co-expression also has the ability to inhibit the glnAp2 promoter activity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5370">
                    <text>the CRP-cAMP complex fully inhibiting concentration-dependent the glnAp2 promoter activity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5371">
                    <text>the CRP-cAMP complex has also inhibited the glnAp2 promoter activity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5372">
                    <text>the CRP-cAMP complex inhibited the glnAp2 promoter activity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5373">
                    <text>the CRP-cAMP complex inhibited the glnAp2 promoter activity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5374">
                    <text>the CRP-cAMP complex inhibits the glnAp2 promoter activity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5375">
                    <text>the CRP-cAMP complex inhibits the glnAp2 promoter activity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5376">
                    <text>the CRP-cAMP complex is able to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5377">
                    <text>the CRP-cAMP complex may also have inhibited the glnAp2 promoter activity in T cells affected by jurkat.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5378">
                    <text>the CRP-cAMP complex may also have inhibited the glnAp2 promoter activity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5379">
                    <text>the CRP-cAMP complex may have completely inhibited the glnAp2 promoter activity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5380">
                    <text>the CRP-cAMP complex may have completely inhibited the glnAp2 promoter activity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5381">
                    <text>the CRP-cAMP complex may have inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5382">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5383">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5384">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5385">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5386">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5387">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5388">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) inhibiting late clathrin-coated vesicles formation events activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5389">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) inhibiting late clathrin-coated vesicles formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5390">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5391">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5392">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also has the ability to inhibit late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5393">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also has the ability to inhibit late clathrin-coated vesicles formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5394">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also inhibited late clathrin-coated vesicle formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5395">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also inhibited late clathrin-coated vesicles formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5396">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also inhibits late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5397">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also inhibits late clathrin-coated vesicle formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5398">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also inhibits late clathrin-coated vesicles formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5399">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I also inhibits late clathrin-coated vesicles formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5400">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can fully inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5401">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can fully inhibit late clathrin-coated vesicles formation events that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5402">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5403">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5404">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can totally inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5405">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can totally inhibit late clathrin-coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5406">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I co-expression also has the ability to inhibit late clathrin-coated vesicle formation events in T-leukemia transnetly affected cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5407">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I co-expression also has the ability to inhibit late clathrin-coated vesicles formation events in T-leukemia transnetly affected cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5408">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I fully inhibiting concentration-dependent late clathrin-coated vesicle formation events and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5409">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I fully inhibiting concentration-dependent late clathrin-coated vesicles formation events and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5410">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has also inhibited late clathrin-coated vesicle formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5411">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I has also inhibited late clathrin-coated vesicles formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5412">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5413">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5414">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5415">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5416">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5417">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5418">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicles formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5419">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5420">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5421">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is able to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5422">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may also have inhibited late clathrin-coated vesicle formation events in T cells affected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5423">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may also have inhibited late clathrin-coated vesicle formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5424">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may also have inhibited late clathrin-coated vesicles formation events in T cells affected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5425">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may also have inhibited late clathrin-coated vesicles formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5426">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have completely inhibited late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5427">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have completely inhibited late clathrin-coated vesicle formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5428">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have completely inhibited late clathrin-coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5429">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have completely inhibited late clathrin-coated vesicles formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5430">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5431">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5432">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5433">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5434">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5435">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5436">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) inhibiting late clathrin coated vesicles formation events activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5437">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) inhibiting late clathrin coated vesicles formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5438">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5439">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5440">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5441">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5442">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also has the ability to inhibit late clathrin coated vesicles formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5443">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also has the ability to inhibit late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5444">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also inhibited late clathrin coated vesicles formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5445">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also inhibited late clathrin-coated vesicle formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5446">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also inhibits late clathrin coated vesicles formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5447">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also inhibits late clathrin coated vesicles formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5448">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also inhibits late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5449">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also inhibits late clathrin-coated vesicle formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5450">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can fully inhibit late clathrin coated vesicles formation events that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5451">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can fully inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5452">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5453">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5454">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can totally inhibit late clathrin coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5455">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can totally inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5456">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I co-expression also has the ability to inhibit late clathrin coated vesicles formation events in T-leukemia transnetly affected cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5457">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I co-expression also has the ability to inhibit late clathrin-coated vesicle formation events in T-leukemia transnetly affected cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5458">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I fully inhibiting concentration-dependent late clathrin coated vesicles formation events and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5459">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I fully inhibiting concentration-dependent late clathrin-coated vesicle formation events and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5460">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has also inhibited late clathrin coated vesicles formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5461">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has also inhibited late clathrin-coated vesicle formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5462">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin coated vesicles formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5463">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5464">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5465">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5466">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin coated vesicles formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5467">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5468">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5469">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5470">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is able to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5471">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5472">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may also have inhibited late clathrin coated vesicles formation events in T cells affected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5473">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may also have inhibited late clathrin coated vesicles formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5474">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may also have inhibited late clathrin-coated vesicle formation events in T cells affected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5475">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may also have inhibited late clathrin-coated vesicle formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5476">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have completely inhibited late clathrin coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5477">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have completely inhibited late clathrin coated vesicles formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5478">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have completely inhibited late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5479">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have completely inhibited late clathrin-coated vesicle formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5480">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have inhibited late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="5481">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="5482">
                    <text>the function of phosphateases and localization would be inhibited if phosphatease were associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="5483">
                    <text>the function or location of A1 will be inhibited if phosphatase is associated with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="5484">
                    <text>the function or location of A1 will be inhibited if phosphatase is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="5485">
                    <text>the function or location of A1 will be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="5486">
                    <text>the function or location of A1 would be inhibited if phosphatase were associated with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="5487">
                    <text>the function or location of A1 would be inhibited if phosphatase were associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="5488">
                    <text>the function or location of A1 would be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="5489">
                    <text>the function or location of A1 would be inhibited if phosphatease were associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="5490">
                    <text>the glnAp2 promoter activity are inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5491">
                    <text>the glnAp2 promoter activity can be inhibited by the CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5492">
                    <text>the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5493">
                    <text>the glnAp2 promoter activity in Jurkat T-leukemia transfect cells has also been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5494">
                    <text>the glnAp2 promoter activity in T cells of Jurkat transfects is also inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5495">
                    <text>the glnAp2 promoter activity in T-lycemic cells transfected, wil is also inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5496">
                    <text>the glnAp2 promoter activity in transfectuously affected T-leukemia cells, wil is also inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5497">
                    <text>the glnAp2 promoter activity in transiently transfected Jurkat T-cells is also inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5498">
                    <text>the glnAp2 promoter activity in transiently transfected Jurkat T-cells was also inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5499">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and can be fully inhibited with the CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5500">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and can be totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5501">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and has been totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5502">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and is able to be fully inhibited with the CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5503">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and is fully inhibited with the CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5504">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and is observed to be totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5505">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and was fully inhibited with the CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5506">
                    <text>the glnAp2 promoter activity is able to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5507">
                    <text>the glnAp2 promoter activity is capable of being inhibited by the CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5508">
                    <text>the glnAp2 promoter activity is capable of being inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5509">
                    <text>the glnAp2 promoter activity is concentration-dependent and saturable and is able to be fully inhibited with the CRP-cAMP complex , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5510">
                    <text>the glnAp2 promoter activity is inhibited by the CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5511">
                    <text>the glnAp2 promoter activity is inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5512">
                    <text>the glnAp2 promoter activity is observed to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5513">
                    <text>the glnAp2 promoter activity may have been inhibited by the CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5514">
                    <text>the glnAp2 promoter activity was inhibited by the CRP-cAMP complex that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5515">
                    <text>the glnAp2 promoter activity was inhibited by the CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5516">
                    <text>the glnAp2 promoter activity was inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5517">
                    <text>the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5518">
                    <text>the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="5519">
                    <text>the regulation of phosphorylated state, state5 and state6 are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5520">
                    <text>the regulation of phosphorylated state, state5 and state6 are inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5521">
                    <text>the regulation of phosphorylated state, state5 and state6 can be inhibited by a proteasome MG132 inhibitor and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5522">
                    <text>the regulation of phosphorylated state, state5 and state6 has been inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5523">
                    <text>the regulation of phosphorylated state, state5 and state6 in Jurkat T-leukemia transfect cells has also been inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5524">
                    <text>the regulation of phosphorylated state, state5 and state6 in T cells of Jurkat transfects is also inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5525">
                    <text>the regulation of phosphorylated state, state5 and state6 in T-lycemic cells transfected, wil is also inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5526">
                    <text>the regulation of phosphorylated state, state5 and state6 in transfectuously affected T-leukemia cells, wil is also inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5527">
                    <text>the regulation of phosphorylated state, state5 and state6 in transiently transfected Jurkat T-cells is also inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5528">
                    <text>the regulation of phosphorylated state, state5 and state6 in transiently transfected Jurkat T-cells was also inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5529">
                    <text>the regulation of phosphorylated state, state5 and state6 is a dependent and saturable concentration and can be fully inhibited with a proteasome MG132 inhibitor and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5530">
                    <text>the regulation of phosphorylated state, state5 and state6 is a dependent and saturable concentration and can be totally inhibited with a proteasome MG132 inhibitor and lactacitstin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5531">
                    <text>the regulation of phosphorylated state, state5 and state6 is a dependent and saturable concentration and has been totally inhibited with a proteasome MG132 inhibitor and lactacitstin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5532">
                    <text>the regulation of phosphorylated state, state5 and state6 is a dependent and saturable concentration and is able to be fully inhibited with a proteasome MG132 inhibitor and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5533">
                    <text>the regulation of phosphorylated state, state5 and state6 is a dependent and saturable concentration and is fully inhibited with a proteasome MG132 inhibitor and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5534">
                    <text>the regulation of phosphorylated state, state5 and state6 is a dependent and saturable concentration and is observed to be totally inhibited with a proteasome MG132 inhibitor and lactacitstin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5535">
                    <text>the regulation of phosphorylated state, state5 and state6 is a dependent and saturable concentration and was fully inhibited with a proteasome MG132 inhibitor and lactacitstin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5536">
                    <text>the regulation of phosphorylated state, state5 and state6 is able to be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5537">
                    <text>the regulation of phosphorylated state, state5 and state6 is capable of being inhibited by a proteasome MG132 inhibitor and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5538">
                    <text>the regulation of phosphorylated state, state5 and state6 is capable of being inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5539">
                    <text>the regulation of phosphorylated state, state5 and state6 is concentration-dependent and saturable and is able to be fully inhibited with a proteasome MG132 inhibitor and lactacitstin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5540">
                    <text>the regulation of phosphorylated state, state5 and state6 is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5541">
                    <text>the regulation of phosphorylated state, state5 and state6 is inhibited by a proteasome MG132 inhibitor and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5542">
                    <text>the regulation of phosphorylated state, state5 and state6 is inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5543">
                    <text>the regulation of phosphorylated state, state5 and state6 is observed to be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5544">
                    <text>the regulation of phosphorylated state, state5 and state6 may have been inhibited by a proteasome MG132 inhibitor and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5545">
                    <text>the regulation of phosphorylated state, state5 and state6 was inhibited by a proteasome MG132 inhibitor and lactacitstin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5546">
                    <text>the regulation of phosphorylated state, state5 and state6 was inhibited by a proteasome MG132 inhibitor and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5547">
                    <text>the regulation of phosphorylated state, state5 and state6 was inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5548">
                    <text>the regulation of phosphorylated state, state5 and state6 were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5549">
                    <text>the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5550">
                    <text>the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="5551">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 are inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5552">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 can be inhibited by inhibitors of the MG132 proteasome and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5553">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 has been inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5554">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 in Jurkat T-leukemia transfect cells has also been inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5555">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 in T cells of Jurkat transfects is also inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5556">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 in T-lycemic cells transfected, wil is also inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5557">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 in transfectuously affected T-leukemia cells, wil is also inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5558">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 in transiently transfected Jurkat T-cells is also inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5559">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 in transiently transfected Jurkat T-cells was also inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5560">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and can be fully inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5561">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and can be totally inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5562">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and has been totally inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5563">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and is able to be fully inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5564">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and is fully inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5565">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and is observed to be totally inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5566">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and was fully inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5567">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is able to be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5568">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is capable of being inhibited by inhibitors of the MG132 proteasome and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5569">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is capable of being inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5570">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is concentration-dependent and saturable and is able to be fully inhibited with inhibitors of the MG132 proteasome and lactacyttin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5571">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by inhibitors of the MG132 proteasome and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5572">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5573">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is observed to be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5574">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 may have been inhibited by inhibitors of the MG132 proteasome and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5575">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5576">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5577">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5578">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by inhibitors of the MG132 proteasome and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5579">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 will be inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="5580">
                    <text>this synthetic peptide binds to P and is able to inhibit its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="5581">
                    <text>this synthetic peptide that binds to P may have inhibited its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>10 mM EDTA has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>10 mM EDTA inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>10 mM EDTA inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>10mM EDTA (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>10mM EDTA (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>10mM EDTA (NO) inhibiting ligand activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>10mM EDTA (NO) inhibiting ligand activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>10mM EDTA activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>10mM EDTA also has the ability to inhibit ligand in transient transfected T-cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>10mM EDTA also inhibited ligand in transfected T-leukemia cells transfected.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>10mM EDTA also inhibits ligand in transient transfected T-cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>10mM EDTA also inhibits ligand in transiently transfected T-leukemia cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>10mM EDTA can fully inhibit ligand that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>10mM EDTA can inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>10mM EDTA can totally inhibit ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>10mM EDTA co-expression also has the ability to inhibit ligand in T-leukemia transnetly affected cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>10mM EDTA fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>10mM EDTA has also inhibited ligand in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>10mM EDTA has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>10mM EDTA inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>10mM EDTA inhibited ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>10mM EDTA inhibited ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>10mM EDTA inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>10mM EDTA inhibits ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>10mM EDTA inhibits ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>10mM EDTA is able to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>10mM EDTA may also have inhibited ligand in T cells affected by jurkat.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>10mM EDTA may also have inhibited ligand in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>10mM EDTA may have completely inhibited ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>10mM EDTA may have completely inhibited ligand which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>10mM EDTA may have inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>A0 inhibited Lrp/PapI.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>A0 inhibited decreased regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>A0 inhibited intermediate events leading to the formation of clathrin coated wells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>A0 inhibited intermediate events that lead to the formation of clathrin-coated cubes.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>A0 inhibited intermediate events that lead to the formation of clathrin-coated paddocks.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>A0 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>A0 inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>A0 inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>A0 inhibits Lrp/PapI.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>A0 inhibits decreased regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>A0 inhibits intermediate events leading to the formation of clathrin coated wells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>A0 inhibits intermediate events that lead to the formation of clathrin-coated cubes.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>A0 inhibits intermediate events that lead to the formation of clathrin-coated paddocks.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>A0 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>A0 inhibits intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>A0 inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>A0 is able to completely inhibit Lrp/PapI that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>A0 is able to completely inhibit decreased regulation of Stat4, Stat5 and Stat6 phosphorylated that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>A0 is able to completely inhibit intermediate events leading to the formation of clathrin coated wells that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>A0 is able to completely inhibit intermediate events that lead to the formation of clathrin-coated cubes that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>A0 is able to completely inhibit intermediate events that lead to the formation of clathrin-coated paddocks that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>A0 is able to completely inhibit intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>A0 is able to completely inhibit intermediate events that lead to the formation of clathrin-coated wells that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>A0 is able to completely inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>A0 is capable of completely inhibiting Lrp/PapI that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>A0 is capable of completely inhibiting decreased regulation of Stat4, Stat5 and Stat6 phosphorylated that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>A0 is capable of completely inhibiting intermediate events leading to the formation of clathrin coated wells that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>A0 is capable of completely inhibiting intermediate events that lead to the formation of clathrin-coated cubes that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>A0 is capable of completely inhibiting intermediate events that lead to the formation of clathrin-coated paddocks that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>A0 is capable of completely inhibiting intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>A0 is capable of completely inhibiting intermediate events that lead to the formation of clathrin-coated wells that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>A0 is capable of completely inhibiting late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>A2 can be inhibited by 10 mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>A2 can be inhibited by 10mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>A2 can be inhibited by EDTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>A2 can be inhibited by N-terminal SH3 domain that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>A2 can be inhibited by N-terminal domain H3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>A2 can be inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>A2 can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>A2 can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>A2 can be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>A2 can be inhibited by This synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>A2 can be inhibited by cell surface receptors for immunoglobulin and lectin type C that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>A2 can be inhibited by cell surface receptors for immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>A2 can be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>A2 can be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>A2 can be inhibited by crew methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>A2 can be inhibited by methylation of prey that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>A2 can be inhibited by methylation of snails that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>A2 can be inhibited by nails methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>A2 can be inhibited by protein extracts from transfect body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>A2 can be inhibited by protein extracts from transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>A2 can be inhibited by rolipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>A2 can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>A2 can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>A2 can be inhibited by this synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>A2 is capable of being inhibited by 10 mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>A2 is capable of being inhibited by 10mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>A2 is capable of being inhibited by EDTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>A2 is capable of being inhibited by N-terminal SH3 domain that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>A2 is capable of being inhibited by N-terminal domain H3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>A2 is capable of being inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>A2 is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>A2 is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>A2 is capable of being inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>A2 is capable of being inhibited by This synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>A2 is capable of being inhibited by cell surface receptors for immunoglobulin and lectin type C that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>A2 is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>A2 is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>A2 is capable of being inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>A2 is capable of being inhibited by crew methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>A2 is capable of being inhibited by methylation of prey that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>A2 is capable of being inhibited by methylation of snails that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>A2 is capable of being inhibited by nails methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>A2 is capable of being inhibited by protein extracts from transfect body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>A2 is capable of being inhibited by protein extracts from transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>A2 is capable of being inhibited by rolipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>A2 is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>A2 is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>A2 is capable of being inhibited by this synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>A2 is inhibited by 10 mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>A2 is inhibited by 10mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>A2 is inhibited by EDTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>A2 is inhibited by N-terminal SH3 domain that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>A2 is inhibited by N-terminal domain H3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>A2 is inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>A2 is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>A2 is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>A2 is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>A2 is inhibited by This synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>A2 is inhibited by cell surface receptors for immunoglobulin and lectin type C that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>A2 is inhibited by cell surface receptors for immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>A2 is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>A2 is inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>A2 is inhibited by crew methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>A2 is inhibited by methylation of prey that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>A2 is inhibited by methylation of snails that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>A2 is inhibited by nails methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>A2 is inhibited by protein extracts from transfect body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>A2 is inhibited by protein extracts from transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>A2 is inhibited by rolipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>A2 is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>A2 is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>A2 is inhibited by this synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>A2 may have been inhibited by 10 mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>A2 may have been inhibited by 10mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>A2 may have been inhibited by EDTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>A2 may have been inhibited by N-terminal SH3 domain that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>A2 may have been inhibited by N-terminal domain H3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>A2 may have been inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>A2 may have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>A2 may have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>A2 may have been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>A2 may have been inhibited by This synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>A2 may have been inhibited by cell surface receptors for immunoglobulin and lectin type C that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>A2 may have been inhibited by cell surface receptors for immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>A2 may have been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>A2 may have been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>A2 may have been inhibited by crew methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>A2 may have been inhibited by methylation of prey that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>A2 may have been inhibited by methylation of snails that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>A2 may have been inhibited by nails methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>A2 may have been inhibited by protein extracts from transfect body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>A2 may have been inhibited by protein extracts from transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>A2 may have been inhibited by rolipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>A2 may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>A2 may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>A2 may have been inhibited by this synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>A2 will be inhibited by 10 mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>A2 will be inhibited by 10mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>A2 will be inhibited by EDTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>A2 will be inhibited by N-terminal SH3 domain that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>A2 will be inhibited by N-terminal domain H3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>A2 will be inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>A2 will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>A2 will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>A2 will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>A2 will be inhibited by This synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>A2 will be inhibited by cell surface receptors for immunoglobulin and lectin type C that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>A2 will be inhibited by cell surface receptors for immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>A2 will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>A2 will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>A2 will be inhibited by crew methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>A2 will be inhibited by methylation of prey that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>A2 will be inhibited by methylation of snails that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>A2 will be inhibited by nails methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>A2 will be inhibited by protein extracts from transfect body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>A2 will be inhibited by protein extracts from transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>A2 will be inhibited by rolipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>A2 will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>A2 will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>A2 will be inhibited by this synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>EDTA of 10 mM (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>EDTA of 10 mM (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>EDTA of 10 mM (NO) inhibiting binding activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>EDTA of 10 mM (NO) inhibiting binding activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>EDTA of 10 mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>EDTA of 10 mM also has the ability to inhibit binding in transient transfected T-cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>EDTA of 10 mM also inhibited binding in transfected T-leukemia cells transfected.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>EDTA of 10 mM also inhibits binding in transient transfected T-cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>EDTA of 10 mM also inhibits binding in transiently transfected T-leukemia cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>EDTA of 10 mM can fully inhibit binding that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>EDTA of 10 mM can inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>EDTA of 10 mM can totally inhibit binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>EDTA of 10 mM co-expression also has the ability to inhibit binding in T-leukemia transnetly affected cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>EDTA of 10 mM fully inhibiting concentration-dependent binding and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>EDTA of 10 mM has also inhibited binding in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>EDTA of 10 mM has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>EDTA of 10 mM inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>EDTA of 10 mM inhibited binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>EDTA of 10 mM inhibited binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>EDTA of 10 mM inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>EDTA of 10 mM inhibits binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>EDTA of 10 mM inhibits binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>EDTA of 10 mM is able to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>EDTA of 10 mM may also have inhibited binding in T cells affected by jurkat.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>EDTA of 10 mM may also have inhibited binding in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>EDTA of 10 mM may have completely inhibited binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>EDTA of 10 mM may have completely inhibited binding which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>EDTA of 10 mM may have inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>For example, P associated with This synthetic peptide can be inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>For example, P associated with This synthetic peptide has been inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>For example, P associated with This synthetic peptide is inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>For example, P associated with This synthetic peptide may be inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>For example, P associated with This synthetic peptide may have been inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>For example, P associated with This synthetic peptide was inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>For example, P is associated with This synthetic peptide and is therefore inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>For example, P may have been associated with This synthetic peptide and has therefore been inhibited in the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10mM EDTA inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10mM EDTA inhibits ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10mM EDTA is able to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10mM EDTA may have inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10mM EDTA may inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM inhibits binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM is able to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM may have inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM may inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI binding is inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI binding was inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI binding will be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI connection is inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI connection was inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI connection will be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI is inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI was inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Lrp/PapI will be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal SH3 domain inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal SH3 domain inhibits intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal SH3 domain is able to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal SH3 domain may have inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal SH3 domain may inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain H3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain H3 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain H3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain H3 may have inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain H3 may inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 inhibits intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 is able to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 may have inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 may have inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 may inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 may inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibits delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I is able to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I may have inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I may inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I may have inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I may inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding was inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and lectin type C inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and lectin type C is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and lectin type C may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and lectin type C may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectin may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectin may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while delayed clattrin-coated vesicles formation events is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while delayed clattrin-coated vesicles formation events was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of a clathrin-coated well is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of a clathrin-coated well was inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of a clathrin-coated well will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated wells is inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated wells was inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events was inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand was inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of prey inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of prey inhibits Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of prey is able to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of prey may have inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of prey may inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of snails inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of snails inhibits Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of snails is able to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of snails may have inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of snails may inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nails methylation inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nails methylation inhibits Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nails methylation is able to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nails methylation may have inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while nails methylation may inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10mM EDTA inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10mM EDTA inhibits ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10mM EDTA is observed to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA of 10 mM inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA of 10 mM inhibits binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while EDTA of 10 mM is observed to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Lrp/PapI binding is observed to be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Lrp/PapI connection is observed to be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Lrp/PapI is observed to be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal SH3 domain inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal SH3 domain inhibits intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal SH3 domain is observed to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain H3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain H3 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain H3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain SH3 inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain SH3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain SH3 inhibits intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain SH3 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain SH3 is observed to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain SH3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibits delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I is observed to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while binding is observed to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and lectin type C inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and lectin type C is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and type C lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while delayed clattrin-coated vesicles formation events is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while intermediate events that lead to the formation of a clathrin-coated well is observed to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while intermediate events that lead to the formation of clathrin-coated pins is observed to be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while intermediate events that lead to the formation of clathrin-coated pins is observed to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while intermediate events that lead to the formation of clathrin-coated wells is observed to be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late clathrin-coated vesicle formation events is observed to be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late clathrin-coated vesicle formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late events of clathrin-coated vesicles formation is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while ligand is observed to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while methylation of prey inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while methylation of prey inhibits Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while methylation of prey is observed to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while methylation of snails inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while methylation of snails inhibits Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while methylation of snails is observed to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nails methylation inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nails methylation inhibits Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nails methylation is observed to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA can inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA has inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA has the ability to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA will inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM can inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM has inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM has the ability to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM will inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI binding can be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI binding has been inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI binding is inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI binding will be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI can be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI connection can be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI connection has been inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI connection is inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI connection will be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI has been inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI is inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI will be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain can inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain has inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain has the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain will inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 can inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 has inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 will inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 can inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 can inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 has inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 has inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 has the ability to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 will inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 will inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I can inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I has inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I has the ability to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I will inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I can inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I has inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I will inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I has inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I will inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that This synthetic peptide can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that This synthetic peptide inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that This synthetic peptide inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that This synthetic peptide inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that This synthetic peptide inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding can be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding has been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that crew methylation can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that crew methylation inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that crew methylation inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that crew methylation inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that crew methylation inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that delayed clattrin-coated vesicles formation events can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that delayed clattrin-coated vesicles formation events has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that delayed clattrin-coated vesicles formation events is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well can be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well has been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins can be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins can be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells can be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells has been inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells is inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events can be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand has been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey can inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey has inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey has the ability to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of prey will inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails can inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails has inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails has the ability to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails will inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation can inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation has inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation has the ability to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation will inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfect body cells can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfect body cells inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfect body cells inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfect body cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfect body cells inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected body cells can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected body cells inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected body cells inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected body cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected body cells inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that rolipram can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that rolipram inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that rolipram inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that rolipram inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that rolipram inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I has inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I will inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that this synthetic peptide can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that this synthetic peptide inhibited A2 activity (promociógnAp2).</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that this synthetic peptide inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that this synthetic peptide inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that this synthetic peptide inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>Here, we have found that Lrp/PapI binding has been inhibited by methylation of prey, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>Here, we have found that Lrp/PapI binding is inhibited by methylation of prey, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>Here, we have found that Lrp/PapI binding will be inhibited by methylation of prey, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>Here, we have found that Lrp/PapI connection has been inhibited by methylation of snails, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="680">
                    <text>Here, we have found that Lrp/PapI connection is inhibited by methylation of snails, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="681">
                    <text>Here, we have found that Lrp/PapI connection will be inhibited by methylation of snails, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="682">
                    <text>Here, we have found that Lrp/PapI has been inhibited by nails methylation, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="683">
                    <text>Here, we have found that Lrp/PapI is inhibited by nails methylation, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="684">
                    <text>Here, we have found that Lrp/PapI will be inhibited by nails methylation, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="685">
                    <text>Here, we have found that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and lectin type C, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="686">
                    <text>Here, we have found that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="687">
                    <text>Here, we have found that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="688">
                    <text>Here, we have found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="689">
                    <text>Here, we have found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="690">
                    <text>Here, we have found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="691">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and lectin type C, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="692">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="693">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="694">
                    <text>Here, we have found that binding has been inhibited by EDTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="695">
                    <text>Here, we have found that binding is inhibited by EDTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="696">
                    <text>Here, we have found that binding will be inhibited by EDTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="697">
                    <text>Here, we have found that delayed clattrin-coated vesicles formation events has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="698">
                    <text>Here, we have found that delayed clattrin-coated vesicles formation events is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="699">
                    <text>Here, we have found that delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="700">
                    <text>Here, we have found that intermediate events that lead to the formation of a clathrin-coated well has been inhibited by N-terminal domain SH3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="701">
                    <text>Here, we have found that intermediate events that lead to the formation of a clathrin-coated well is inhibited by N-terminal domain SH3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="702">
                    <text>Here, we have found that intermediate events that lead to the formation of a clathrin-coated well will be inhibited by N-terminal domain SH3, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="703">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain H3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="704">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain SH3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="705">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain H3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="706">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="707">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="708">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="709">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated wells has been inhibited by N-terminal SH3 domain, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="710">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated wells is inhibited by N-terminal SH3 domain, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="711">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="712">
                    <text>Here, we have found that late clathrin-coated vesicle formation events has been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="713">
                    <text>Here, we have found that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="714">
                    <text>Here, we have found that late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="715">
                    <text>Here, we have found that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="716">
                    <text>Here, we have found that late clathrin-coated vesicle formation events will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="717">
                    <text>Here, we have found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="718">
                    <text>Here, we have found that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="719">
                    <text>Here, we have found that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="720">
                    <text>Here, we have found that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="721">
                    <text>Here, we have found that ligand has been inhibited by 10mM EDTA, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="722">
                    <text>Here, we have found that ligand is inhibited by 10mM EDTA, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="723">
                    <text>Here, we have found that ligand will be inhibited by 10mM EDTA, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="724">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA has the ability to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="725">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA is able to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="726">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA is observed to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="727">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA of 10 mM has the ability to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="728">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA of 10 mM is able to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="729">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA of 10 mM is observed to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="730">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI binding has been inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="731">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI binding is able to be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="732">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI binding is inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="733">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI binding will be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="734">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI connection has been inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="735">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI connection is able to be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="736">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI connection is inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="737">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI connection will be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="738">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI has been inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="739">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI is able to be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="740">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI is inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="741">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Lrp/PapI will be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="742">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal SH3 domain has the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="743">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal SH3 domain is able to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="744">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal SH3 domain is observed to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="745">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain H3 has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="746">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain H3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="747">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain H3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="748">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain SH3 has the ability to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="749">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain SH3 has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="750">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain SH3 is able to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="751">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain SH3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="752">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain SH3 is observed to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="753">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain SH3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="754">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="755">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="756">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="757">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="758">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="759">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="760">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="761">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="762">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="763">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="764">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="765">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="766">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I has the ability to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="767">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I is able to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="768">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I is observed to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="769">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="770">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="771">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="772">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="773">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="774">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="775">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding has been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="776">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding is able to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="777">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="778">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="779">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="780">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="781">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="782">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="783">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="784">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="785">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="786">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="787">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="788">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that delayed clattrin-coated vesicles formation events has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="789">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that delayed clattrin-coated vesicles formation events is able to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="790">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that delayed clattrin-coated vesicles formation events is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="791">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="792">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well has been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="793">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well is able to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="794">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="795">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of a clathrin-coated well will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="796">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="797">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="798">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins is able to be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="799">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins is able to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="800">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="801">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="802">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="803">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="804">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells has been inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="805">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells is able to be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="806">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells is inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="807">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="808">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="809">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="810">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is able to be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="811">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="812">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="813">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="814">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="815">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="816">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="817">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation is able to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="818">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="819">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="820">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand has been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="821">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is able to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="822">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="823">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="824">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that methylation of prey has the ability to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="825">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that methylation of prey is able to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="826">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that methylation of prey is observed to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="827">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that methylation of snails has the ability to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="828">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that methylation of snails is able to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="829">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that methylation of snails is observed to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="830">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nails methylation has the ability to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="831">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nails methylation is able to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="832">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nails methylation is observed to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="833">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="834">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="835">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="836">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="837">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibits ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="838">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA is observed to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="839">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="840">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibits binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="841">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM is observed to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="842">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="843">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibits intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="844">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain is observed to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="845">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="846">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="847">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="848">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="849">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="850">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibits intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="851">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="852">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 is observed to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="853">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="854">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="855">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibits delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="856">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I is observed to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="857">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="858">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="859">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="860">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="861">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="862">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="863">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="864">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="865">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="866">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="867">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="868">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="869">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="870">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="871">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="872">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that methylation of prey inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="873">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that methylation of prey inhibits Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="874">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that methylation of prey is observed to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="875">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that methylation of snails inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="876">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that methylation of snails inhibits Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="877">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that methylation of snails is observed to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="878">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nails methylation inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="879">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nails methylation inhibits Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="880">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that nails methylation is observed to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="881">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="882">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="883">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="884">
                    <text>In this study, we found that Lrp/PapI binding will be inhibited by methylation of prey, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="885">
                    <text>In this study, we found that Lrp/PapI connection will be inhibited by methylation of snails, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="886">
                    <text>In this study, we found that Lrp/PapI will be inhibited by nails methylation, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="887">
                    <text>In this study, we found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and lectin type C, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="888">
                    <text>In this study, we found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="889">
                    <text>In this study, we found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="890">
                    <text>In this study, we found that binding will be inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="891">
                    <text>In this study, we found that delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="892">
                    <text>In this study, we found that intermediate events that lead to the formation of a clathrin-coated well will be inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="893">
                    <text>In this study, we found that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="894">
                    <text>In this study, we found that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="895">
                    <text>In this study, we found that intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="896">
                    <text>In this study, we found that late clathrin-coated vesicle formation events will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="897">
                    <text>In this study, we found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="898">
                    <text>In this study, we found that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="899">
                    <text>In this study, we found that ligand will be inhibited by 10mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="900">
                    <text>In this work, we found that Lrp/PapI binding is inhibited by methylation of prey, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="901">
                    <text>In this work, we found that Lrp/PapI binding was inhibited by methylation of prey, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="902">
                    <text>In this work, we found that Lrp/PapI binding was inhibited by methylation of prey, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="903">
                    <text>In this work, we found that Lrp/PapI connection is inhibited by methylation of snails, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="904">
                    <text>In this work, we found that Lrp/PapI connection was inhibited by methylation of snails, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="905">
                    <text>In this work, we found that Lrp/PapI connection was inhibited by methylation of snails, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="906">
                    <text>In this work, we found that Lrp/PapI is inhibited by nails methylation, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="907">
                    <text>In this work, we found that Lrp/PapI was inhibited by nails methylation, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="908">
                    <text>In this work, we found that Lrp/PapI was inhibited by nails methylation, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="909">
                    <text>In this work, we found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="910">
                    <text>In this work, we found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="911">
                    <text>In this work, we found that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="912">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and lectin type C, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="913">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and lectin type C, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="914">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="915">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="916">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="917">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="918">
                    <text>In this work, we found that binding is inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="919">
                    <text>In this work, we found that binding was inhibited by EDTA of 10 mM, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="920">
                    <text>In this work, we found that binding was inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="921">
                    <text>In this work, we found that delayed clattrin-coated vesicles formation events is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="922">
                    <text>In this work, we found that delayed clattrin-coated vesicles formation events was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="923">
                    <text>In this work, we found that delayed clattrin-coated vesicles formation events was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="924">
                    <text>In this work, we found that intermediate events that lead to the formation of a clathrin-coated well is inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="925">
                    <text>In this work, we found that intermediate events that lead to the formation of a clathrin-coated well was inhibited by N-terminal domain SH3, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="926">
                    <text>In this work, we found that intermediate events that lead to the formation of a clathrin-coated well was inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="927">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain H3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="928">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="929">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="930">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="931">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="932">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="933">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated wells is inhibited by N-terminal SH3 domain, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="934">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated wells was inhibited by N-terminal SH3 domain, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="935">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated wells was inhibited by N-terminal SH3 domain, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="936">
                    <text>In this work, we found that late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="937">
                    <text>In this work, we found that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="938">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="939">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="940">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="941">
                    <text>In this work, we found that late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="942">
                    <text>In this work, we found that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="943">
                    <text>In this work, we found that late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="944">
                    <text>In this work, we found that late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="945">
                    <text>In this work, we found that ligand is inhibited by 10mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="946">
                    <text>In this work, we found that ligand was inhibited by 10mM EDTA, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="947">
                    <text>In this work, we found that ligand was inhibited by 10mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="948">
                    <text>Lrp/PapI are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="949">
                    <text>Lrp/PapI are inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="950">
                    <text>Lrp/PapI binding are inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="951">
                    <text>Lrp/PapI binding can be inhibited by methylation of prey which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="952">
                    <text>Lrp/PapI binding has been inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="953">
                    <text>Lrp/PapI binding in Jurkat T-leukemia transfect cells has also been inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="954">
                    <text>Lrp/PapI binding in T cells of Jurkat transfects is also inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="955">
                    <text>Lrp/PapI binding in T-lycemic cells transfected, wil is also inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="956">
                    <text>Lrp/PapI binding in transfectuously affected T-leukemia cells, wil is also inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="957">
                    <text>Lrp/PapI binding in transiently transfected Jurkat T-cells is also inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="958">
                    <text>Lrp/PapI binding in transiently transfected Jurkat T-cells was also inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="959">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and can be fully inhibited with methylation of prey, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="960">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and can be totally inhibited with methylation of prey, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="961">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and has been totally inhibited with methylation of prey, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="962">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and is able to be fully inhibited with methylation of prey, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="963">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and is fully inhibited with methylation of prey, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="964">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and is observed to be totally inhibited with methylation of prey, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="965">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and was fully inhibited with methylation of prey, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="966">
                    <text>Lrp/PapI binding is able to be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="967">
                    <text>Lrp/PapI binding is capable of being inhibited by methylation of prey which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="968">
                    <text>Lrp/PapI binding is capable of being inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="969">
                    <text>Lrp/PapI binding is concentration-dependent and saturable and is able to be fully inhibited with methylation of prey , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="970">
                    <text>Lrp/PapI binding is inhibited by methylation of prey which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="971">
                    <text>Lrp/PapI binding is inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="972">
                    <text>Lrp/PapI binding is observed to be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="973">
                    <text>Lrp/PapI binding may have been inhibited by methylation of prey which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="974">
                    <text>Lrp/PapI binding was inhibited by methylation of prey that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="975">
                    <text>Lrp/PapI binding was inhibited by methylation of prey which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="976">
                    <text>Lrp/PapI binding was inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="977">
                    <text>Lrp/PapI binding will be inhibited by methylation of prey which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="978">
                    <text>Lrp/PapI binding will be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="979">
                    <text>Lrp/PapI can be inhibited by nails methylation which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="980">
                    <text>Lrp/PapI connection are inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="981">
                    <text>Lrp/PapI connection can be inhibited by methylation of snails which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="982">
                    <text>Lrp/PapI connection has been inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="983">
                    <text>Lrp/PapI connection in Jurkat T-leukemia transfect cells has also been inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="984">
                    <text>Lrp/PapI connection in T cells of Jurkat transfects is also inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="985">
                    <text>Lrp/PapI connection in T-lycemic cells transfected, wil is also inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="986">
                    <text>Lrp/PapI connection in transfectuously affected T-leukemia cells, wil is also inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="987">
                    <text>Lrp/PapI connection in transiently transfected Jurkat T-cells is also inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="988">
                    <text>Lrp/PapI connection in transiently transfected Jurkat T-cells was also inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="989">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and can be fully inhibited with methylation of snails, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="990">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and can be totally inhibited with methylation of snails, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="991">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and has been totally inhibited with methylation of snails, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="992">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and is able to be fully inhibited with methylation of snails, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="993">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and is fully inhibited with methylation of snails, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="994">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and is observed to be totally inhibited with methylation of snails, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="995">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and was fully inhibited with methylation of snails, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="996">
                    <text>Lrp/PapI connection is able to be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="997">
                    <text>Lrp/PapI connection is capable of being inhibited by methylation of snails which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="998">
                    <text>Lrp/PapI connection is capable of being inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="999">
                    <text>Lrp/PapI connection is concentration-dependent and saturable and is able to be fully inhibited with methylation of snails , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1000">
                    <text>Lrp/PapI connection is inhibited by methylation of snails which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1001">
                    <text>Lrp/PapI connection is inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1002">
                    <text>Lrp/PapI connection is observed to be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1003">
                    <text>Lrp/PapI connection may have been inhibited by methylation of snails which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1004">
                    <text>Lrp/PapI connection was inhibited by methylation of snails that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1005">
                    <text>Lrp/PapI connection was inhibited by methylation of snails which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1006">
                    <text>Lrp/PapI connection was inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1007">
                    <text>Lrp/PapI connection will be inhibited by methylation of snails which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1008">
                    <text>Lrp/PapI connection will be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1009">
                    <text>Lrp/PapI has been inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1010">
                    <text>Lrp/PapI in Jurkat T-leukemia transfect cells has also been inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1011">
                    <text>Lrp/PapI in T cells of Jurkat transfects is also inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1012">
                    <text>Lrp/PapI in T-lycemic cells transfected, wil is also inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1013">
                    <text>Lrp/PapI in transfectuously affected T-leukemia cells, wil is also inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1014">
                    <text>Lrp/PapI in transiently transfected Jurkat T-cells is also inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1015">
                    <text>Lrp/PapI in transiently transfected Jurkat T-cells was also inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1016">
                    <text>Lrp/PapI is a dependent and saturable concentration and can be fully inhibited with nails methylation, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1017">
                    <text>Lrp/PapI is a dependent and saturable concentration and can be totally inhibited with nails methylation, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1018">
                    <text>Lrp/PapI is a dependent and saturable concentration and has been totally inhibited with nails methylation, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1019">
                    <text>Lrp/PapI is a dependent and saturable concentration and is able to be fully inhibited with nails methylation, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1020">
                    <text>Lrp/PapI is a dependent and saturable concentration and is fully inhibited with nails methylation, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1021">
                    <text>Lrp/PapI is a dependent and saturable concentration and is observed to be totally inhibited with nails methylation, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1022">
                    <text>Lrp/PapI is a dependent and saturable concentration and was fully inhibited with nails methylation, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1023">
                    <text>Lrp/PapI is able to be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1024">
                    <text>Lrp/PapI is capable of being inhibited by nails methylation which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1025">
                    <text>Lrp/PapI is capable of being inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1026">
                    <text>Lrp/PapI is concentration-dependent and saturable and is able to be fully inhibited with nails methylation , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1027">
                    <text>Lrp/PapI is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1028">
                    <text>Lrp/PapI is inhibited by nails methylation which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1029">
                    <text>Lrp/PapI is inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1030">
                    <text>Lrp/PapI is observed to be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1031">
                    <text>Lrp/PapI may have been inhibited by nails methylation which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1032">
                    <text>Lrp/PapI was inhibited by nails methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1033">
                    <text>Lrp/PapI was inhibited by nails methylation which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1034">
                    <text>Lrp/PapI was inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1035">
                    <text>Lrp/PapI were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1036">
                    <text>Lrp/PapI will be inhibited by nails methylation which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1037">
                    <text>Lrp/PapI will be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1038">
                    <text>N-terminal SH3 domain (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1039">
                    <text>N-terminal SH3 domain (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1040">
                    <text>N-terminal SH3 domain (NO) inhibiting intermediate events that lead to the formation of clathrin-coated wells activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1041">
                    <text>N-terminal SH3 domain (NO) inhibiting intermediate events that lead to the formation of clathrin-coated wells activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1042">
                    <text>N-terminal SH3 domain activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1043">
                    <text>N-terminal SH3 domain also has the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells in transient transfected T-cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1044">
                    <text>N-terminal SH3 domain also inhibited intermediate events that lead to the formation of clathrin-coated wells in transfected T-leukemia cells transfected.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1045">
                    <text>N-terminal SH3 domain also inhibits intermediate events that lead to the formation of clathrin-coated wells in transient transfected T-cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1046">
                    <text>N-terminal SH3 domain also inhibits intermediate events that lead to the formation of clathrin-coated wells in transiently transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1047">
                    <text>N-terminal SH3 domain can fully inhibit intermediate events that lead to the formation of clathrin-coated wells that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1048">
                    <text>N-terminal SH3 domain can inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1049">
                    <text>N-terminal SH3 domain can totally inhibit intermediate events that lead to the formation of clathrin-coated wells that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1050">
                    <text>N-terminal SH3 domain co-expression also has the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells in T-leukemia transnetly affected cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1051">
                    <text>N-terminal SH3 domain fully inhibiting concentration-dependent intermediate events that lead to the formation of clathrin-coated wells and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1052">
                    <text>N-terminal SH3 domain has also inhibited intermediate events that lead to the formation of clathrin-coated wells in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1053">
                    <text>N-terminal SH3 domain has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1054">
                    <text>N-terminal SH3 domain inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1055">
                    <text>N-terminal SH3 domain inhibited intermediate events that lead to the formation of clathrin-coated wells activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1056">
                    <text>N-terminal SH3 domain inhibited intermediate events that lead to the formation of clathrin-coated wells activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1057">
                    <text>N-terminal SH3 domain inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1058">
                    <text>N-terminal SH3 domain inhibits intermediate events that lead to the formation of clathrin-coated wells activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1059">
                    <text>N-terminal SH3 domain inhibits intermediate events that lead to the formation of clathrin-coated wells activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1060">
                    <text>N-terminal SH3 domain is able to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1061">
                    <text>N-terminal SH3 domain may also have inhibited intermediate events that lead to the formation of clathrin-coated wells in T cells affected by jurkat.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1062">
                    <text>N-terminal SH3 domain may also have inhibited intermediate events that lead to the formation of clathrin-coated wells in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1063">
                    <text>N-terminal SH3 domain may have completely inhibited intermediate events that lead to the formation of clathrin-coated wells that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1064">
                    <text>N-terminal SH3 domain may have completely inhibited intermediate events that lead to the formation of clathrin-coated wells which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1065">
                    <text>N-terminal SH3 domain may have inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1066">
                    <text>N-terminal domain H3 (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1067">
                    <text>N-terminal domain H3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1068">
                    <text>N-terminal domain H3 (NO) inhibiting intermediate events that lead to the formation of clathrin-coated pins activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1069">
                    <text>N-terminal domain H3 (NO) inhibiting intermediate events that lead to the formation of clathrin-coated pins activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1070">
                    <text>N-terminal domain H3 activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1071">
                    <text>N-terminal domain H3 also has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins in transient transfected T-cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1072">
                    <text>N-terminal domain H3 also inhibited intermediate events that lead to the formation of clathrin-coated pins in transfected T-leukemia cells transfected.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1073">
                    <text>N-terminal domain H3 also inhibits intermediate events that lead to the formation of clathrin-coated pins in transient transfected T-cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1074">
                    <text>N-terminal domain H3 also inhibits intermediate events that lead to the formation of clathrin-coated pins in transiently transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1075">
                    <text>N-terminal domain H3 can fully inhibit intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1076">
                    <text>N-terminal domain H3 can inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1077">
                    <text>N-terminal domain H3 can totally inhibit intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1078">
                    <text>N-terminal domain H3 co-expression also has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins in T-leukemia transnetly affected cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1079">
                    <text>N-terminal domain H3 fully inhibiting concentration-dependent intermediate events that lead to the formation of clathrin-coated pins and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1080">
                    <text>N-terminal domain H3 has also inhibited intermediate events that lead to the formation of clathrin-coated pins in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1081">
                    <text>N-terminal domain H3 has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1082">
                    <text>N-terminal domain H3 inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1083">
                    <text>N-terminal domain H3 inhibited intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1084">
                    <text>N-terminal domain H3 inhibited intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1085">
                    <text>N-terminal domain H3 inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1086">
                    <text>N-terminal domain H3 inhibits intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1087">
                    <text>N-terminal domain H3 inhibits intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1088">
                    <text>N-terminal domain H3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1089">
                    <text>N-terminal domain H3 may also have inhibited intermediate events that lead to the formation of clathrin-coated pins in T cells affected by jurkat.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1090">
                    <text>N-terminal domain H3 may also have inhibited intermediate events that lead to the formation of clathrin-coated pins in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1091">
                    <text>N-terminal domain H3 may have completely inhibited intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1092">
                    <text>N-terminal domain H3 may have completely inhibited intermediate events that lead to the formation of clathrin-coated pins which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1093">
                    <text>N-terminal domain H3 may have inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1094">
                    <text>N-terminal domain SH3 (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1095">
                    <text>N-terminal domain SH3 (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1096">
                    <text>N-terminal domain SH3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1097">
                    <text>N-terminal domain SH3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1098">
                    <text>N-terminal domain SH3 (NO) inhibiting intermediate events that lead to the formation of a clathrin-coated well activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1099">
                    <text>N-terminal domain SH3 (NO) inhibiting intermediate events that lead to the formation of a clathrin-coated well activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1100">
                    <text>N-terminal domain SH3 (NO) inhibiting intermediate events that lead to the formation of clathrin-coated pins activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1101">
                    <text>N-terminal domain SH3 (NO) inhibiting intermediate events that lead to the formation of clathrin-coated pins activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1102">
                    <text>N-terminal domain SH3 activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1103">
                    <text>N-terminal domain SH3 activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1104">
                    <text>N-terminal domain SH3 also has the ability to inhibit intermediate events that lead to the formation of a clathrin-coated well in transient transfected T-cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1105">
                    <text>N-terminal domain SH3 also has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins in transient transfected T-cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1106">
                    <text>N-terminal domain SH3 also inhibited intermediate events that lead to the formation of a clathrin-coated well in transfected T-leukemia cells transfected.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1107">
                    <text>N-terminal domain SH3 also inhibited intermediate events that lead to the formation of clathrin-coated pins in transfected T-leukemia cells transfected.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1108">
                    <text>N-terminal domain SH3 also inhibits intermediate events that lead to the formation of a clathrin-coated well in transient transfected T-cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1109">
                    <text>N-terminal domain SH3 also inhibits intermediate events that lead to the formation of a clathrin-coated well in transiently transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1110">
                    <text>N-terminal domain SH3 also inhibits intermediate events that lead to the formation of clathrin-coated pins in transient transfected T-cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1111">
                    <text>N-terminal domain SH3 also inhibits intermediate events that lead to the formation of clathrin-coated pins in transiently transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1112">
                    <text>N-terminal domain SH3 can fully inhibit intermediate events that lead to the formation of a clathrin-coated well that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1113">
                    <text>N-terminal domain SH3 can fully inhibit intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1114">
                    <text>N-terminal domain SH3 can inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1115">
                    <text>N-terminal domain SH3 can inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1116">
                    <text>N-terminal domain SH3 can totally inhibit intermediate events that lead to the formation of a clathrin-coated well that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1117">
                    <text>N-terminal domain SH3 can totally inhibit intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1118">
                    <text>N-terminal domain SH3 co-expression also has the ability to inhibit intermediate events that lead to the formation of a clathrin-coated well in T-leukemia transnetly affected cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1119">
                    <text>N-terminal domain SH3 co-expression also has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins in T-leukemia transnetly affected cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1120">
                    <text>N-terminal domain SH3 fully inhibiting concentration-dependent intermediate events that lead to the formation of a clathrin-coated well and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1121">
                    <text>N-terminal domain SH3 fully inhibiting concentration-dependent intermediate events that lead to the formation of clathrin-coated pins and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1122">
                    <text>N-terminal domain SH3 has also inhibited intermediate events that lead to the formation of a clathrin-coated well in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1123">
                    <text>N-terminal domain SH3 has also inhibited intermediate events that lead to the formation of clathrin-coated pins in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1124">
                    <text>N-terminal domain SH3 has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1125">
                    <text>N-terminal domain SH3 inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1126">
                    <text>N-terminal domain SH3 inhibited intermediate events that lead to the formation of a clathrin-coated well activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1127">
                    <text>N-terminal domain SH3 inhibited intermediate events that lead to the formation of a clathrin-coated well activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1128">
                    <text>N-terminal domain SH3 inhibited intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1129">
                    <text>N-terminal domain SH3 inhibited intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1130">
                    <text>N-terminal domain SH3 inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1131">
                    <text>N-terminal domain SH3 inhibits intermediate events that lead to the formation of a clathrin-coated well activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1132">
                    <text>N-terminal domain SH3 inhibits intermediate events that lead to the formation of a clathrin-coated well activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1133">
                    <text>N-terminal domain SH3 inhibits intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1134">
                    <text>N-terminal domain SH3 inhibits intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1135">
                    <text>N-terminal domain SH3 is able to inhibit intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1136">
                    <text>N-terminal domain SH3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1137">
                    <text>N-terminal domain SH3 may also have inhibited intermediate events that lead to the formation of a clathrin-coated well in T cells affected by jurkat.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1138">
                    <text>N-terminal domain SH3 may also have inhibited intermediate events that lead to the formation of a clathrin-coated well in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1139">
                    <text>N-terminal domain SH3 may also have inhibited intermediate events that lead to the formation of clathrin-coated pins in T cells affected by jurkat.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1140">
                    <text>N-terminal domain SH3 may also have inhibited intermediate events that lead to the formation of clathrin-coated pins in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1141">
                    <text>N-terminal domain SH3 may have completely inhibited intermediate events that lead to the formation of a clathrin-coated well that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1142">
                    <text>N-terminal domain SH3 may have completely inhibited intermediate events that lead to the formation of a clathrin-coated well which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1143">
                    <text>N-terminal domain SH3 may have completely inhibited intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1144">
                    <text>N-terminal domain SH3 may have completely inhibited intermediate events that lead to the formation of clathrin-coated pins which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1145">
                    <text>N-terminal domain SH3 may have inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1146">
                    <text>N-terminal domain SH3 may have inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1147">
                    <text>NK-mediated cytotoxicity are inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1148">
                    <text>NK-mediated cytotoxicity are inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1149">
                    <text>NK-mediated cytotoxicity are inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1150">
                    <text>NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and lectin type C which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1151">
                    <text>NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1152">
                    <text>NK-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1153">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1154">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1155">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1156">
                    <text>NK-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1157">
                    <text>NK-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1158">
                    <text>NK-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1159">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1160">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1161">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1162">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1163">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1164">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1165">
                    <text>NK-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1166">
                    <text>NK-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1167">
                    <text>NK-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1168">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1169">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1170">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1171">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1172">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1173">
                    <text>NK-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1174">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin and lectin type C, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1175">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1176">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1177">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin and lectin type C, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1178">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1179">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1180">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin and lectin type C, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1181">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1182">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1183">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin and lectin type C, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1184">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1185">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1186">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin and lectin type C, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1187">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1188">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1189">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin and lectin type C, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1190">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1191">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1192">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors for immunoglobulin and lectin type C, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1193">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1194">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1195">
                    <text>NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1196">
                    <text>NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1197">
                    <text>NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1198">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and lectin type C which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1199">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1200">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1201">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1202">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1203">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1204">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin and lectin type C , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1205">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin and type C lectin , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1206">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin and type C lectins superfamilies , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1207">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1208">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1209">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1210">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1211">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1212">
                    <text>NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1213">
                    <text>NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1214">
                    <text>NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1215">
                    <text>NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1216">
                    <text>NK-mediated cytotoxicity may have been inhibited by cell surface receptors for immunoglobulin and lectin type C which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1217">
                    <text>NK-mediated cytotoxicity may have been inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1218">
                    <text>NK-mediated cytotoxicity may have been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1219">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and lectin type C that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1220">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and lectin type C which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1221">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1222">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1223">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1224">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1225">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1226">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1227">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1228">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and lectin type C which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1229">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1230">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1231">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1232">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1233">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1234">
                    <text>P has been strongly inhibited by This synthetic peptide, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1235">
                    <text>P has been strongly inhibited by this synthetic peptide, by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1236">
                    <text>P is observed to be strongly inhibited by This synthetic peptide, by 21-folds.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1237">
                    <text>P is observed to be strongly inhibited by this synthetic peptide, by 21-folds.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1238">
                    <text>P is strongly inhibited by This synthetic peptide by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1239">
                    <text>P is strongly inhibited by This synthetic peptide, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1240">
                    <text>P is strongly inhibited by this synthetic peptide by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1241">
                    <text>P is strongly inhibited by this synthetic peptide, by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1242">
                    <text>P was strongly inhibited by This synthetic peptide 21 times.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1243">
                    <text>P was strongly inhibited by this synthetic peptide 21 times.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1244">
                    <text>PDE4C is one of the four mammalian genes that codify P and is inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1245">
                    <text>PDE4C is one of the four mammalian genes that codify P and is inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1246">
                    <text>PDE4C is one of the four mammalian genes that codify P inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1247">
                    <text>PDE4C is one of the four mammalian genes that codify P inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1248">
                    <text>PDE4C is one of the four mammalian genes that codify P that can be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1249">
                    <text>PDE4C is one of the four mammalian genes that codify P that can be inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1250">
                    <text>PDE4C is one of the four mammalian genes that codify P that have been inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1251">
                    <text>PDE4C is one of the four mammalian genes that codify P that have been inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1252">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit of PKA and is inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1253">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit of PKA inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1254">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit of PKA that can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1255">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit of PKA that have been inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1256">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha isoforms as C beta of the PKA catalytic subunit and is inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1257">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha isoforms as C beta of the PKA catalytic subunit inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1258">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha isoforms as C beta of the PKA catalytic subunit that can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1259">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha isoforms as C beta of the PKA catalytic subunit that have been inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1260">
                    <text>PDE4C is one of the four mammalian genes that codify both the C-alpha isoforms and the beta C of the catalytic subunit PKA and is inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1261">
                    <text>PDE4C is one of the four mammalian genes that codify both the C-alpha isoforms and the beta C of the catalytic subunit PKA inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1262">
                    <text>PDE4C is one of the four mammalian genes that codify both the C-alpha isoforms and the beta C of the catalytic subunit PKA that can be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1263">
                    <text>PDE4C is one of the four mammalian genes that codify both the C-alpha isoforms and the beta C of the catalytic subunit PKA that have been inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1264">
                    <text>PDE4C is one of the four mammalian genes that codify cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1265">
                    <text>PDE4C is one of the four mammalian genes that codify cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1266">
                    <text>PDE4C is one of the four mammalian genes that codify cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1267">
                    <text>PDE4C is one of the four mammalian genes that codify cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1268">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific isoforms PDE4 and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1269">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific isoforms PDE4 inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1270">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific isoforms PDE4 that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1271">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific isoforms PDE4 that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1272">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific isoform phosphodiesterase and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1273">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific isoform phosphodiesterase inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1274">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific isoform phosphodiesterase that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1275">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific isoform phosphodiesterase that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1276">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit Lrp/PapI.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1277">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit decreased regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="1278">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit intermediate events leading to the formation of clathrin coated wells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="1279">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit intermediate events that lead to the formation of clathrin-coated cubes.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="1280">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit intermediate events that lead to the formation of clathrin-coated paddocks.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="1281">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1282">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1283">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1284">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit Lrp/PapI.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1285">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit decreased regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="1286">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit intermediate events leading to the formation of clathrin coated wells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="1287">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated cubes.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="1288">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated paddocks.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="1289">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1290">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1291">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1292">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1293">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1294">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I (NO) inhibiting delayed clattrin-coated vesicles formation events activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1295">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I (NO) inhibiting delayed clattrin-coated vesicles formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1296">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1297">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I also has the ability to inhibit delayed clattrin-coated vesicles formation events in transient transfected T-cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1298">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I also inhibited delayed clattrin-coated vesicles formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1299">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I also inhibits delayed clattrin-coated vesicles formation events in transient transfected T-cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1300">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I also inhibits delayed clattrin-coated vesicles formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1301">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I can fully inhibit delayed clattrin-coated vesicles formation events that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1302">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I can inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1303">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I can totally inhibit delayed clattrin-coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1304">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I co-expression also has the ability to inhibit delayed clattrin-coated vesicles formation events in T-leukemia transnetly affected cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1305">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I fully inhibiting concentration-dependent delayed clattrin-coated vesicles formation events and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1306">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I has also inhibited delayed clattrin-coated vesicles formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1307">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1308">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1309">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited delayed clattrin-coated vesicles formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1310">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited delayed clattrin-coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1311">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1312">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibits delayed clattrin-coated vesicles formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1313">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibits delayed clattrin-coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1314">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I is able to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1315">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I may also have inhibited delayed clattrin-coated vesicles formation events in T cells affected by jurkat.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1316">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I may also have inhibited delayed clattrin-coated vesicles formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1317">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I may have completely inhibited delayed clattrin-coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1318">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I may have completely inhibited delayed clattrin-coated vesicles formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1319">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I may have inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1320">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1321">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1322">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I (NO) inhibiting late events of clathrin-coated vesicles formation activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1323">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I (NO) inhibiting late events of clathrin-coated vesicles formation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1324">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1325">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I also has the ability to inhibit late events of clathrin-coated vesicles formation in transient transfected T-cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1326">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I also inhibited late events of clathrin-coated vesicles formation in transfected T-leukemia cells transfected.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1327">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I also inhibits late events of clathrin-coated vesicles formation in transient transfected T-cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1328">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I also inhibits late events of clathrin-coated vesicles formation in transiently transfected T-leukemia cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1329">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I can fully inhibit late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1330">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I can inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1331">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I can totally inhibit late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1332">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I co-expression also has the ability to inhibit late events of clathrin-coated vesicles formation in T-leukemia transnetly affected cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1333">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I fully inhibiting concentration-dependent late events of clathrin-coated vesicles formation and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1334">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I has also inhibited late events of clathrin-coated vesicles formation in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1335">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1336">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1337">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited late events of clathrin-coated vesicles formation activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1338">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited late events of clathrin-coated vesicles formation activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1339">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1340">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits late events of clathrin-coated vesicles formation activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1341">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits late events of clathrin-coated vesicles formation activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1342">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1343">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I may also have inhibited late events of clathrin-coated vesicles formation in T cells affected by jurkat.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1344">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I may also have inhibited late events of clathrin-coated vesicles formation in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1345">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I may have completely inhibited late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1346">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I may have completely inhibited late events of clathrin-coated vesicles formation which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1347">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I may have inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1348">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1349">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1350">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1351">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1352">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1353">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I also has the ability to inhibit late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1354">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I also inhibited late clathrin-coated vesicle formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1355">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I also inhibits late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1356">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I also inhibits late clathrin-coated vesicle formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1357">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I can fully inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1358">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1359">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I can totally inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1360">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I co-expression also has the ability to inhibit late clathrin-coated vesicle formation events in T-leukemia transnetly affected cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1361">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I fully inhibiting concentration-dependent late clathrin-coated vesicle formation events and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1362">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I has also inhibited late clathrin-coated vesicle formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1363">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1364">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1365">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1366">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1367">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1368">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1369">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1370">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1371">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may also have inhibited late clathrin-coated vesicle formation events in T cells affected by jurkat.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1372">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may also have inhibited late clathrin-coated vesicle formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1373">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may have completely inhibited late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1374">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may have completely inhibited late clathrin-coated vesicle formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1375">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1376">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit Lrp/PapI.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1377">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit decreased regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="1378">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit intermediate events leading to the formation of clathrin coated wells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="1379">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated cubes.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="1380">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated paddocks.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="1381">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1382">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1383">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1384">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then Lrp/PapI binding was inhibited by 50 mg/ml methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1385">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then Lrp/PapI connection was inhibited by 50 mg/ml methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1386">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then Lrp/PapI was inhibited by 50 mg/ml nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1387">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1388">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1389">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1390">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then binding was inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1391">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then delayed clattrin-coated vesicles formation events was inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1392">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well was inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1393">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1394">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1395">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells was inhibited by 50 mg/ml N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1396">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1397">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1398">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1399">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then ligand was inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1400">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI binding has been inhibited by 50 mg/ml methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1401">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI binding was about to be inhibited by 50 mg/ml methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1402">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI binding was inhibited by 50 mg/ml methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1403">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI binding will be inhibited by 50 mg/ml methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1404">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI connection has been inhibited by 50 mg/ml methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1405">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI connection was about to be inhibited by 50 mg/ml methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1406">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI connection was inhibited by 50 mg/ml methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1407">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI connection will be inhibited by 50 mg/ml methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1408">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI has been inhibited by 50 mg/ml nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1409">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI was about to be inhibited by 50 mg/ml nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1410">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI was inhibited by 50 mg/ml nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1411">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI will be inhibited by 50 mg/ml nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1412">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1413">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1414">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1415">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1416">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1417">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1418">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1419">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1420">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1421">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1422">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1423">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1424">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding has been inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1425">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding was about to be inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1426">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding was inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1427">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding will be inhibited by 50 mg/ml EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1428">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then delayed clattrin-coated vesicles formation events has been inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1429">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then delayed clattrin-coated vesicles formation events was about to be inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1430">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then delayed clattrin-coated vesicles formation events was inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1431">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then delayed clattrin-coated vesicles formation events will be inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1432">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well has been inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1433">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well was about to be inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1434">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well was inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1435">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well will be inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1436">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins has been inhibited by 50 mg/ml N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1437">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins has been inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1438">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was about to be inhibited by 50 mg/ml N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1439">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was about to be inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1440">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1441">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1442">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins will be inhibited by 50 mg/ml N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1443">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins will be inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1444">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells has been inhibited by 50 mg/ml N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1445">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells was about to be inhibited by 50 mg/ml N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1446">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells was inhibited by 50 mg/ml N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1447">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells will be inhibited by 50 mg/ml N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1448">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events has been inhibited by 50 mg/ml Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1449">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events has been inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1450">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1451">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1452">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1453">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1454">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1455">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1456">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation has been inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1457">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation was about to be inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1458">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1459">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicles formation will be inhibited by 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1460">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand has been inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1461">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1462">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand was inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1463">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand will be inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1464">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then Lrp/PapI binding will be inhibited by 50 mg/ml of methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1465">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then Lrp/PapI connection will be inhibited by 50 mg/ml of methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1466">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then Lrp/PapI will be inhibited by 50 mg/ml of nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1467">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1468">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1469">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1470">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then binding will be inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1471">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then delayed clattrin-coated vesicles formation events will be inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1472">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then intermediate events that lead to the formation of a clathrin-coated well will be inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1473">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then intermediate events that lead to the formation of clathrin-coated pins will be inhibited by 50 mg/ml of N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1474">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then intermediate events that lead to the formation of clathrin-coated pins will be inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1475">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then intermediate events that lead to the formation of clathrin-coated wells will be inhibited by 50 mg/ml of N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1476">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1477">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1478">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late events of clathrin-coated vesicles formation will be inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1479">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then ligand will be inhibited by 50 mg/ml of 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1480">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml 10mM EDTA to inhibiting ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1481">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml EDTA of 10 mM to inhibiting binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1482">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml N-terminal SH3 domain to inhibiting intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1483">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml N-terminal domain H3 to inhibiting intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1484">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml N-terminal domain SH3 to inhibiting intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1485">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml N-terminal domain SH3 to inhibiting intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1486">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I to inhibiting delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1487">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I to inhibiting late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1488">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1489">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin and lectin type C to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1490">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin and type C lectin to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1491">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin and type C lectins superfamilies to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1492">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml methylation of prey to inhibiting Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1493">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml methylation of snails to inhibiting Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1494">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml nails methylation to inhibiting Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1495">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1496">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of 10mM EDTA to inhibiting ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1497">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of EDTA of 10 mM to inhibiting binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1498">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of N-terminal SH3 domain to inhibiting intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1499">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of N-terminal domain H3 to inhibiting intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1500">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of N-terminal domain SH3 to inhibiting intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1501">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of N-terminal domain SH3 to inhibiting intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1502">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I to inhibiting delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1503">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I to inhibiting late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1504">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1505">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin and lectin type C to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1506">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin and type C lectin to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1507">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin and type C lectins superfamilies to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1508">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of methylation of prey to inhibiting Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1509">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of methylation of snails to inhibiting Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1510">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of nails methylation to inhibiting Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1511">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I to inhibiting late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1512">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then Lrp/PapI binding was inhibited by 50 mg/ml of methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1513">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then Lrp/PapI connection was inhibited by 50 mg/ml of methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1514">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then Lrp/PapI was inhibited by 50 mg/ml of nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1515">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1516">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1517">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1518">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then binding was inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1519">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then delayed clattrin-coated vesicles formation events was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1520">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well was inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1521">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml of N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1522">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1523">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells was inhibited by 50 mg/ml of N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1524">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1525">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1526">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1527">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then ligand was inhibited by 50 mg/ml of 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1528">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI binding is inhibited by 50 mg/ml of methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1529">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI binding was about to be inhibited by 50 mg/ml of methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1530">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI binding was inhibited by 50 mg/ml of methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="1531">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI connection is inhibited by 50 mg/ml of methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1532">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI connection was about to be inhibited by 50 mg/ml of methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1533">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI connection was inhibited by 50 mg/ml of methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="1534">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI is inhibited by 50 mg/ml of nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1535">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI was about to be inhibited by 50 mg/ml of nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1536">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI was inhibited by 50 mg/ml of nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1537">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1538">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1539">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1540">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1541">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1542">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1543">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1544">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1545">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1546">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding is inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1547">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding was about to be inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1548">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding was inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1549">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then delayed clattrin-coated vesicles formation events is inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1550">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then delayed clattrin-coated vesicles formation events was about to be inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1551">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then delayed clattrin-coated vesicles formation events was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="1552">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well is inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1553">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well was about to be inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1554">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of a clathrin-coated well was inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="1555">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins is inhibited by 50 mg/ml of N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1556">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins is inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1557">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was about to be inhibited by 50 mg/ml of N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1558">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was about to be inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1559">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml of N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1560">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml of N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1561">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells is inhibited by 50 mg/ml of N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1562">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells was about to be inhibited by 50 mg/ml of N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1563">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated wells was inhibited by 50 mg/ml of N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1564">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events is inhibited by 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1565">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events is inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1566">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1567">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1568">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1569">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1570">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation is inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1571">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation was about to be inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1572">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="1573">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand is inhibited by 50 mg/ml of 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1574">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml of 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1575">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was inhibited by 50 mg/ml of 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="1576">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit Lrp/PapI involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="1577">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit decreased regulation of Stat4, Stat5 and Stat6 phosphorylated involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="1578">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit intermediate events leading to the formation of clathrin coated wells involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="1579">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit intermediate events that lead to the formation of clathrin-coated cubes involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="1580">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit intermediate events that lead to the formation of clathrin-coated paddocks involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="1581">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit intermediate events that lead to the formation of clathrin-coated pins involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="1582">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit intermediate events that lead to the formation of clathrin-coated wells involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="1583">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit late clathrin-coated vesicle formation events involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="1584">
                    <text>This synthetic peptide binding to P can inhibit the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="1585">
                    <text>This synthetic peptide binding to P may have inhibited the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="1586">
                    <text>This synthetic peptide binds to P and is able to inhibit the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="1587">
                    <text>This synthetic peptide binds to P to inhibit the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="1588">
                    <text>This synthetic peptide can strongly inhibit P by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1589">
                    <text>This synthetic peptide has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1590">
                    <text>This synthetic peptide has strongly inhibited P by 21-folds.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1591">
                    <text>This synthetic peptide has the ability to inhibit phosphorylase-specific P-isoforms coded by PDE4C.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1592">
                    <text>This synthetic peptide has the ability to strongly inhibit P by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1593">
                    <text>This synthetic peptide has the ability to strongly inhibit P by 21-folds.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1594">
                    <text>This synthetic peptide inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1595">
                    <text>This synthetic peptide inhibited P coded by PDE4C.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1596">
                    <text>This synthetic peptide inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1597">
                    <text>This synthetic peptide inhibits P codified by PDE4C.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1598">
                    <text>This synthetic peptide is able to inhibit P coded by PDE4C.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1599">
                    <text>This synthetic peptide is able to inhibit P.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1600">
                    <text>This synthetic peptide is able to strongly inhibit P by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1601">
                    <text>This synthetic peptide may have strongly inhibited P by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1602">
                    <text>This synthetic peptide may inhibit P coded by PDE4C.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1603">
                    <text>This synthetic peptide strongly inhibited P by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1604">
                    <text>This synthetic peptide strongly inhibits P by 21-folds.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1605">
                    <text>This synthetic peptide that binds to P may have inhibited the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="1606">
                    <text>This synthetic peptide will strongly inhibit P by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1607">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and P are inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1608">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and P are inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1609">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and P can be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1610">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and P can be inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1611">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both alpha and C beta isoforms of the catalytic subunit of PKA are inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1612">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both alpha and C beta isoforms of the catalytic subunit of PKA can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1613">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both alpha isoforms as C beta of the PKA catalytic subunit are inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1614">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both alpha isoforms as C beta of the PKA catalytic subunit can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1615">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the C-alpha isoforms and the beta C of the catalytic subunit PKA are inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1616">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the C-alpha isoforms and the beta C of the catalytic subunit PKA can be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1617">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1618">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1619">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple AMP-specific isoforms PDE4 are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1620">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple AMP-specific isoforms PDE4 can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1621">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple cyclic PDE4 AMP-specific isoform phosphodiesterase are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1622">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple cyclic PDE4 AMP-specific isoform phosphodiesterase can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1623">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and This synthetic peptide is able to inhibit P equally.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1624">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transfect body cells is able to inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA equally.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1625">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transfected body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit of PKA equally.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1626">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transfected body cells is able to inhibit both alpha isoforms as C beta of the PKA catalytic subunit equally.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1627">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1628">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit multiple AMP-specific isoforms PDE4 equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1629">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1630">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and this synthetic peptide is able to inhibit P equally.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1631">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that This synthetic peptide could have inhibited P with equal effectiveness.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1632">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transfect body cells could have inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1633">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transfected body cells could have inhibited both alpha and C beta isoforms of the catalytic subunit of PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1634">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts from transfected body cells could have inhibited both alpha isoforms as C beta of the PKA catalytic subunit with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1635">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1636">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited multiple AMP-specific isoforms PDE4 with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1637">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1638">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that this synthetic peptide could have inhibited P with equal effectiveness.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1639">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and This synthetic peptide can inhibit P equally effectively.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1640">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transfect body cells can inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1641">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transfected body cells can inhibit both alpha and C beta isoforms of the catalytic subunit of PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1642">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transfected body cells can inhibit both alpha isoforms as C beta of the PKA catalytic subunit equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1643">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1644">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit multiple AMP-specific isoforms PDE4 equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1645">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1646">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and this synthetic peptide can inhibit P equally effectively.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1647">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that This synthetic peptide has inhibited P with equal effectiveness.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1648">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transfect body cells has inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1649">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transfected body cells has inhibited both alpha and C beta isoforms of the catalytic subunit of PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1650">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transfected body cells has inhibited both alpha isoforms as C beta of the PKA catalytic subunit with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1651">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1652">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited multiple AMP-specific isoforms PDE4 with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1653">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1654">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that this synthetic peptide has inhibited P with equal effectiveness.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1655">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that This synthetic peptide inhibits P equally effectively.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1656">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transfect body cells inhibits both the C-alpha isoforms and the beta C of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1657">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transfected body cells inhibits both alpha and C beta isoforms of the catalytic subunit of PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1658">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transfected body cells inhibits both alpha isoforms as C beta of the PKA catalytic subunit equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1659">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1660">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits multiple AMP-specific isoforms PDE4 equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1661">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits multiple cyclic PDE4 AMP-specific isoform phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1662">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that this synthetic peptide inhibits P equally effectively.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1663">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and P are observed to be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1664">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and P are observed to be inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1665">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and P can be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1666">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and P can be inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1667">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both alpha and C beta isoforms of the catalytic subunit of PKA are observed to be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1668">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both alpha and C beta isoforms of the catalytic subunit of PKA can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1669">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both alpha isoforms as C beta of the PKA catalytic subunit are observed to be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1670">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both alpha isoforms as C beta of the PKA catalytic subunit can be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1671">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the C-alpha isoforms and the beta C of the catalytic subunit PKA are observed to be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1672">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the C-alpha isoforms and the beta C of the catalytic subunit PKA can be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1673">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1674">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1675">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple AMP-specific isoforms PDE4 are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1676">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple AMP-specific isoforms PDE4 can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1677">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple cyclic PDE4 AMP-specific isoform phosphodiesterase are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1678">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple cyclic PDE4 AMP-specific isoform phosphodiesterase can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1679">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1680">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1681">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="1682">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1683">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1684">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1685">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1686">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1687">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1688">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1689">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1690">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1691">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="1692">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="1693">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by crew methylation.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="1694">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="1695">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="1696">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="1697">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="1698">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="1699">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="1700">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="1701">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="1702">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1703">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1704">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1705">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="1706">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1707">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1708">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1709">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1710">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1711">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1712">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1713">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1714">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1715">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="1716">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="1717">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by crew methylation.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="1718">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="1719">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="1720">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="1721">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="1722">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="1723">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="1724">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="1725">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="1726">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1727">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and This synthetic peptide can inhibit P with equal effectiveness.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1728">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfect body cells can inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1729">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfected body cells can inhibit both alpha and C beta isoforms of the catalytic subunit of PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1730">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfected body cells can inhibit both alpha isoforms as C beta of the PKA catalytic subunit with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1731">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1732">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit multiple AMP-specific isoforms PDE4 with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1733">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and rolipram can inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1734">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that This synthetic peptide is capable of inhibiting P equally effectively.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1735">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transfect body cells is capable of inhibiting both the C-alpha isoforms and the beta C of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1736">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transfected body cells is capable of inhibiting both alpha and C beta isoforms of the catalytic subunit of PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1737">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transfected body cells is capable of inhibiting both alpha isoforms as C beta of the PKA catalytic subunit equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1738">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1739">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting multiple AMP-specific isoforms PDE4 equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1740">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting multiple cyclic PDE4 AMP-specific isoform phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1741">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that this synthetic peptide is capable of inhibiting P equally effectively.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1742">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and this synthetic peptide can inhibit P with equal effectiveness.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1743">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that This synthetic peptide may have inhibited P with equal effectiveness.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1744">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfect body cells may have inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1745">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfected body cells may have inhibited both alpha and C beta isoforms of the catalytic subunit of PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1746">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfected body cells may have inhibited both alpha isoforms as C beta of the PKA catalytic subunit with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1747">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1748">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited multiple AMP-specific isoforms PDE4 with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1749">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that rolipram may have inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1750">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that this synthetic peptide may have inhibited P with equal effectiveness.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1751">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1752">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1753">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="1754">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1755">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1756">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1757">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1758">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1759">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1760">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1761">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1762">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1763">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="1764">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="1765">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by crew methylation.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="1766">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="1767">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="1768">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="1769">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="1770">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="1771">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="1772">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="1773">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="1774">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1775">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1776">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1777">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="1778">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1779">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1780">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1781">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1782">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1783">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1784">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1785">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1786">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1787">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="1788">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="1789">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by crew methylation.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="1790">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="1791">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="1792">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="1793">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="1794">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="1795">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="1796">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="1797">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="1798">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1799">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and P will be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1800">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and P will be inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1801">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both alpha and C beta isoforms of the catalytic subunit of PKA will be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1802">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both alpha isoforms as C beta of the PKA catalytic subunit will be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1803">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the C-alpha isoforms and the beta C of the catalytic subunit PKA will be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1804">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1805">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple AMP-specific isoforms PDE4 will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1806">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and multiple cyclic PDE4 AMP-specific isoform phosphodiesterase will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1807">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1808">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1809">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="1810">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1811">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1812">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1813">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1814">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1815">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1816">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1817">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1818">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1819">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="1820">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="1821">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by crew methylation.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="1822">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="1823">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="1824">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="1825">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="1826">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="1827">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="1828">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="1829">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="1830">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1831">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1832">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1833">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="1834">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1835">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1836">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1837">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1838">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1839">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1840">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1841">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1842">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1843">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="1844">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="1845">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by crew methylation.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="1846">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="1847">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="1848">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="1849">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="1850">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="1851">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="1852">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="1853">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="1854">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1855">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1856">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="1857">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="1858">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="1859">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="1860">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="1861">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="1862">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="1863">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="1864">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1865">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1866">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1867">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="1868">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="1869">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by crew methylation.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="1870">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="1871">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="1872">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="1873">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="1874">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="1875">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="1876">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="1877">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="1878">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="1879">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and This synthetic peptide inhibited P with equal effectiveness.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1880">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transfect body cells inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1881">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transfected body cells inhibited both alpha and C beta isoforms of the catalytic subunit of PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1882">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and protein extracts from transfected body cells inhibited both alpha isoforms as C beta of the PKA catalytic subunit with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1883">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1884">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited multiple AMP-specific isoforms PDE4 with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="1885">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="1886">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and this synthetic peptide inhibited P with equal effectiveness.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="1887">
                    <text>binding are inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1888">
                    <text>binding can be inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1889">
                    <text>binding has been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1890">
                    <text>binding in Jurkat T-leukemia transfect cells has also been inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1891">
                    <text>binding in T cells of Jurkat transfects is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1892">
                    <text>binding in T-lycemic cells transfected, wil is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1893">
                    <text>binding in transfectuously affected T-leukemia cells, wil is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1894">
                    <text>binding in transiently transfected Jurkat T-cells is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1895">
                    <text>binding in transiently transfected Jurkat T-cells was also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1896">
                    <text>binding is a dependent and saturable concentration and can be fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1897">
                    <text>binding is a dependent and saturable concentration and can be totally inhibited with EDTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1898">
                    <text>binding is a dependent and saturable concentration and has been totally inhibited with EDTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1899">
                    <text>binding is a dependent and saturable concentration and is able to be fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1900">
                    <text>binding is a dependent and saturable concentration and is fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1901">
                    <text>binding is a dependent and saturable concentration and is observed to be totally inhibited with EDTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1902">
                    <text>binding is a dependent and saturable concentration and was fully inhibited with EDTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1903">
                    <text>binding is able to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1904">
                    <text>binding is capable of being inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1905">
                    <text>binding is capable of being inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1906">
                    <text>binding is concentration-dependent and saturable and is able to be fully inhibited with EDTA of 10 mM , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1907">
                    <text>binding is inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1908">
                    <text>binding is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1909">
                    <text>binding is observed to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1910">
                    <text>binding may have been inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1911">
                    <text>binding was inhibited by EDTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1912">
                    <text>binding was inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1913">
                    <text>binding was inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1914">
                    <text>binding will be inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1915">
                    <text>binding will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="1916">
                    <text>both alpha and C beta isoforms of the catalytic subunit of PKA has been strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1917">
                    <text>both alpha and C beta isoforms of the catalytic subunit of PKA is observed to be strongly inhibited by protein extracts from transfected body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1918">
                    <text>both alpha and C beta isoforms of the catalytic subunit of PKA is strongly inhibited by protein extracts from transfected body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1919">
                    <text>both alpha and C beta isoforms of the catalytic subunit of PKA is strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1920">
                    <text>both alpha and C beta isoforms of the catalytic subunit of PKA was strongly inhibited by protein extracts from transfected body cells 21 times.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="1921">
                    <text>both alpha isoforms as C beta of the PKA catalytic subunit has been strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1922">
                    <text>both alpha isoforms as C beta of the PKA catalytic subunit is observed to be strongly inhibited by protein extracts from transfected body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1923">
                    <text>both alpha isoforms as C beta of the PKA catalytic subunit is strongly inhibited by protein extracts from transfected body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1924">
                    <text>both alpha isoforms as C beta of the PKA catalytic subunit is strongly inhibited by protein extracts from transfected body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1925">
                    <text>both alpha isoforms as C beta of the PKA catalytic subunit was strongly inhibited by protein extracts from transfected body cells 21 times.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="1926">
                    <text>both the C-alpha isoforms and the beta C of the catalytic subunit PKA has been strongly inhibited by protein extracts from transfect body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1927">
                    <text>both the C-alpha isoforms and the beta C of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from transfect body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1928">
                    <text>both the C-alpha isoforms and the beta C of the catalytic subunit PKA is strongly inhibited by protein extracts from transfect body cells by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1929">
                    <text>both the C-alpha isoforms and the beta C of the catalytic subunit PKA is strongly inhibited by protein extracts from transfect body cells, by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1930">
                    <text>both the C-alpha isoforms and the beta C of the catalytic subunit PKA was strongly inhibited by protein extracts from transfect body cells 21 times.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="1931">
                    <text>cell surface receptors for immunoglobulin and lectin type C (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1932">
                    <text>cell surface receptors for immunoglobulin and lectin type C (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1933">
                    <text>cell surface receptors for immunoglobulin and lectin type C (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1934">
                    <text>cell surface receptors for immunoglobulin and lectin type C (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1935">
                    <text>cell surface receptors for immunoglobulin and lectin type C activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1936">
                    <text>cell surface receptors for immunoglobulin and lectin type C also has the ability to inhibit NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1937">
                    <text>cell surface receptors for immunoglobulin and lectin type C also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1938">
                    <text>cell surface receptors for immunoglobulin and lectin type C also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1939">
                    <text>cell surface receptors for immunoglobulin and lectin type C also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1940">
                    <text>cell surface receptors for immunoglobulin and lectin type C can fully inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1941">
                    <text>cell surface receptors for immunoglobulin and lectin type C can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1942">
                    <text>cell surface receptors for immunoglobulin and lectin type C can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1943">
                    <text>cell surface receptors for immunoglobulin and lectin type C co-expression also has the ability to inhibit NK-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1944">
                    <text>cell surface receptors for immunoglobulin and lectin type C fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1945">
                    <text>cell surface receptors for immunoglobulin and lectin type C has also inhibited NK-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1946">
                    <text>cell surface receptors for immunoglobulin and lectin type C has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1947">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1948">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1949">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1950">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="1951">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1952">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1953">
                    <text>cell surface receptors for immunoglobulin and lectin type C is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1954">
                    <text>cell surface receptors for immunoglobulin and lectin type C may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1955">
                    <text>cell surface receptors for immunoglobulin and lectin type C may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1956">
                    <text>cell surface receptors for immunoglobulin and lectin type C may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1957">
                    <text>cell surface receptors for immunoglobulin and lectin type C may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1958">
                    <text>cell surface receptors for immunoglobulin and lectin type C may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1959">
                    <text>cell surface receptors for immunoglobulin and type C lectin (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1960">
                    <text>cell surface receptors for immunoglobulin and type C lectin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1961">
                    <text>cell surface receptors for immunoglobulin and type C lectin (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1962">
                    <text>cell surface receptors for immunoglobulin and type C lectin (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1963">
                    <text>cell surface receptors for immunoglobulin and type C lectin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1964">
                    <text>cell surface receptors for immunoglobulin and type C lectin also has the ability to inhibit NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1965">
                    <text>cell surface receptors for immunoglobulin and type C lectin also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1966">
                    <text>cell surface receptors for immunoglobulin and type C lectin also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1967">
                    <text>cell surface receptors for immunoglobulin and type C lectin also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1968">
                    <text>cell surface receptors for immunoglobulin and type C lectin can fully inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1969">
                    <text>cell surface receptors for immunoglobulin and type C lectin can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1970">
                    <text>cell surface receptors for immunoglobulin and type C lectin can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1971">
                    <text>cell surface receptors for immunoglobulin and type C lectin co-expression also has the ability to inhibit NK-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1972">
                    <text>cell surface receptors for immunoglobulin and type C lectin fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1973">
                    <text>cell surface receptors for immunoglobulin and type C lectin has also inhibited NK-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1974">
                    <text>cell surface receptors for immunoglobulin and type C lectin has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1975">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1976">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1977">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1978">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="1979">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1980">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1981">
                    <text>cell surface receptors for immunoglobulin and type C lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1982">
                    <text>cell surface receptors for immunoglobulin and type C lectin may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1983">
                    <text>cell surface receptors for immunoglobulin and type C lectin may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1984">
                    <text>cell surface receptors for immunoglobulin and type C lectin may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1985">
                    <text>cell surface receptors for immunoglobulin and type C lectin may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1986">
                    <text>cell surface receptors for immunoglobulin and type C lectin may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1987">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1988">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1989">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1990">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1991">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1992">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies also has the ability to inhibit NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1993">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1994">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1995">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1996">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies can fully inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1997">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies can inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1998">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="1999">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies co-expression also has the ability to inhibit NK-mediated cytotoxicity in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2000">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2001">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies has also inhibited NK-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2002">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="2003">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="2004">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2005">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2006">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="2007">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2008">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2009">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2010">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2011">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2012">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2013">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2014">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="2015">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="2016">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="2017">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                </example>
                <example src="REPLACE" no="2018">
                    <text>crew methylation has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="2019">
                    <text>crew methylation inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="2020">
                    <text>crew methylation inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="2021">
                    <text>cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2022">
                    <text>cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2023">
                    <text>cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2024">
                    <text>cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2025">
                    <text>cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2026">
                    <text>decreased regulation of Stat4, Stat5 and Stat6 phosphorylated are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="2027">
                    <text>decreased regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="2028">
                    <text>decreased regulation of Stat4, Stat5 and Stat6 phosphorylated were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="2029">
                    <text>delayed clattrin-coated vesicles formation events are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2030">
                    <text>delayed clattrin-coated vesicles formation events can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2031">
                    <text>delayed clattrin-coated vesicles formation events has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2032">
                    <text>delayed clattrin-coated vesicles formation events in Jurkat T-leukemia transfect cells has also been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2033">
                    <text>delayed clattrin-coated vesicles formation events in T cells of Jurkat transfects is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2034">
                    <text>delayed clattrin-coated vesicles formation events in T-lycemic cells transfected, wil is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2035">
                    <text>delayed clattrin-coated vesicles formation events in transfectuously affected T-leukemia cells, wil is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2036">
                    <text>delayed clattrin-coated vesicles formation events in transiently transfected Jurkat T-cells is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2037">
                    <text>delayed clattrin-coated vesicles formation events in transiently transfected Jurkat T-cells was also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2038">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and can be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2039">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and can be totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2040">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and has been totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2041">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and is able to be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2042">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and is fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2043">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and is observed to be totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2044">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and was fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2045">
                    <text>delayed clattrin-coated vesicles formation events is able to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2046">
                    <text>delayed clattrin-coated vesicles formation events is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2047">
                    <text>delayed clattrin-coated vesicles formation events is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2048">
                    <text>delayed clattrin-coated vesicles formation events is concentration-dependent and saturable and is able to be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2049">
                    <text>delayed clattrin-coated vesicles formation events is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2050">
                    <text>delayed clattrin-coated vesicles formation events is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2051">
                    <text>delayed clattrin-coated vesicles formation events is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2052">
                    <text>delayed clattrin-coated vesicles formation events may have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2053">
                    <text>delayed clattrin-coated vesicles formation events was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2054">
                    <text>delayed clattrin-coated vesicles formation events was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2055">
                    <text>delayed clattrin-coated vesicles formation events was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2056">
                    <text>delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2057">
                    <text>delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="2058">
                    <text>intermediate events leading to the formation of clathrin coated wells are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="2059">
                    <text>intermediate events leading to the formation of clathrin coated wells is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="2060">
                    <text>intermediate events leading to the formation of clathrin coated wells were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="2061">
                    <text>intermediate events that lead to the formation of a clathrin-coated well are inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2062">
                    <text>intermediate events that lead to the formation of a clathrin-coated well can be inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2063">
                    <text>intermediate events that lead to the formation of a clathrin-coated well has been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2064">
                    <text>intermediate events that lead to the formation of a clathrin-coated well in Jurkat T-leukemia transfect cells has also been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2065">
                    <text>intermediate events that lead to the formation of a clathrin-coated well in T cells of Jurkat transfects is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2066">
                    <text>intermediate events that lead to the formation of a clathrin-coated well in T-lycemic cells transfected, wil is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2067">
                    <text>intermediate events that lead to the formation of a clathrin-coated well in transfectuously affected T-leukemia cells, wil is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2068">
                    <text>intermediate events that lead to the formation of a clathrin-coated well in transiently transfected Jurkat T-cells is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2069">
                    <text>intermediate events that lead to the formation of a clathrin-coated well in transiently transfected Jurkat T-cells was also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2070">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and can be fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2071">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and can be totally inhibited with N-terminal domain SH3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2072">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and has been totally inhibited with N-terminal domain SH3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2073">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and is able to be fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2074">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and is fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2075">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and is observed to be totally inhibited with N-terminal domain SH3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2076">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and was fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2077">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is able to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2078">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is capable of being inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2079">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is capable of being inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2080">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is concentration-dependent and saturable and is able to be fully inhibited with N-terminal domain SH3 , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2081">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2082">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2083">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is observed to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2084">
                    <text>intermediate events that lead to the formation of a clathrin-coated well may have been inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2085">
                    <text>intermediate events that lead to the formation of a clathrin-coated well was inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2086">
                    <text>intermediate events that lead to the formation of a clathrin-coated well was inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2087">
                    <text>intermediate events that lead to the formation of a clathrin-coated well was inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2088">
                    <text>intermediate events that lead to the formation of a clathrin-coated well will be inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2089">
                    <text>intermediate events that lead to the formation of a clathrin-coated well will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="2090">
                    <text>intermediate events that lead to the formation of clathrin-coated cubes are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="2091">
                    <text>intermediate events that lead to the formation of clathrin-coated cubes is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="2092">
                    <text>intermediate events that lead to the formation of clathrin-coated cubes were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="2093">
                    <text>intermediate events that lead to the formation of clathrin-coated paddocks are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="2094">
                    <text>intermediate events that lead to the formation of clathrin-coated paddocks is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="2095">
                    <text>intermediate events that lead to the formation of clathrin-coated paddocks were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="2096">
                    <text>intermediate events that lead to the formation of clathrin-coated pins are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2097">
                    <text>intermediate events that lead to the formation of clathrin-coated pins are inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2098">
                    <text>intermediate events that lead to the formation of clathrin-coated pins are inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2099">
                    <text>intermediate events that lead to the formation of clathrin-coated pins can be inhibited by N-terminal domain H3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2100">
                    <text>intermediate events that lead to the formation of clathrin-coated pins can be inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2101">
                    <text>intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2102">
                    <text>intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2103">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in Jurkat T-leukemia transfect cells has also been inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2104">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in Jurkat T-leukemia transfect cells has also been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2105">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in T cells of Jurkat transfects is also inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2106">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in T cells of Jurkat transfects is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2107">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in T-lycemic cells transfected, wil is also inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2108">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in T-lycemic cells transfected, wil is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2109">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in transfectuously affected T-leukemia cells, wil is also inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2110">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in transfectuously affected T-leukemia cells, wil is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2111">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in transiently transfected Jurkat T-cells is also inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2112">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in transiently transfected Jurkat T-cells is also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2113">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in transiently transfected Jurkat T-cells was also inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2114">
                    <text>intermediate events that lead to the formation of clathrin-coated pins in transiently transfected Jurkat T-cells was also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2115">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and can be fully inhibited with N-terminal domain H3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2116">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and can be fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2117">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and can be totally inhibited with N-terminal domain H3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2118">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and can be totally inhibited with N-terminal domain SH3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2119">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and has been totally inhibited with N-terminal domain H3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2120">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and has been totally inhibited with N-terminal domain SH3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2121">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and is able to be fully inhibited with N-terminal domain H3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2122">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and is able to be fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2123">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and is fully inhibited with N-terminal domain H3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2124">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and is fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2125">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and is observed to be totally inhibited with N-terminal domain H3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2126">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and is observed to be totally inhibited with N-terminal domain SH3, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2127">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and was fully inhibited with N-terminal domain H3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2128">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and was fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2129">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is able to be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2130">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is able to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2131">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is capable of being inhibited by N-terminal domain H3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2132">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is capable of being inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2133">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is capable of being inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2134">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is capable of being inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2135">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is concentration-dependent and saturable and is able to be fully inhibited with N-terminal domain H3 , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2136">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is concentration-dependent and saturable and is able to be fully inhibited with N-terminal domain SH3 , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2137">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2138">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain H3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2139">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2140">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2141">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2142">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is observed to be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2143">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is observed to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2144">
                    <text>intermediate events that lead to the formation of clathrin-coated pins may have been inhibited by N-terminal domain H3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2145">
                    <text>intermediate events that lead to the formation of clathrin-coated pins may have been inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2146">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2147">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2148">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2149">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2150">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2151">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2152">
                    <text>intermediate events that lead to the formation of clathrin-coated pins were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2153">
                    <text>intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2154">
                    <text>intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2155">
                    <text>intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2156">
                    <text>intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="2157">
                    <text>intermediate events that lead to the formation of clathrin-coated wells are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2158">
                    <text>intermediate events that lead to the formation of clathrin-coated wells are inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2159">
                    <text>intermediate events that lead to the formation of clathrin-coated wells can be inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2160">
                    <text>intermediate events that lead to the formation of clathrin-coated wells has been inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2161">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in Jurkat T-leukemia transfect cells has also been inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2162">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in T cells of Jurkat transfects is also inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2163">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in T-lycemic cells transfected, wil is also inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2164">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in transfectuously affected T-leukemia cells, wil is also inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2165">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in transiently transfected Jurkat T-cells is also inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2166">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in transiently transfected Jurkat T-cells was also inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2167">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and can be fully inhibited with N-terminal SH3 domain, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2168">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and can be totally inhibited with N-terminal SH3 domain, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2169">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and has been totally inhibited with N-terminal SH3 domain, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2170">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and is able to be fully inhibited with N-terminal SH3 domain, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2171">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and is fully inhibited with N-terminal SH3 domain, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2172">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and is observed to be totally inhibited with N-terminal SH3 domain, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2173">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and was fully inhibited with N-terminal SH3 domain, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2174">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is able to be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2175">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is capable of being inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2176">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is capable of being inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2177">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is concentration-dependent and saturable and is able to be fully inhibited with N-terminal SH3 domain , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2178">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2179">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2180">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2181">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is observed to be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2182">
                    <text>intermediate events that lead to the formation of clathrin-coated wells may have been inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2183">
                    <text>intermediate events that lead to the formation of clathrin-coated wells was inhibited by N-terminal SH3 domain that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2184">
                    <text>intermediate events that lead to the formation of clathrin-coated wells was inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2185">
                    <text>intermediate events that lead to the formation of clathrin-coated wells was inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2186">
                    <text>intermediate events that lead to the formation of clathrin-coated wells were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2187">
                    <text>intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2188">
                    <text>intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="2189">
                    <text>its binding to C3b will be inhibited if P is associated with this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="REPLACE" no="2190">
                    <text>its binding to C3b would be inhibited if P is associated with this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="REPLACE" no="2191">
                    <text>late clathrin-coated vesicle formation events are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2192">
                    <text>late clathrin-coated vesicle formation events are inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2193">
                    <text>late clathrin-coated vesicle formation events are inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2194">
                    <text>late clathrin-coated vesicle formation events can be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2195">
                    <text>late clathrin-coated vesicle formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2196">
                    <text>late clathrin-coated vesicle formation events has been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2197">
                    <text>late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2198">
                    <text>late clathrin-coated vesicle formation events in Jurkat T-leukemia transfect cells has also been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2199">
                    <text>late clathrin-coated vesicle formation events in Jurkat T-leukemia transfect cells has also been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2200">
                    <text>late clathrin-coated vesicle formation events in T cells of Jurkat transfects is also inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2201">
                    <text>late clathrin-coated vesicle formation events in T cells of Jurkat transfects is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2202">
                    <text>late clathrin-coated vesicle formation events in T-lycemic cells transfected, wil is also inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2203">
                    <text>late clathrin-coated vesicle formation events in T-lycemic cells transfected, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2204">
                    <text>late clathrin-coated vesicle formation events in transfectuously affected T-leukemia cells, wil is also inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2205">
                    <text>late clathrin-coated vesicle formation events in transfectuously affected T-leukemia cells, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2206">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells is also inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2207">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2208">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells was also inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2209">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells was also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2210">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be fully inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2211">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2212">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be totally inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2213">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2214">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and has been totally inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2215">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and has been totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2216">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is able to be fully inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2217">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2218">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is fully inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2219">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2220">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is observed to be totally inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2221">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is observed to be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2222">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and was fully inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2223">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and was fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2224">
                    <text>late clathrin-coated vesicle formation events is able to be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2225">
                    <text>late clathrin-coated vesicle formation events is able to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2226">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2227">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2228">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2229">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2230">
                    <text>late clathrin-coated vesicle formation events is concentration-dependent and saturable and is able to be fully inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2231">
                    <text>late clathrin-coated vesicle formation events is concentration-dependent and saturable and is able to be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2232">
                    <text>late clathrin-coated vesicle formation events is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2233">
                    <text>late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2234">
                    <text>late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2235">
                    <text>late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2236">
                    <text>late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2237">
                    <text>late clathrin-coated vesicle formation events is observed to be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2238">
                    <text>late clathrin-coated vesicle formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2239">
                    <text>late clathrin-coated vesicle formation events may have been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2240">
                    <text>late clathrin-coated vesicle formation events may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2241">
                    <text>late clathrin-coated vesicle formation events was inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2242">
                    <text>late clathrin-coated vesicle formation events was inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2243">
                    <text>late clathrin-coated vesicle formation events was inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2244">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2245">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2246">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2247">
                    <text>late clathrin-coated vesicle formation events were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2248">
                    <text>late clathrin-coated vesicle formation events will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2249">
                    <text>late clathrin-coated vesicle formation events will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2250">
                    <text>late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2251">
                    <text>late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2252">
                    <text>late events of clathrin-coated vesicles formation are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2253">
                    <text>late events of clathrin-coated vesicles formation can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2254">
                    <text>late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2255">
                    <text>late events of clathrin-coated vesicles formation in Jurkat T-leukemia transfect cells has also been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2256">
                    <text>late events of clathrin-coated vesicles formation in T cells of Jurkat transfects is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2257">
                    <text>late events of clathrin-coated vesicles formation in T-lycemic cells transfected, wil is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2258">
                    <text>late events of clathrin-coated vesicles formation in transfectuously affected T-leukemia cells, wil is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2259">
                    <text>late events of clathrin-coated vesicles formation in transiently transfected Jurkat T-cells is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2260">
                    <text>late events of clathrin-coated vesicles formation in transiently transfected Jurkat T-cells was also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2261">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and can be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2262">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and can be totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2263">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and has been totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2264">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and is able to be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2265">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and is fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2266">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and is observed to be totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2267">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and was fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2268">
                    <text>late events of clathrin-coated vesicles formation is able to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2269">
                    <text>late events of clathrin-coated vesicles formation is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2270">
                    <text>late events of clathrin-coated vesicles formation is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2271">
                    <text>late events of clathrin-coated vesicles formation is concentration-dependent and saturable and is able to be fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2272">
                    <text>late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2273">
                    <text>late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2274">
                    <text>late events of clathrin-coated vesicles formation is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2275">
                    <text>late events of clathrin-coated vesicles formation may have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2276">
                    <text>late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2277">
                    <text>late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2278">
                    <text>late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2279">
                    <text>late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2280">
                    <text>late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="2281">
                    <text>ligand are inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2282">
                    <text>ligand can be inhibited by 10mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2283">
                    <text>ligand has been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2284">
                    <text>ligand in Jurkat T-leukemia transfect cells has also been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2285">
                    <text>ligand in T cells of Jurkat transfects is also inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2286">
                    <text>ligand in T-lycemic cells transfected, wil is also inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2287">
                    <text>ligand in transfectuously affected T-leukemia cells, wil is also inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2288">
                    <text>ligand in transiently transfected Jurkat T-cells is also inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2289">
                    <text>ligand in transiently transfected Jurkat T-cells was also inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2290">
                    <text>ligand is a dependent and saturable concentration and can be fully inhibited with 10mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2291">
                    <text>ligand is a dependent and saturable concentration and can be totally inhibited with 10mM EDTA, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2292">
                    <text>ligand is a dependent and saturable concentration and has been totally inhibited with 10mM EDTA, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2293">
                    <text>ligand is a dependent and saturable concentration and is able to be fully inhibited with 10mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2294">
                    <text>ligand is a dependent and saturable concentration and is fully inhibited with 10mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2295">
                    <text>ligand is a dependent and saturable concentration and is observed to be totally inhibited with 10mM EDTA, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2296">
                    <text>ligand is a dependent and saturable concentration and was fully inhibited with 10mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2297">
                    <text>ligand is able to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2298">
                    <text>ligand is capable of being inhibited by 10mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2299">
                    <text>ligand is capable of being inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2300">
                    <text>ligand is concentration-dependent and saturable and is able to be fully inhibited with 10mM EDTA , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2301">
                    <text>ligand is inhibited by 10mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2302">
                    <text>ligand is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2303">
                    <text>ligand is observed to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2304">
                    <text>ligand may have been inhibited by 10mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2305">
                    <text>ligand was inhibited by 10mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2306">
                    <text>ligand was inhibited by 10mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2307">
                    <text>ligand was inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2308">
                    <text>ligand will be inhibited by 10mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2309">
                    <text>ligand will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2310">
                    <text>methylation of prey (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2311">
                    <text>methylation of prey (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2312">
                    <text>methylation of prey (NO) inhibiting Lrp/PapI binding activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2313">
                    <text>methylation of prey (NO) inhibiting Lrp/PapI binding activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2314">
                    <text>methylation of prey activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2315">
                    <text>methylation of prey also has the ability to inhibit Lrp/PapI binding in transient transfected T-cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2316">
                    <text>methylation of prey also inhibited Lrp/PapI binding in transfected T-leukemia cells transfected.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2317">
                    <text>methylation of prey also inhibits Lrp/PapI binding in transient transfected T-cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2318">
                    <text>methylation of prey also inhibits Lrp/PapI binding in transiently transfected T-leukemia cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2319">
                    <text>methylation of prey can fully inhibit Lrp/PapI binding that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2320">
                    <text>methylation of prey can inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2321">
                    <text>methylation of prey can totally inhibit Lrp/PapI binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2322">
                    <text>methylation of prey co-expression also has the ability to inhibit Lrp/PapI binding in T-leukemia transnetly affected cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2323">
                    <text>methylation of prey fully inhibiting concentration-dependent Lrp/PapI binding and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2324">
                    <text>methylation of prey has also inhibited Lrp/PapI binding in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2325">
                    <text>methylation of prey has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="2326">
                    <text>methylation of prey inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="2327">
                    <text>methylation of prey inhibited Lrp/PapI binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2328">
                    <text>methylation of prey inhibited Lrp/PapI binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2329">
                    <text>methylation of prey inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="2330">
                    <text>methylation of prey inhibits Lrp/PapI binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2331">
                    <text>methylation of prey inhibits Lrp/PapI binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2332">
                    <text>methylation of prey is able to inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2333">
                    <text>methylation of prey may also have inhibited Lrp/PapI binding in T cells affected by jurkat.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2334">
                    <text>methylation of prey may also have inhibited Lrp/PapI binding in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2335">
                    <text>methylation of prey may have completely inhibited Lrp/PapI binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2336">
                    <text>methylation of prey may have completely inhibited Lrp/PapI binding which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2337">
                    <text>methylation of prey may have inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="2338">
                    <text>methylation of snails (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2339">
                    <text>methylation of snails (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2340">
                    <text>methylation of snails (NO) inhibiting Lrp/PapI connection activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2341">
                    <text>methylation of snails (NO) inhibiting Lrp/PapI connection activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2342">
                    <text>methylation of snails activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2343">
                    <text>methylation of snails also has the ability to inhibit Lrp/PapI connection in transient transfected T-cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2344">
                    <text>methylation of snails also inhibited Lrp/PapI connection in transfected T-leukemia cells transfected.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2345">
                    <text>methylation of snails also inhibits Lrp/PapI connection in transient transfected T-cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2346">
                    <text>methylation of snails also inhibits Lrp/PapI connection in transiently transfected T-leukemia cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2347">
                    <text>methylation of snails can fully inhibit Lrp/PapI connection that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2348">
                    <text>methylation of snails can inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2349">
                    <text>methylation of snails can totally inhibit Lrp/PapI connection that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2350">
                    <text>methylation of snails co-expression also has the ability to inhibit Lrp/PapI connection in T-leukemia transnetly affected cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2351">
                    <text>methylation of snails fully inhibiting concentration-dependent Lrp/PapI connection and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2352">
                    <text>methylation of snails has also inhibited Lrp/PapI connection in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2353">
                    <text>methylation of snails has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="2354">
                    <text>methylation of snails inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="2355">
                    <text>methylation of snails inhibited Lrp/PapI connection activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2356">
                    <text>methylation of snails inhibited Lrp/PapI connection activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2357">
                    <text>methylation of snails inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="2358">
                    <text>methylation of snails inhibits Lrp/PapI connection activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2359">
                    <text>methylation of snails inhibits Lrp/PapI connection activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2360">
                    <text>methylation of snails is able to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2361">
                    <text>methylation of snails may also have inhibited Lrp/PapI connection in T cells affected by jurkat.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2362">
                    <text>methylation of snails may also have inhibited Lrp/PapI connection in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2363">
                    <text>methylation of snails may have completely inhibited Lrp/PapI connection that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2364">
                    <text>methylation of snails may have completely inhibited Lrp/PapI connection which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2365">
                    <text>methylation of snails may have inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="2366">
                    <text>multiple AMP-specific isoforms PDE4 has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2367">
                    <text>multiple AMP-specific isoforms PDE4 is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2368">
                    <text>multiple AMP-specific isoforms PDE4 is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2369">
                    <text>multiple AMP-specific isoforms PDE4 is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2370">
                    <text>multiple AMP-specific isoforms PDE4 was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2371">
                    <text>multiple cyclic PDE4 AMP-specific isoform phosphodiesterase has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2372">
                    <text>multiple cyclic PDE4 AMP-specific isoform phosphodiesterase is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2373">
                    <text>multiple cyclic PDE4 AMP-specific isoform phosphodiesterase is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2374">
                    <text>multiple cyclic PDE4 AMP-specific isoform phosphodiesterase is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2375">
                    <text>multiple cyclic PDE4 AMP-specific isoform phosphodiesterase was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2376">
                    <text>nails methylation (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2377">
                    <text>nails methylation (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2378">
                    <text>nails methylation (NO) inhibiting Lrp/PapI activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2379">
                    <text>nails methylation (NO) inhibiting Lrp/PapI activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2380">
                    <text>nails methylation activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2381">
                    <text>nails methylation also has the ability to inhibit Lrp/PapI in transient transfected T-cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2382">
                    <text>nails methylation also inhibited Lrp/PapI in transfected T-leukemia cells transfected.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2383">
                    <text>nails methylation also inhibits Lrp/PapI in transient transfected T-cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2384">
                    <text>nails methylation also inhibits Lrp/PapI in transiently transfected T-leukemia cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2385">
                    <text>nails methylation can fully inhibit Lrp/PapI that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2386">
                    <text>nails methylation can inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2387">
                    <text>nails methylation can totally inhibit Lrp/PapI that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2388">
                    <text>nails methylation co-expression also has the ability to inhibit Lrp/PapI in T-leukemia transnetly affected cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2389">
                    <text>nails methylation fully inhibiting concentration-dependent Lrp/PapI and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2390">
                    <text>nails methylation has also inhibited Lrp/PapI in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2391">
                    <text>nails methylation has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="2392">
                    <text>nails methylation inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="2393">
                    <text>nails methylation inhibited Lrp/PapI activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2394">
                    <text>nails methylation inhibited Lrp/PapI activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2395">
                    <text>nails methylation inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="2396">
                    <text>nails methylation inhibits Lrp/PapI activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2397">
                    <text>nails methylation inhibits Lrp/PapI activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2398">
                    <text>nails methylation is able to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2399">
                    <text>nails methylation may also have inhibited Lrp/PapI in T cells affected by jurkat.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2400">
                    <text>nails methylation may also have inhibited Lrp/PapI in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2401">
                    <text>nails methylation may have completely inhibited Lrp/PapI that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2402">
                    <text>nails methylation may have completely inhibited Lrp/PapI which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2403">
                    <text>nails methylation may have inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2404">
                    <text>protein extracts from transfect body cells can strongly inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2405">
                    <text>protein extracts from transfect body cells has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="2406">
                    <text>protein extracts from transfect body cells has strongly inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2407">
                    <text>protein extracts from transfect body cells has the ability to inhibit phosphorylase-specific both the C-alpha isoforms and the beta C of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2408">
                    <text>protein extracts from transfect body cells has the ability to strongly inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2409">
                    <text>protein extracts from transfect body cells has the ability to strongly inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2410">
                    <text>protein extracts from transfect body cells inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="2411">
                    <text>protein extracts from transfect body cells inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2412">
                    <text>protein extracts from transfect body cells inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="2413">
                    <text>protein extracts from transfect body cells inhibits both the C-alpha isoforms and the beta C of the catalytic subunit PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2414">
                    <text>protein extracts from transfect body cells is able to inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2415">
                    <text>protein extracts from transfect body cells is able to inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2416">
                    <text>protein extracts from transfect body cells is able to strongly inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2417">
                    <text>protein extracts from transfect body cells may have strongly inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2418">
                    <text>protein extracts from transfect body cells may inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2419">
                    <text>protein extracts from transfect body cells strongly inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2420">
                    <text>protein extracts from transfect body cells strongly inhibits both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2421">
                    <text>protein extracts from transfect body cells will strongly inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="2422">
                    <text>protein extracts from transfected body cells can strongly inhibit both alpha and C beta isoforms of the catalytic subunit of PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2423">
                    <text>protein extracts from transfected body cells can strongly inhibit both alpha isoforms as C beta of the PKA catalytic subunit by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2424">
                    <text>protein extracts from transfected body cells has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="2425">
                    <text>protein extracts from transfected body cells has strongly inhibited both alpha and C beta isoforms of the catalytic subunit of PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2426">
                    <text>protein extracts from transfected body cells has strongly inhibited both alpha isoforms as C beta of the PKA catalytic subunit by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2427">
                    <text>protein extracts from transfected body cells has the ability to inhibit phosphorylase-specific both alpha and C beta isoforms of the catalytic subunit of PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2428">
                    <text>protein extracts from transfected body cells has the ability to inhibit phosphorylase-specific both alpha isoforms as C beta of the PKA catalytic subunit-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2429">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both alpha and C beta isoforms of the catalytic subunit of PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2430">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both alpha and C beta isoforms of the catalytic subunit of PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2431">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both alpha isoforms as C beta of the PKA catalytic subunit by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2432">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both alpha isoforms as C beta of the PKA catalytic subunit by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2433">
                    <text>protein extracts from transfected body cells inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="2434">
                    <text>protein extracts from transfected body cells inhibited both alpha and C beta isoforms of the catalytic subunit of PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2435">
                    <text>protein extracts from transfected body cells inhibited both alpha isoforms as C beta of the PKA catalytic subunit coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2436">
                    <text>protein extracts from transfected body cells inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="2437">
                    <text>protein extracts from transfected body cells inhibits both alpha and C beta isoforms of the catalytic subunit of PKA codified by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2438">
                    <text>protein extracts from transfected body cells inhibits both alpha isoforms as C beta of the PKA catalytic subunit codified by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2439">
                    <text>protein extracts from transfected body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit of PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2440">
                    <text>protein extracts from transfected body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit of PKA.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2441">
                    <text>protein extracts from transfected body cells is able to inhibit both alpha isoforms as C beta of the PKA catalytic subunit coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2442">
                    <text>protein extracts from transfected body cells is able to inhibit both alpha isoforms as C beta of the PKA catalytic subunit.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2443">
                    <text>protein extracts from transfected body cells is able to strongly inhibit both alpha and C beta isoforms of the catalytic subunit of PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2444">
                    <text>protein extracts from transfected body cells is able to strongly inhibit both alpha isoforms as C beta of the PKA catalytic subunit by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2445">
                    <text>protein extracts from transfected body cells may have strongly inhibited both alpha and C beta isoforms of the catalytic subunit of PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2446">
                    <text>protein extracts from transfected body cells may have strongly inhibited both alpha isoforms as C beta of the PKA catalytic subunit by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2447">
                    <text>protein extracts from transfected body cells may inhibit both alpha and C beta isoforms of the catalytic subunit of PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2448">
                    <text>protein extracts from transfected body cells may inhibit both alpha isoforms as C beta of the PKA catalytic subunit coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2449">
                    <text>protein extracts from transfected body cells strongly inhibited both alpha and C beta isoforms of the catalytic subunit of PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2450">
                    <text>protein extracts from transfected body cells strongly inhibited both alpha isoforms as C beta of the PKA catalytic subunit by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2451">
                    <text>protein extracts from transfected body cells strongly inhibits both alpha and C beta isoforms of the catalytic subunit of PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2452">
                    <text>protein extracts from transfected body cells strongly inhibits both alpha isoforms as C beta of the PKA catalytic subunit by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2453">
                    <text>protein extracts from transfected body cells will strongly inhibit both alpha and C beta isoforms of the catalytic subunit of PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="2454">
                    <text>protein extracts from transfected body cells will strongly inhibit both alpha isoforms as C beta of the PKA catalytic subunit by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="2455">
                    <text>rolipram can strongly inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2456">
                    <text>rolipram can strongly inhibit multiple AMP-specific isoforms PDE4 by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2457">
                    <text>rolipram can strongly inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2458">
                    <text>rolipram has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="2459">
                    <text>rolipram has strongly inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2460">
                    <text>rolipram has strongly inhibited multiple AMP-specific isoforms PDE4 by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2461">
                    <text>rolipram has strongly inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2462">
                    <text>rolipram has the ability to inhibit phosphorylase-specific cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2463">
                    <text>rolipram has the ability to inhibit phosphorylase-specific multiple AMP-specific isoforms PDE4-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2464">
                    <text>rolipram has the ability to inhibit phosphorylase-specific multiple cyclic PDE4 AMP-specific isoform phosphodiesterase-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2465">
                    <text>rolipram has the ability to strongly inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2466">
                    <text>rolipram has the ability to strongly inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2467">
                    <text>rolipram has the ability to strongly inhibit multiple AMP-specific isoforms PDE4 by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2468">
                    <text>rolipram has the ability to strongly inhibit multiple AMP-specific isoforms PDE4 by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2469">
                    <text>rolipram has the ability to strongly inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2470">
                    <text>rolipram has the ability to strongly inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2471">
                    <text>rolipram inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="2472">
                    <text>rolipram inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2473">
                    <text>rolipram inhibited multiple AMP-specific isoforms PDE4 coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2474">
                    <text>rolipram inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2475">
                    <text>rolipram inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="2476">
                    <text>rolipram inhibits cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2477">
                    <text>rolipram inhibits multiple AMP-specific isoforms PDE4 codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2478">
                    <text>rolipram inhibits multiple cyclic PDE4 AMP-specific isoform phosphodiesterase codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2479">
                    <text>rolipram is able to inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2480">
                    <text>rolipram is able to inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2481">
                    <text>rolipram is able to inhibit multiple AMP-specific isoforms PDE4 coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2482">
                    <text>rolipram is able to inhibit multiple AMP-specific isoforms PDE4.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2483">
                    <text>rolipram is able to inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2484">
                    <text>rolipram is able to inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2485">
                    <text>rolipram is able to strongly inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2486">
                    <text>rolipram is able to strongly inhibit multiple AMP-specific isoforms PDE4 by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2487">
                    <text>rolipram is able to strongly inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2488">
                    <text>rolipram may have strongly inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2489">
                    <text>rolipram may have strongly inhibited multiple AMP-specific isoforms PDE4 by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2490">
                    <text>rolipram may have strongly inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2491">
                    <text>rolipram may inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2492">
                    <text>rolipram may inhibit multiple AMP-specific isoforms PDE4 coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2493">
                    <text>rolipram may inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2494">
                    <text>rolipram strongly inhibited cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2495">
                    <text>rolipram strongly inhibited multiple AMP-specific isoforms PDE4 by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2496">
                    <text>rolipram strongly inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2497">
                    <text>rolipram strongly inhibits cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2498">
                    <text>rolipram strongly inhibits multiple AMP-specific isoforms PDE4 by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2499">
                    <text>rolipram strongly inhibits multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2500">
                    <text>rolipram will strongly inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2501">
                    <text>rolipram will strongly inhibit multiple AMP-specific isoforms PDE4 by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="2502">
                    <text>rolipram will strongly inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="2503">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="2504">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="2505">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="2506">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2507">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2508">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2509">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2510">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2511">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I also has the ability to inhibit late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2512">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I also inhibited late clathrin-coated vesicle formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2513">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I also inhibits late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2514">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I also inhibits late clathrin-coated vesicle formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2515">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I can fully inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2516">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2517">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I can totally inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2518">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I co-expression also has the ability to inhibit late clathrin-coated vesicle formation events in T-leukemia transnetly affected cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2519">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I fully inhibiting concentration-dependent late clathrin-coated vesicle formation events and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2520">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I has also inhibited late clathrin-coated vesicle formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2521">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="2522">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="2523">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2524">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2525">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="2526">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2527">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2528">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2529">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may also have inhibited late clathrin-coated vesicle formation events in T cells affected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2530">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may also have inhibited late clathrin-coated vesicle formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2531">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may have completely inhibited late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2532">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may have completely inhibited late clathrin-coated vesicle formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2533">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="2534">
                    <text>the binding to C3b will be inhibited if P is associated with This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="2535">
                    <text>the binding to C3b would be inhibited if P is associated with This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="2536">
                    <text>the binding to C3b would be inhibited if P were associated with This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="2537">
                    <text>this synthetic peptide can strongly inhibit P by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2538">
                    <text>this synthetic peptide has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="2539">
                    <text>this synthetic peptide has strongly inhibited P by 21-folds.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2540">
                    <text>this synthetic peptide has the ability to inhibit phosphorylase-specific P-isoforms coded by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2541">
                    <text>this synthetic peptide has the ability to strongly inhibit P by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2542">
                    <text>this synthetic peptide has the ability to strongly inhibit P by 21-folds.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2543">
                    <text>this synthetic peptide inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="2544">
                    <text>this synthetic peptide inhibited P coded by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2545">
                    <text>this synthetic peptide inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="2546">
                    <text>this synthetic peptide inhibits P codified by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2547">
                    <text>this synthetic peptide is able to inhibit P coded by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2548">
                    <text>this synthetic peptide is able to inhibit P.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2549">
                    <text>this synthetic peptide is able to strongly inhibit P by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2550">
                    <text>this synthetic peptide may have strongly inhibited P by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2551">
                    <text>this synthetic peptide may inhibit P coded by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2552">
                    <text>this synthetic peptide strongly inhibited P by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2553">
                    <text>this synthetic peptide strongly inhibits P by 21-folds.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="2554">
                    <text>this synthetic peptide will strongly inhibit P by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
